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Thesis Summary 
 
Drug delivery to the central nervous system (CNS) is significantly hindered by the 
presence of the blood brain barrier (BBB) and blood cerebrospinal fluid barrier (BCSFB) 
and associated drug efflux transporter proteins. The aim of this work was to modulate 
the expression of breast cancer resistance protein (BCRP) at each barrier site using 
phytochemical modulators. In-vitro cellular models of both the BBB (porcine brain 
microvascular endothelial cells (PBMEC/C1-2)) and BCSFB (rat choroid plexus cells 
(Z310)) were utilised and 18 phytochemical modulators screened for their cellular 
toxicity with IC50 values for the majority of phytochemicals being in excess of 100 µM. 
Intracellular accumulation of Hoechst 33342 (H33342) was assessed in each barrier 
cell line to determine short-term modulation of BCRP efflux or long-term modulation of 
protein expression. Incubations with modulators demonstrated significant inhibition of 
BCRP efflux activity for a range of modulators in both cell lines with TMF (1-100 µM) 
demonstrating a > 6 fold increase in intracellular accumulation. Similarly, many 
modulators demonstrated proposed protein-level modulation of BCRP resulting in 
increases or decreases in H33342 accumulation following a 24 hour exposure.  
Western blotting subsequently confirmed that quercetin and naringin for PBMEC/C1-2 
and baiclain and flavone for Z310 induced BCRP expression (to 2-3 fold of control) 
whereas curcumin and 17-β-estradiol for PBMEC/C1-2 and silymarin, quercetin and 
17-β-estradiol for Z310 down-regulated BCRP expression (to 0.24-0.4 fold of control). 
This was further confirmed in substrate transport studies using 12- well permeable 
insert models, which demonstrated functional changes in the permeability of BCRP 
substrates across both barrier models. 
Subsequently the regulation of BCRP by AhR was confirmed through siRNA 
knockdown of AhR, which resulted in a significant decrease in BCRP gene expression 
in both cell lines. Furthermore the induction/down-regulation effects on BCRP were, in 
general, diminished following AhR knockdown, suggesting AhR plays an important role 
in mediating the genomic/proteomic alterations in BCRP expression when exposed to 
phytochemicals. 
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qPCR    Quantitative polymerase chain reaction 
RNA    Ribonucleic acid  
RT    Room temperature 
RT-PCR   Reverse transcriptase polymerase chain reaction 
s     Second  
SFM    Serum free media 
t     Time  
TAE    Tris-Acetate EDTA buffer 
TBST    Tris-Buffered Saline with Tween 20 
T-25     25 cm2 tissue culture flask  
T-75     75 cm2 tissue culture flask 
TEER    Transendothelial or epithelial resistance  
TJ     Tight junctions  
U     Units 
UV    Ultraviolet 
V     Volts  
v     Volume  
w     Weigh  
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1.1.  Background 
 
The development of neurodegenerative diseases is one of the most devastating 
illnesses which can affect people across all age groups (Manji and DeSouza, 2008). 
The World Health Organization (WHO) reported that neurological disorders contributed 
to 92 million disability adjusted life years (DALYs) in 2005 and which is thought to 
increase to 103 million (approximately 12% rise) in 2030 (Eigenmann et al., 2013). In 
Europe the WHO described that CNS disorders contributes 37% of the total disease 
burden (Stins et al., 2001, Prudhomme et al., 1996), with an estimated cost of treatment 
thought to be  at $798 billion (Prudhomme et al., 1996). Age related neurodegenerative 
diseases, such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), are major 
health problems in developed countries. AD is the sixth leading cause of deaths in the 
USA and an estimated 5 million Americans are living with AD (Hurd  et al., 2013). The 
treatment costs for AD and other ‘dementias’ (in United States) was estimated to be 
$226 billion in 2015 and is expected to rise to $1.2 trillion by 2050 (Kameremail et al., 
2015). This figure is made even more striking when considering that in 2010 it was 
estimated that there were 35.6 million people with dementia with the figure nearly 
doubling every 20 years, increasing to 65.7 million in 2030, and 115.4 million in 2050 
(Wimo and Prince, 2010). 
Similarly, PD is the second most neurodegenerative illness after AD in United States. 
10 million people are living with PD worldwide. The economic burden of PD exceeds 
$14.4 billion in 2010 and expected to be double by 2040 (Kowal et al., 2013).The total 
annual cost of care in the UK has been estimated at approximately £599 million per 
year for 100,000 individuals with PD only (2015b). Costs to the National Health Service 
(NHS) were approximately 38% of the total care costs (Findley et al., 2003). 
A major cause of this increase in the incidence of untreated CNS disorders is not due 
to a lack of therapeutics, but rather a lack of understanding of CNS disease pathology 
and how this may impact upon the delivery of drugs to the CNS. In recent years, the 
pharmaceutical industry have struggled to provide novel drug therapies for CNS 
disorders, primarily as a result of higher cost to market, longer development times (an 
average 13 years) compared to non-CNS diseases (an average 8 -10 years) (Alavijeh 
et al., 2005), higher risk of clinical failure and changing regulatory hurdles (Manji and 
DeSouza, 2008). A report by the Tufts Centre for the Study of Drug Development (Tufts 
CSDD) suggests that only 8.2 % of CNS drug candidates ever become available for 
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clinical use, compared with 15% for non-CNS indicated drugs (Riordan and Cutler, 
2012).   
 
1.2. The physiology of the brain and central nervous system 
 
The brain is a highly vascularised organ with a combined microvascular surface area 
of 150-200 cm2/g , which results in a large area for molecular/fluid transfer (12-18 m2) 
in the adult human brain (Abbott et al., 2010, Tang et al., 2014, Zhao et al., 2009a). 
The delivery of drugs to the CNS is often hindered by its complex anatomy and 
physiology (Abbott, 2005). The CNS is a complicated and delicate organ and has its 
own self-protective mechanism to exchange nutrients, neurotoxins, pathogens and 
xenobiotics. This self-protective mechanism has become a significant hurdle to deliver 
drugs to the brain (Begley, 2003).  A key obstacle to the delivery of drugs to the CNS 
is the presence of physiological barriers located between the blood and brain (termed 
the blood brain barrier [BBB]) and the blood and cerebrospinal fluid (termed the blood 
cerebrospinal fluid barrier [BCSFB]). A prerequisite for therapeutic molecules to gain 
access to the CNS biophase is the permeation of these barriers (Begley, 2003). 
 
1.2.1.   The blood brain barrier 
 
1.2.1.1. Discovery  
 
In 1878, the German scientist Paul Ehrlich injected several mice with trypan blue dye 
and discovered that the dye stained all other tissue and organs except for the brain and 
the spinal cord. Thereafter Edwin Goldman (one of Ehrlich’s student), injected the same 
dye into the cerebrospinal fluid (CSF) and found that it stained the brain but no other 
body organs (Goldmann, 1909, Goldmann, 1913). Ehrlich’s experimental findings were 
later confirmed by a number of other researches (Goldmann, 1909, Goldmann, 1913) 
(Friedemann, 1942) and led to the idea of a compartmentalisation between the brain 
and cerebral capillaries, that is to say that BBB.  
1.2.1.2. Physiology of the blood brain barrier  
 
 
The BBB is essentially formed by microvascular endothelial cells, which surround blood 
capillaries within the brain (Figure 1.1). The BBB is further formed into a complex mesh 
of astrocytes, basement membranes, pericytes and neurons (Stamatovic et al., 2008), 
and which is often termed the ‘neurovascular unit’. Endothelial cells primarily form the 
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‘barrier’ function by hindering xenobiotic transport, with endothelial cells held tightly 
packed together with adjacent endothelial cells through a tight network of tight junctions 
(TJs). Furthermore endothelial cells have no fenestrations (Fenstermacher and Kaye, 
1988), an increased number of mitochondria (Oldendorf et al., 1977) and low 
pinocytotic activity (Sedlakova et al., 1999) which restricts the diffusion of hydrophilic 
solutes (Abbott, 2002).  
 
Endothelial cells and the neurovascular unit (NVU) function to regulate transport and 
metabolism of substances from blood to brain and brain to the peripheral blood. As part 
of the NVU, astrocytes form networks which surround the endothelial cells and 
basement membrane (Bernoud et al., 1998). The NVU also includes a basement 
membrane which is comprised of a range extracellular matrix proteins such as 
collagen, elastin, fibronectin, laminin and proteoglycans and  cell adhesion molecules 
(CAMs), as well as signalling proteins (Carvey et al., 2009, Wolburg et al., 2009). 
Disruption of basement membrane can lead to alteration of brain micro vessel 
cytoskeleton which can affect the barrier integrity (Cardoso et al., 2010).  
 
Pericytes communicate with the other elements of the NVU through signalling 
pathways and regulate the normal function of the BBB (Ryota et al., 2007). From a BBB 
perspective, neurons are known to induce enzymes, which regulate the function of 
blood vessels (Persidsky et al., 2006).  
 
 
 Figure 1.1: Schematic representation of the blood brain barrier.  
Blood capillaries are surrounded by  endothelial cells which also have astrocytes and pericytes overlying 
that together form the blood brain barrier (Chen and Liu, 2012). 
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Tight Junctions (TJs) are formed by contact zones between cells or between parts of 
the same cell, in which the intercellular cleft is occluded. TJs are regulated by a set of 
interacting proteins including occludin, claudins and junctional adhesion molecules 
(JAMs) that seals the space between adjacent endothelial cells (Figure 1.2) and further 
hinder the passage of xenobiotic across the BBB.   
Occludin (molecular weight ~65kDa) was the first reported TJ transmembrane protein. 
Occludin contains two equal extracellular loops, four transmembrane domains and 
three cytoplasmic domains. The C-terminal domain forms an α-helix coiled loop 
structure (Li et al., 2005) and mediates communication with other cytoplasmic proteins 
such as ZO-1, ZO-2 and ZO-3 and interactions with other regulatory proteins (Peng et 
al., 2003).  
 
      Figure 1.2: Structure of tight junctions.  
Adjacent endothelial cells are linked by tight junction, which expresses TJs proteins such as claudins, 
occludin that interact with each other and seals the space between the cells. AJs are the junctions formed 
between the cells or surrounding matrix. 
 
Claudin (molecular weight ~20-27 kDa) is a major constituent of TJs. Claudin binds to 
claudins present on the adjacent endothelial cells and to cytoplasmic proteins (ZO-1, 
ZO-2 and ZO-3) and contributes to the tightly linked endothelial cell structure (Furuse 
et al., 1999). Adheren junctions (AJs) are cellular junctions formed between two 
adjacent endothelial cells. The main functions of AJs are to mediate cell adhesion, cell 
polarity and also contribute to the BBB function (Hawkins and Davis, 2005). The main 
constituents of AJs are cadherin and catenins. Cadherin mediates cell adhesion, limits 
cell proliferation and decreases cellular permeability (Cook et al., 2008). Catenins act 
as linking proteins which link cadherin adhesion to the cortical actin cytoskeleton. 
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1.2.2. The blood cerebrospinal fluid barrier 
 
1.2.2.1.   Discovery 
 
The cerebrospinal fluid (CSF) was first described in a document by ancient Egyptians 
as ‘water surrounding the brain’ over 2700 years ago (Hajdu, 2003). This was followed 
by a description by Hippocrates (129-219 AD) who described the water in the skull as 
‘hydrocephalus’. Galen  (130-200 AD.) identified a ‘fluid’ found to be leaking from the 
nasal cavity of sick patients was a originating from the pituitary gland (Nutton, 1973). 
In 1664 Thomas Willis first correctly evaluated the choroid plexus as a source of CSF 
production in a body of work called the “Cerebri Anatome” (Stephen Porter et al., 1977). 
In the mid-1700s Albrecht von Haller (Frixione, 2006) describes the circulation of CSF 
and thereafter the ventricle structures and presence of CSF within brain and spinal cord 
was identified.  
 
1.2.2.2. Physiology of the blood cerebrospinal fluid barrier 
 
The choroid plexuses (CP) are highly vascular tissues found in all four cerebral 
ventricles (Figure 1.3). The CP is comprised of a rich capillary bed of pia matter and 
choroidal epithelial cells (Siegel GJ et al., 1999) and consists of three layers of cells: 
apical epithelial cells, connective tissues and inner layer of endothelial cells.  
 
The primary function of the CP is to secrete cerebrospinal fluid (CSF) (Pollay and Curl, 
1967).  CSF is formed by the filtration of plasma by choroidal capillaries (Xie and 
Hammarlund-Udenaes, 1998). The osmotically active ions such as Na+, Cl-, K+ ,HCO3- 
and water from the plasma are filtered to the CSF. The total volume of CSF is estimated 
to be 150-200 mL in humans, 1.4-2.3 mL in rabbits (Siegel GJ et al., 1999, Brown et 
al., 2004) and 0.28-0.3 mL in rats (Han et al., 2009). The rate of CSF production in 
humans is 0.3-0.4 mL/min and 0.003 mL/min in rodents (Hammarlund-Udenaes, 2000).  
 
Villi and microvilli present on the choroidal epithelial cells enhances the macroscopic 
folding of the choroid plexus and increases the surface area of choroidal epithelial 
(Nolte, 1993). The surface area of the CP is reported to range from 0.02-5 m2 (Cornford 
et al., 1997, Dohrmann, 1970b, Pardridge, 2011), and if assumed to be in the range of 
> 1 m2, places the surface area within an order of magnitude of brain microvascular 
endothelial cell surface area. 
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 Figure 1.3: Location of the choroid plexus within the human brain.  
Lateral, central, third and fourth ventricles are the primary location of the choroid epithelial tissue and the 
sites of cerebrospinal fluid secretion into ventricles (1991b). 
 
 
The epithelial cells of the choroid plexus form a barrier which restricts the free 
movement of molecules from blood into the CSF and brain biophase-to-CSF-to-blood 
(Siegel GJ et al., 1999) and is termed the blood-cerebrospinal fluid barrier (BCSFB) 
(Figure 1.4).  
  
1.2.2.3. Functional role of the choroid plexuses 
In addition to the secretion of CSF, the CP epithelium also synthesises large numbers 
of bioactive peptides (Redzic et al., 2005) such as adrenomodulin, endothelin-1 and 
vasopressin (Chodobski et al., 1997). The level of these peptides and proteins change 
during CNS disorders, supporting the evidence that the CP plays important role in the 
brain injury and repair process 
(http://alzheimers.org.uk/site/scripts/download_info.php?downloadID=1491, 2014, 
Happich et al., 2016).  
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Figure 1.4: The CP epithelial structure.  
Microvilli structure on the CSF-facing region of the CP act to increase the surface area of the apical 
membrane of the choroid plexus epithelial cells.  These cells also express a variety of drug efflux 
transporters (Siegel GJ et al., 1999).  
 
 
The adult human brain weights approximately 1400 g whereas the CP tissue weighs 
only 2-3 g, however perfusion to the CP capillaries is 5 to 10 times greater than the 
mean blood flow (mL/min/g) to brain (Nolte, 1988, Thomsen et al., 2015, Wimo and 
Prince, 2010, 2015b). When considering that the total surface area of the CP may also 
be within the same order of magnitude as the BBB (Johanson et al., 2008a, Christy and 
Fishman, 1961, Pardridge, 1991, Blasberg et al., 1975, Tang et al., 2014), the 
importance of the CP infiltration of plasma across the choroidal capillaries (Johanson 
et al., 2008a) clearly is vitally important in helping to maintain and stabilise the fluid 
environment within the brain and CNS. 
 
1.2.2.4. Barrier function of the BCSFB  
The BCSFB is situated between the systemic circulation and the CSF and hence, acts 
to restrict the entry of xenobiotics into the CSF in addition to aiding in the removal of 
compounds from the CSF back into the systemic circulation (Redzic et al., 2005). This 
barrier function is imparted as a result of the network of tight junctions between the 
epithelial cells which regulate exchange of compounds between the blood and CSF 
(Ebada et al., 2011).  
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Furthermore, the surface area of the choroidal epithelial is significantly enhanced 
because of villi and microvilli structures projecting from the apical surface of the cells 
into the ventricle (Figure 1.4).  This increases the surface area available for drug 
transfer and fluid secretion (Redzic and Segal, 2004). 
1.3. Drug transport across the BBB and BCSFB 
 
1.3.1.   Transport pathways 
 
Although a number of cellular factors govern the permeability of drugs across the BBB 
and BCSFB and include the expression of membrane transporters, transcytotic vesicles 
and the inherent barrier function formed by the endothelial/epithelial (Persidsky et al., 
2006), the physicochemical properties of any compounds attempting to permeate 
across the BBB and BCSFB is also a driving factor in its ability to distribute into the 
CNS. The primary physicochemical factors governing molecular transport include 
lipophilicity and ionisation states, molecular size and the extent of plasma protein 
binding. In order for a drug molecule to diffuse across the BBB and BCSFB, passive 
transport is a common pathway and highly dependent upon the lipophilicity and 
molecular weight of the drug (Figure 1.5). Other drug molecules can often exploit 
energy-dependant carrier mediated transport pathways to enable drug transfer across 
concentrations gradients (Figure 1.5).  On the other hand larger peptides/proteins can 
often exploit cell-surface receptors to enable transport across cell membranes in a 
process termed receptor-mediated transcytosis (Figure 1.5) (Norinder and Haeberlein, 
2002). 
 
The 'Rule of 5' of Lipinski states that poor drug absorption is more common if the 
molecular weight is > 500 Da, log P > 5 and more than 5 hydrogen bond donors and 
10 hydrogen bond acceptors are present in a drug molecule (Lipinski, 2000). However 
in the case of drug delivery across the BBB and BCSFB, CNS –indicated drugs possess 
the above properties but Lipinski’s role often do not apply as the majority of these drugs 
display limited measurable CNS uptake (Evans and Skalak, 1980).  
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 Figure 1.5: A schematic representation of drug transport pathways across the BBB.  
The primary pathways for drug transport across cellular barriers include passive transport, carrier-
mediated transport, absorptive-mediated and receptor-mediated transcytosis(Norinder and Haeberlein, 
2002).  
 
 
The rate and extent of drug transport across the barriers are the two key factors, which 
govern their eventual delivery into the CNS. The permeability rate of a molecule at the 
BBB or BCSFB is reflected in the rate of drug entry to the CNS and processes which 
hinder the permeation of drugs across the barriers.  Furthermore permeability rate may 
also inherently be hindered by poor physicochemical properties of the drug molecules. 
The extent of drug transport into the CNS is primarily a factor of the ability of the drug 
to partition into the CNS and is often related to fraction of drug which is not bound onto 
either plasma protein (free fraction in plasma) or within CNS tissues (e.g. free fraction 
in brain) (Figure 1.6) (Summerfield et al., 2007). 
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Figure 1.6: Schematic illustration of the equilibrium processes at the BBB and BCSFB. 
(Billiau et al., 1981) 
 
Compartmentalisation of CNS barriers and factors governing the equilibrium of drug distribution 
within the CNS.  Arrows indicate direction of transport. 
 
 
1.3.2. Transporter proteins 
 Adenosine 5’- triphosphate binding cassette (ABC) transporter proteins form a major 
family of drug transporter proteins which play a significant role in hindering the tissue 
distribution of many drugs, particularly at CNS barrier (2015a, Kameremail et al., 2015, 
Nicolazzo and Katneni, 2009).  The term ‘ABC transporters’ was introduced in 1992 
(Higgins, 1992) and it is now known that 49 human ABC transporters exist (The 
Nutrition, Metabolism and Genomics Group, Wageningen University, Netherlands: 
http://nutrigene.4t.com/humanabc.htm) and are divided into several subclasses on the 
similarities between their nucleotide binding domains (NBD) (Table 1.1). 
 
Table 1.1: List of important human ABC genes 
Family Alternative name Transporters hindering drug transport 
ABCA  ABC1  ABCA2     
ABCB  MDR  ABCB1 (P-gp)    
    ABCB4 (MDR2)    
ABCC  MRP  ABCC1 (MRP1)    
    ABCC2-6    
    ABCC10     
    ABCC11     
ABCD  ALD       
ABCE  OABP       
ABCF  GCH20       
ABCG    ABCG2 (BCRP)   
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The ABC transporter family are one of the largest known transporter protein families and 
are widely distributed in all major tissues and in many different species (Schinkel and 
Jonker, 2012). ABC transporter proteins generally consist of a membrane-spanning 
region termed the trans-membrane domain (TMD) and a cytoplasmically located 
nucleotide-binding domain (NBD) (Figure 1.7). To function they require energy released 
from the hydrolysis of adenosine 5’-triphosphate (ATP), process which takes place within 
the NBD (Gupta et al., 2004) and which leads to the ‘transport’ process of molecules 
across cell membranes (Abbott, 2005, Nies et al., 2004).Typically, drug transporters are 
located apically or basolaterally at cell membranes and exhibit an influx (into the cell) or 
efflux (out of the cell) property. 
   
 
 
 Figure 1.7: A typical structure of ABC transporter  
The structure of an ABC transport typically includes TMDs, which often contain 6 trans-membrane (TM) 
segments followed by a NBD, and the functional transporter is formed from a second repeating unit of 
TMD-NBD. ‘Half transporters’ are formed of one TMD and one NBD that, upon translation, combine to 
form a functional unit (Reginald A Kavishe et al., 2009). 
 
Functionally active transporters are often formed from two linked monomer units (NBD-
TMD-NBD-TMD) but can formed from multiple-monomer units combined in an intricate 
three and four-dimensional structure. Well-known example of ABC-transporters, which 
hinder the distribution drugs into tissues, includes breast cancer resistance protein 
(BCRP), P-glycoprotein (P-gp) and multidrug resistance protein (MRP). 
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1.3.3.     Breast cancer resistance protein 
 
BCRP is a member of the G-family of ATP-binding cassette. BCRP was first identified 
from human MCF-7 breast cancer cells and termed it as a breast cancer resistant 
protein (Doyle et al., 1998). At the same time another group described the role of this 
transporter in mitoxantrone resistance and termed it mitoxantrone resistance factor 
(MXR) (Miyake et al., 1999), with a third group (Allikmets et al., 1998) reporting its 
discovery in placental tissue and terming it called ABCP (Staud and Pavek, 2005). 
BCRP is composed of one single N-terminal intracellular NBD followed by six trans-
membrane domain (Mao, 2005) and four N-glycosylation (Figure 1.8). 
 
 
 
 Figure 1.8:  Breast cancer resistance protein structure  
BCRP is known as a half transporters consisting of one nucleotide binding domain (NBD) and one trans-
membrane binding domain (TMD), comprised of 6 trans-membrane spanning regions. 
 
 
BCRP is often termed a half transporter and is thought to homodimerise through the 
formation of disulfide bridges in order to function (You and Morris, 2007). A study  (Kage 
et al., 2002) confirmed that BCRP migrated as a 70 kDa band on a SDS-PAGE gel in 
the presence of reducing agent, but 140 kDa band in the absence of reducing agent 
suggesting BCRP could exist in the monomeric (70 kDa) and dimer (140 kDa) structure. 
However recent studies have suggested that BCRP may exist as higher order 
oligomers (Saito et al., 2006, Xu et al., 2004).The role of oligomerisation in BCRP is 
not clear yet but it has been suggested that the function of BCRP could be regulated 
by the dynamic association and dissociation of BCRP monomers by protein-protein 
interactions (Mo and Zhang, 2009).Therefore, prevention of oligomerisation or 
prevention of formation of higher active oligomers may be a future strategy to inhibit 
BCRP. 
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Chemotherapeutic agents were the first identified substrates for BCRP and it is now 
known that BCRP possess a diverse substrate specificity (Table 1.2) (Mao, 2005). 
BCRP confers resistant to a wide range of drugs and particularly anti-neoplastic agents 
such as topotecan, doxorubicin, mitoxanthrone, irinotecan, etoposide, methotrexate 
(MTX) and imatinib (Breedveld et al., 2004). 
 
    Table1.2: Substrates and inhibitors of BCRP 
 
Substrates  Inhibitors 
Drugs  Drugs 
Mitoxantrone,Topotecan 
Doxorubicin,Epirubicin, 
Metoxantrate,Imatinib, 
Getfitinib,Ciprofloxacin, 
Erythromycin 
Folic Acid 
 
Fumitremorgin C (FTC) 
KO143, GF120918, 
Digoxin,Dexamethasone, 
Cyclosporin A, Flavopiridol 
Novobiocin, Gefitnib 
 
 
 
 
    
 
Dyes     
Pheophorbide a,     
Rhodamine 123, 
BODIPY Prazosin, 
Hoechst 33342, 
Lysotracker Green 
    
    
    
    
 
Natural compounds Natural compounds 
Genistein, Quercetin 
17β-Estradiol Sulphate 
 
  
Estrone, Chrysin, 
Biochanin A,Naringin 
Acastein,Genistein, 
Quercetin, 
17β-Estradiol Sulphate 
 
 
 
    
        
 
1.3.4. Expression and localisation of BCRP 
BCRP has been reported to be expressed at the BBB in many species including mice, 
bovine and porcine origins) (Warren et al., 2009), where its function is thought to be a 
protective one in preventing the entry of drugs and xenobiotics into the brain biophase 
through its’ inherent efflux transporter properties. Elsewhere, it has been reported to 
be expressed in the gut, blood-testis barrier (Bart et al., 2004), placenta (Doyle and 
Ross, 2003b) intestine and mammary glands (Jonker et al., 2005) of humans.  
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At the BBB, BCRP is located abluminally (Bendayan et al., 2006) and functions to 
transport xenobiotics in a brain-to-blood direction. However, at the BCSFB, BCRP is 
located luminally and results in transfer of drugs into the CSF from the brain biophase 
or blood (Figure 1.9). The high expression of BCRP in key sanctuary sites such as the 
small intestine, breast, liver, kidney, blood brain barrier and placenta confirms its 
important role in controlling the distribution of drugs into the most tissues. 
              
     Figure 1.9: Localisation of drug transporters at the BBB and BCSFB. 
At the BBB, the ABC transporters such as BCRP located abluminally (blood side), whereas at the BCSFB 
BCRP is expressed at the luminal side (brain side). The dashed lines represent bulk fluid flow (brain to 
BCSFB is the bulk flow of ISF and CSF to blood is CSF drainage) (solid arrows represent direction of 
transport). 
 
 
The absolute protein expression of transporter proteins has recently been reported 
using quantitative proteomics approaches at the BBB and BCSFB (Lee et al., 2003) 
from human brain capillaries using liquid chromatography-tandem mass spectrometric 
quantification method (Esser, 2009). BCRP protein expression was reported to be 8.14 
fmol/µg protein, and is higher than another well characterised drug efflux transporter 
protein, P-gp (6.06 fmol/µg protein), reinforcing the importance of BCRP. Furthermore, 
in monkeys the protein expression of BCRP has been reported to be 12.5-16.2 (fmol/µg 
protein) compared to P-gp: (6.49-2.65 fmol/µg protein) (Caldwell and Yan, 2013). In 
mice, BCRP was found to be expressed 1.85-fold greater than P-gp in mice (Lee et al., 
2003) and in a further human study from freshly isolated human brain capillary 
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endothelial cells, BCRP expression was 1.6-fold higher than that of P-gp (Dauchy et 
al., 2008b).  
Similarly, the absolute protein quantification of transporters at the choroid plexus was 
investigated in the isolated rat and human choroid plexus plasma membrane fractions. 
It was reported that the levels of BCRP in humans were 6.56- and 2.12-fold greater 
than those of mdr1a (P-gp) and Bcrp in rat, respectively (Uchida et al., 2015).  
1.4. The role of BCRP in health and disease 
 
BCRP is widely expressed in tissues and cells and plays important role in tissue and 
cellular protection. BCRP protects normal tissues such as the placenta, hepatocytes, 
intestinal mucosal and brain by eliminating xenobiotics and toxic compounds (Doyle 
and Ross, 2003a). Its role at the BBB has recently been elucidated using positron 
emission tomography (PET) and single photon emission computed tomography 
(SPECT), powerful nuclear imagining techniques. A PET method has been developed 
to investigate the BCRP function at the BBB in a BCRP wild-type and knockout mouse 
model (Takashima et al., 2013). In their study [11C] tariquidar, a BCRP (Pohl et al., 
2006) substrate, was used to assess the BCRP function by PET and it was 
demonstrated that knockdown of BCRP resulted in significantly increased signal 
intensity in the brain compared to wild-type mice.    
BCRP also imparts a protective role from relatively toxic molecules. Heterocyclic 
amines and polycyclic aromatic hydrocarbons (a group of chemical components formed 
while cooking or barbecue food (meat) at high temperatures) (Ebert et al., 2005) in 
addition to  protoporphyrin IX (a metabolic product of δ-aminolevulinic acid) and 
hematoporphyrin (a sonosensitizers) (Krishnamurthy et al., 2004) are common 
substrates for BCRP. Furthermore, BCRP also play important role in the control of and 
transport of folic acid (water soluble vitamins which plays important role in growth, 
differentiation and homeostasis) and it’s conjugates (Volk and Schneider, 2003).  
Other endogenous substrates include steroids such as estrone and estradiol (Imai et 
al., 2003). Estrone is hormone associated with the female reproductive functions and 
estradiol is a female sex hormone produced by the ovaries.  Moreover, BCRP function 
in the elimination of uric acid was discovered in proximal tubular cells (Woodward et 
al., 2009). BCRP has also been implicated in limiting the progression of Alzheimer’s 
disease (AD) because of the neurotoxic β-amyloid peptides being substrates for BCRP 
(Zhang et al., 2004b) (Zhao et al., 2010). Furthermore, BCRP genomic and protein 
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expression was found to be increased in AD brain (Zhao et al., 2010) (Xiong et al., 
2009) highlighting the important role BCRP plays in brain protection for age associated 
CNS disorders.   
BCRP has also been implicated in disease states, particularly in relation to tumour cells 
and the associated multi-drug resistance phenomena, whereby BCRP is 
overexpressed because of exposure to antineoplastic agents. In cell culture systems, 
the multi drug resistance cell lines MCF-7 (myeloma 8226 and colon carcinoma cell 
line) shows resistance to BCRP substrates such as mitoxantrone, topotecan, 
flavopiridol and doxorubicin with an associated overexpression of BCRP mRNA (Zhao 
et al., 2013, Novotna et al., 2014). 
1.5. Other CNS drug transporter proteins 
 
1.5.1.  P-glycoprotein (P-gp) 
 
P-glycoprotein (P-gp) was one of the first efflux transporter proteins discovered in 1976 
(Juliano and Ling, 1976).  P-gp was found to be highly expressed in Chinese hamster 
ovarian cells when discovered, and was resistance to a wide variety of amphiphilic 
drugs (Juliano and Ling, 1976). P-gp has an apparent molecular weight of 170 kDa 
(Löscher and Potschka, 2005) and a member of the P-gp family are found in humans 
(ABCB1) with and three members identified in mice (mdr1a, mdr1b and mdr2) 
(Gottesman and Pastan, 1993). P-gp exhibits a high nucleotide sequence homology to 
other members of the B-subfamily (Cornford et al., 1997). The primary role of P-gp is 
similar to that of BCRP, to protect tissue from toxic compounds through efflux transport 
processes. It is highly expressed at the luminal membrane of endothelial cells forming 
the blood–brain and blood–testis barriers (Schinkel, 1999, Cordon-Cardo et al., 1989, 
Dohrmann, 1970a, Melaine et al., 2002), blood-mammary barrier (Edwards et al., 2005) 
and the maternal–fetal barrier of the placenta (Gil et al., 2005). 
 
1.5.2.    Multidrug resistance protein (MRP)  
 
Multidrug resistance protein (MRP) was first discovered in 1992 in human small cell   
lung carcinoma cell line H69AR (Cole et al., 1992). The MRP family of transporter 
proteins (ABCC1-6, 10-11), together with the ATP-gated chloride channel, CFTR 
(ABCC7), and the ATP-dependent sulfonylurea receptors, SURs (ABCC8, 9), comprise 
the ‘C’ branch of the ABC superfamily (Table 1.1). There is also an overlap with the 
substrate specificity of MRP1 and P-gp. MRP1 transports a large number of drugs 
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including antineoplastic or therapeutic agents, including folate-based antimetabolites, 
anthracyclines, vinca-alkaloids, antiandrogens, and numerous glutathione (GSH)- and 
glucuronide conjugates of these compounds as well as organic anions and heavy 
metals (Deeley and Cole, 2006). Transport of several compounds by MRP1 depends 
on the presence of reduced glutathione (GSH). This has been confirmed by using 
MRP1 overexpressing cell lines, where in the presence of transport inhibitor 
(probenecid), decreased GSH release and increased drug accumulation (Versantvoort 
et al., 1995).  MRP transports organic molecules and confer resistance to a wide variety 
of drugs. 
 
1.6. Current approaches to assess drug delivery across the BBB/BCSFB 
 
Currently there are no ex-vivo models, which can mimic the function of the BBB or 
BCSFB to study the transport of drugs.  However, a number of surrogate in-vitro, in -
vivo and in-silico models exists to support the development of approaches to 
mechanistically understand and predict how drug molecules are able to cross the BBB 
and BCSFB.  Core to the development of such models is the requirement that they 
should include aspects of the expression of tight junctional proteins (Roberts et al., 
2008) along with the distribution and functional expression of efflux transporters such 
as P-gp, BCRP and MRPs (Miller, 2010, Kusuhara and Sugiyama, 2005, Naik and 
Cucullo, 2012), which are vitally important in controlling the rate and extent drug 
distribution into the CNS. 
 
1.6.1. In-vitro models 
  
1.6.1.1. Non-cerebral cell lines 
 
A large number of studies reporting the use of different types of epithelial cells or 
endothelial cells of non-cerebral origin for the study of different aspects of BBB and 
BCSFB function have been reported and include Madin-Darby canine kidney (MDCK) 
cells (Wang et al., 2005) (Nazer et al., 2008) and human umbilical endothelial cells 
(HUVECs) (Langford et al., 2005). The use of these cell lines as a BBB models is limited 
because of their non-cerebral origin, although they are useful for screening for drug 
transporter substrates.  
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1.6.1.2. Rodent origin cell lines 
 
Rat brain endothelial (RBE) cell lines have been established and characterised by Roux 
et al (Roux et al., 1994) to develop an in-vitro BBB model. RBE cells express most of 
the enzymes and transporters that are considered as specific for the blood-brain 
endothelium. Other rat origin cell lines include GP8, GPNT. The bEND.3-5 cells are 
murine origin and have been widely used for the signalling (Stins et al., 2001), 
permeability and drug uptake studies (Prudhomme et al., 1996, Eigenmann et al., 
2013). Other mouse origin brain cell lines include cEND and bEND3, and have been 
widely used to study brain drug transport (Franke et al., 2000, 1991b, 1991a).  
 
Z310 (Zheng and Zhao, 2002) and TR-CSFB (Kitazawa et al., 2001) cell lines are 
immortalised in nature and obtained from rat CP tissues. They have been established 
and characterised for drug transporter expression, TJs proteins and drug transport 
(Juliane Kläs et al., 2010, Szmydynger-Chodobska et al., 2007), in an attempt to mimic 
the BCSFB. The choroid plexus cell lines such as TR-CSFB shows low TEER values, 
requires growth at lower temperatures, and have been less widely characterised 
(Juliane Kläs et al., 2010, Kitazawa et al., 2001). The CP epithelial cells form leaky 
barriers (TEER value of 150-200Ω.cm2) compared to BBB cell systems (Hakvoort et 
al., 1998, Baehr et al., 2006) and monolayer formation and resistances are greater for 
Z310 cells (~140 Ω.cm2) (Kitazawa et al., 2001) compared with TR-CSF cells (90 
Ω.cm2) (Hosoya et al., 2004).  Furhermore, the Z310 cell lline has previoulsy been 
demonstrated to expression BCRP (Halwachs et al., 2011, Kaur and Badhan, 2015). 
1.6.1.3. Bovine origin cell lines  
 
Bovine brain endothelial cells have been widely used to develop an in-vitro BBB model, 
and cell monolayers typically give resistance values in the range of 160-200 Ω.cm2 
(Zhang et al., 2004b, Zhao et al., 2010). Bovine immortalised cell lines include t-BBEC-
117(Allen et al., 2002a), SV-BEC (Stephen Porter et al., 1977) and BBEC-SV (Frixione, 
2006).  Additionally, primary bovine blood brain barrier cell models have been used to 
study BBB properties and drug transport (Spector et al., 2015, Lindsey and 
Papoutsakis, 2012, Tan et al., 2010), but as a novel BBB model, are often restricted in 
use due to the historical risk of Creutzfeldt-Jakob disease infections in brain tissues. 
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1.6.1.4. Porcine origin cell lines 
 
The most widely used immortalised porcine BBB model is the PBMEC/C1-2 cell line 
(Teifel and Friedl, 1996). The presence of tight junctions gives a relatively high 
monolayer resistance of 250–300 Ωcm2, and it has been well characterised for drug 
permeation and drug transporter protein studies (Lauer et al., 2004, Neuhaus et al., 
2010, Neuhaus et al., 2012). Primary cultured porcine brain microvascular endothelial 
cells (PBMECs) have recently increased in use, having been first developed (Ulrike 
Tontsch and Bauer, 1989) and subsequently modified by Patabendige et al 
(Patabendige et al., 2013). Such cellular models give robust monolayer with high TEER 
values in excess of 800 Ω.cm2.  Furthermore, the expression of endothelial brain cell 
markers and drug transporter proteins has been extensively studied using these cells 
(Skinner et al., 2009, Cohen-Kashi-Malina et al., 2012, Patabendige et al., 2013). 
 
1.6.1.5. Human original cell lines 
 Due to the restricted availability of human brain tissues for the isolation of primary 
human brain endothelial cells, the development of a reliable immortalised human brain 
cerebral endothelial cell line was fulfilled in the hCMEC/D3 (Weksler et al., 2005) which 
has been shown to retain important BBB characteristics and which has been 
extensively studied for the expression of junctional proteins (Cohen-Kashi-Malina et al., 
2012), drug transporters such as BCRP (Dauchy et al., 2009, Skinner et al., 2009), 
neurosignalling (Hammarlund-Udenaes, 2000, Xie and Hammarlund-Udenaes, 1998, 
Thomsen et al., 2015) and drug transport studies (Wimo and Prince, 2010). Other 
conditionally immortalised human brain microvascular endothelial cell lines include  
TY08 (2015b), hBMEC (Stins et al., 2001) and BB-19 (Prudhomme et al., 1996) and 
have been characterised for the markers of brain endothelial cells and expression of 
drug transporters. A comparative study between the four cell lines confirmed that 
hBMEC is the most suitable human cell line to develop an in-vitro BBB model 
(Eigenmann et al., 2013). 
 Only one human chorodial epithelial immortalised cell culture model has been 
developed, and is derived from choroid plexus papilloma cells (HIBCPP) (Ishiwata et 
al., 2005). The use of HIBCPP is limited due the lack of morphological characteristics 
of epithelial cells (cells differ in size and do not display cobblestone like appearance) 
and difference in protein expression and metabolism (due to isolation from anaplastic 
choroid plexus rather than a normal human) (Schwerk et al., 2012). Furthermore, 
HIBCPP cells have not been recommended to be used after more than 30 passages 
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and hence may limit studies. HIBCPP cells have tendency to grow in multiple layers, a 
careful consideration of seeding density and trypsinisation is required to obtain a 
monolayer (Ishiwata et al., 2005).  
1.6.2. In-silico models  
 
As a result of the variability in available in-vitro cellular models and the limited use of 
in-vivo models to assess CNS drug delivery, in-silico approaches such as 
pharmacokinetic modelling and simulations, have often been used to collate a range of 
different in-vitro data (e.g. physicochemical, metabolic and permeability) generated to 
describe the pharmacokinetics of a drug to be able to predict both brain and CSF 
temporal drug concentrations (Ball et al., 2012, Badhan et al., 2014). 
1.6.3. In-vivo models  
 
To been able to predict and assess distribution of drugs in-vivo, the brain slice method 
is precise and robust technique to measure the uptake of drugs into the brain tissues 
by determining unbound drug concentration in ex-vivo brain sections. Further the 
temporal concentration of drugs can also be measured directly by micro dialysis  
techniques (Hammarlund-Udenaes, 2000). This involves the insertion of a probe into 
the tissue or fluid and multiple regional brain sampling from the same animal can be 
achieved. This technique has been used in the pre-clinical studies (Xie and 
Hammarlund-Udenaes, 1998, Zhang et al., 2015, Wei et al., 2015, Kitamura et al., 
2015, Chiang et al., 2015). However, poor recovery of lipophilic compounds, low 
throughput and local tissue damage at the site of probe insertion limit its use in drug 
discovery (Hammarlund-Udenaes, 2000).  
 
Another widely used technique is that of in-situ brain perfusion, which allows the 
quantitative measurement of brain uptake of solutes by perfusion of saline or blood to 
the right external carotid artery and been commonly applied to a wide variety of drugs 
(Zhao et al., 2009b, Youdim et al., 2004, Tournier et al., 2015, Suzuki et al., 2015, 
Cisternino et al., 2001, Alata et al., 2014).  
 
In-vivo molecular imaging approaches such PET has also been widely used to 
investigate BCRP function at the BBB in a BCRP wild-type and knockout mouse model 
(Takashima et al., 2013) for a range of radiolabelled compounds including [11C] 
tariquidar, [125I]-or [3H]-Aβ peptides (Zhang et al., 2013), [11C] sorafenib (Asakawa et 
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al., 2011) , [11C] XR9576(Kawamura et al., 2010) and [11C] elacridar (Bankstahl et al., 
2013).  
 
1.7. The regulation of BCRP at the BBB and BCSFB 
 
The transcriptional regulation of BCRP at both the BBB and BCSFB, as with many ABC 
transporters, is thought to be governed by a range of nuclear hormone receptors (Wang 
and Negishi, 2003, Xu et al., 2005) and the interference of these signalling pathways 
under physiological and pathophysiological conditions provides a new approach to 
modulate BCRP function at the CNS barrier (Mahringer and Fricker, 2010, Hartz and 
Bauer, 2011, Bauer et al., 2006). Many members of the nuclear receptor superfamily 
are known to regulate drug transporters includes the pregnane-X-receptor (PXR), the 
constitutive androstane receptor (CAR) and the aryl hydrocarbon receptor (AhR) 
(Jacob et al., 2011, Xu et al., 2005, Dauchy et al., 2008a, Granberg et al., 2003) (Table 
1.3). The regulation of many of the transporter proteins is controlled by endogenous 
and exogenous compounds which act to activate the receptors and subsequently leads 
to changes in transporter gene expression.  
 
 Table 1.3: Regulation of drug transporters by nuclear hormone receptors  
Nuclear receptor Drug transporters 
PXR P-gp (Bauer et al., 2004, Narang et al., 2008a, Ott et 
al., 2009, Chan et al., 2011), BCRP and Mrp2 (Narang 
et al., 2008a)  
GR P-gp and BCRP(Narang et al., 2008a) 
CAR P-gp,  Mrp2 (Narang et al., 2008a, Wang et al., 
2010),BCRP(Lemmen et al., 2013)  
PPARα BCRP (Hoque et al., 2012) 
ER BCRP(Hartz et al., 2010, Mahringer and Fricker, 2010, 
Imai et al., 2005b, Wang et al., 2006, Wang et al., 
2008b) 
AhR P-gp, BCRP and Mrp2 (Wang et al., 2011, Fernandez-
Salguero et al., 1996, Guo et al., 2000, Tompkins et al., 
2010).  
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PXR is a xenobiotic-activated nuclear transcription factor which translocates from the 
cytoplasm to the nucleus following ligand binding, leading to transcriptional activation 
of a range of drug metabolising enzymes and transporter proteins (Geick et al., 2001a, 
Kast et al., 2002, Xu et al., 2005). A large number of endogenous and exogenous 
compounds can activate PXR and include St.John’s wort, bile acids, steroids and 
antibiotics (di Masi et al., 2009, Mahringer et al., 2011, Chang, 2009). PXR has been 
found to be expressed in rat brain capillaries (Bauer et al., 2004) and regulates phase-
I metabolising enzymes such as CYP3A4, CYP2B6, CYP2Cs, and CYP7A and phase-
II metabolising enzymes such as sulfotransferases (SULTs), glutathione S-
transferases (GSTs) and UDP-glucuronosyltransferases (UGTs) (Wang and LeCluyse, 
2003, Geick et al., 2001b). PXR also regulates the expression of ABC drug transporters 
such as P-gp (Bauer et al., 2004, Geick et al., 2001b), Mrp2 (Bauer et al., 2008a, 
Johnson et al., 2002) and Mrp3 (Teng et al., 2003). Pregnenolone 16α-carbonitrile 
(PCN) and dexamethasone, both ligands for rodent PXR increased the expression of 
P-gp, Mrp1 and BCRP in the rodent brain capillaries (Bauer et al., 2006, Narang et al., 
2008b, Bauer et al., 2004). 
 
CAR functions in the similar way as PXR and demonstrating an overlapping ligand 
profile as PXR (Moore et al., 2003). Typical ligands for CAR includes bile acids, 
environmental pollutants and therapeutic drugs (Stanley et al., 2006). Wang et al 
(Wang et al., 2010) identified the expression of CAR in rat and mouse brain capillaries 
and demonstrating that it plays a role in regulation of ABC transporters.  
 
Cyclooxygenase-2 (COX-2) is an enzyme involved in the production of prostanoids and 
a key enzyme involved in the development of inflammatory responses. The role of 
COX-2 in the regulation of drug transporters proteins have been demonstrated in a 
number of studies.  Bauer et al (Bauer et al., 2008b) reported that the expression of       
P-gp was increased in isolated rat brain capillaries when exposed to glutamate and that 
P-gp expression was attenuated by using an NMDA receptor antagonist and COX-2 
inhibitors. The study suggested that the inhibition of COX-2 can enhance the uptake of 
antiepileptic drugs (Bauer et al., 2008b). This study was further supported by 
Schlichtiger et al (Schlichtiger et al., 2010), where exposure to celecoxib, a COX-2 
inhibitor, significantly reduced the occurrence of seizures in a phenobarbital-resistant 
epilepsy rat model. In a further study by Yousif et al (Yousif et al., 2012), the expression 
of BCRP and P-gp was increased after exposure to morphine in rat brain vessels. This 
up-regulation was reversed in the presence of MK-801 (NMDA antagonist) and 
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meloxicam (COX-2 inhibitor), suggesting the role of NMDA and COX-2 in regulation of 
BCRP and P-gp in the rat brain. 
 
The regulation of drug transporter proteins at CNS barriers (primarily the BBB) has 
been limited, and regulation has largely been demonstrated for a limited range of 
transporters by nuclear receptors such as PXR, CAR, Estrogen receptor (ER) and AhR 
(Bauer et al., 2004, Bauer et al., 2006, Hartz et al., 2010).   
 
The regulation of BCRP has largely been under-researched and is currently not well 
characterised.  In the 5’-flanking section of the gene promoter region of BCRP a novel 
estrogen responsive element (ERE) is present and it is thought that transcriptional 
regulation of BCRP may involve the activation and binding of 17-β-estradiol (E2) within 
an estrogen receptor (ER) complex (Ee et al., 2004a). Hormonal regulation of BCRP 
by progesterone and testosterone was further identified and studied in human placental 
BeWo cells. These studies confirmed that progesterone and testosterone increased, 
whereas E2 decreased, the mRNA and protein expression of BCRP in human placental 
BeWo cells (Wang et al., 2008b, Wang et al., 2006). Other studies have also 
demonstrated that E2 plays a significant role in down regulating BCRP expression in 
brain capillaries (Hartz et al., 2010) (Mahringer and Fricker, 2010).   
 
Cytokines such as tumour necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) have 
also been shown to down-regulate BCRP mRNA expression in primary porcine brain 
endothelial cells (von Wedel-Parlow et al., 2009) human hCMEC/D3 cells (Poller et al., 
2010). 
 
1.8. Regulation of BCRP by the Aryl Hydrocarbon Receptor 
 
The aryl hydrocarbon receptor (AhR) has been reported to be highly expressed in the 
kidney, liver, whole brain, brain microvessels and the choroid plexus (Dauchy et al., 
2008a, Jacob et al., 2011) (Dauchy et al., 2008a, Dauchy et al., 2009, Kainu et al., 
1995). The prototypical ligand for the induction of AhR activity are dioxins such as the 
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and induction of AhR activity by TCDD was 
first studied in hepatic cells (Poland et al., 1976). The majority of the genes known to 
be regulated by AhR are involved in xenobiotic metabolism and include CYP1A1, 
CYP1A2 and CYP1B1 (Nebert et al., 1993) (Nebert et al., 2000).   
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1.8.1. Structure and function of AhR 
 
AhR is a member of the bHLH-PAS family of DNA-binding proteins. The bHLH domain 
is a specific DNA binding domain and the HLH region interacts with cellular proteins 
such as the AhR nuclear translocator (ARNT) and chaperone proteins such as the heat 
shock protein 90 (HSP90) (Figure 1.10).  
 
The PER-ARNT-SIM (PAS) signalling domain plays an important role in controlling a 
conformational change in the structure of the AhR complex upon ligand binding 
(Fukunaga et al., 1995, Hoffman et al., 1991). 
 
 
 
 Figure 1.10: Schematic representation of the AhR domain.  
The bHLH motif is present at the N-terminal and facilitates the binding of transcription factor to DNA. PAS 
acts as a ligand binding domain and the C-terminal region consists of transcriptional activation domain.  
 
 
 
AhR is located in the cytoplasm and agonist binding at the PAS domain leads to a 
conformational change in the receptor (Wilhelmsson et al., 1990). This conformational 
change alters its binding with chaperones and as a result of this, the receptor complex 
migrates into the nucleus (Ikuta et al., 1998, Ikuta et al., 2000).  Within the nucleus of 
the cell, AhR then undergoes heterodimerisation with another bHLH-PAS protein ARNT 
(T et al., 1998, Reyes et al., 1992). The AHR/ARNT heterodimer complex then interacts 
with the responsive elements of the target genes and leads to activation of target genes 
expression.  When in the nucleus of the cell, AhR dissociate from its chaperones and 
the resulting AhR translocate to the cytoplasm where it can be degraded by 
proteasomes, a process that can be inhibited when using proteasome inhibitors such 
MG-132 (Davarinos and Pollenz, 1999). 
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At the BBB, AhR regulates the expression of drug metabolising enzymes such as 
CYP1A1 and CYP1B1 and ABC transporters (Granberg et al., 2003, Dauchy et al., 
2008a). Guo et al (Guo et al., 2000) treated MCF10A-Neo cells (transfected human 
breast cancer epithelium cell) with the AhR ligand TCDD and found the transcriptional 
activation of CYP1A1. Jacob et al (Jacob et al., 2011) examined rat brain microvessels 
after exposure to a range of AhR ligands such  as TCDD, Δ9-tetrahydrocannabinol (Δ9-
THC) and diesel exhaust particles. It was reported that AhR activation mediated the 
up-regulation of CYP1A1 gene and protein after exposure, which was capable of being 
reversed using the AhR antagonist CH-223191.  
 
Whilst most studies have focused on the role of AhR in regulating the expression of 
xenobiotic metabolism pathways (e.g. CYP isozymes), a few studies have 
demonstrated the role AhR plays in regulating BCRP expression. 3-
methylcholanthrene (3MC) is a known AhR agonists and has shown to activate 
estrogen receptor-α (Abdelrahim et al., 2006). Tompkins et al (Tompkins et al., 2010) 
demonstrated AhR mediated an 80-fold induction of BCRP in LS174T cells when 
exposed to 3MC, which was reduced by 65% in AhR  knockdown cells (Tompkins et 
al., 2010). Wang et al (Wang et al., 2011) demonstrated that TCDD up-regulated the 
expression and transporter activity of BCRP in rat brain capillaries. In a further study 
by Campos et al (Campos et al., 2012), exposure of TCDD to rat spinal cord capillaries 
increased protein expression of BCRP. 
  
AhR is therefore an important regulatory element in controlling the homeostatic balance 
of xenobiotic transporter/clearance pathways, but is also a potentially important target 
for modulating the expression of drug transporter proteins such as BCRP at the BBB 
and BCSFB, with a view to enhancing the delivery of therapeutic agents into the CNS. 
This is particularly important when considering the poor progress made in the clinical 
translation of BCRP inhibitors, which have demonstrated in-vitro inhibition of BCRP.  
First generation inhibitors of BCRP such as cyclosporine A and verapamil showed 
limited clinical efficacy in trials due to significant toxicity and interaction with drug 
metabolising enzymes cytochrome P450 3A (CYP3A) (Suzuki and Sugiyama, 2000). 
Second generation inhibitors such as topotecan, irinotecan and SN-38 are analogous 
of first generation inhibitors and also possess both cellular toxicity and an ability to 
mediate drug–drug interactions at the level of phase-I metabolic enzymes. Third 
generation inhibitors represent molecules that have been recently developed and 
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include fungal toxins such as fumitremorgin-C and Ko143, but their use is limited due 
to severe neurotoxicity (Nutton, 1973, Allen et al., 2002a) (Allen et al., 2002b).  
 
Whilst the activity of many inhibitors of BCRP is positive, their toxicity often precludes 
clinical progression. Therefore there is a need to identity and develop newer inhibitors 
or modulators of both drug transporters and their regulatory elements to enable a broad 
approach to the modulation of the transport function at CNS barriers. One potential 
novel group of candidate compound which are often perceived as being ‘safe’ are 
natural product derived phytochemicals, typically flavonoids, which have demonstrated 
an ability to modulate the expression and function of xenobiotic clearance pathways 
(Frixione, 2006, Spector et al., 2015, Lindsey and Papoutsakis, 2012, Tan et al., 2010). 
Flavonoids are a class of polyphenolic compounds that are found in fruits, vegetables 
and wine.  Previous reports demonstrated that flavonoids belonging to the subclasses 
of flavones, flavonols, flavanones and catechins are able to act directly as AhR 
antagonists (Ashida et al., 2000, Ciolino et al., 1998a, Nishiumi et al., 2007b) and hence 
may present as a viable group of candidate molecules with which to exploit the 
modulation of target gene activity, i.e. BCRP in the CNS, as a novel mechanisms to 
reverse the barrier function BCRP provides to drug entry into the brain and wider CNS. 
1.8.2. Structure of flavonoids 
 
Over 6500 compounds has been identified as belonging to the general category of 
‘flavonoids’ (Morris and Zhang, 2006). Flavonoids consists a backbone of two aromatic 
rings (A and C ring) and a heterocyclic benzene ring (B ring) (Figure 1.11). Flavonoids 
are divided into several sub-groups based on the position of the substitution group (Rx) 
attached and level of oxidation (Middleton Jr, 1998). The main subclasses includes: 
flavones (e.g. flavone), flavonols (e.g. quercetin, fistein), flavonones (e.g. flavanone, 
hesperetin and naringin), flavanonol (e.g. taxifolin), isoflavones (e.g. genistein, 
daidzein), flavan-3-ols (e.g. catechin , epicatechin) (Narayana et al., 2001).   
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 Figure 1.11: The structure of flavonoid.   
Flavonids consist of two aromatic rings (A and B) linked through three carbons that usually form a 
heterocyclic ring (C). Based on the pattern of hydroxylation and substitution (Rx), there are 7 subclasses 
of flavonoids. 
 
1.8.3. Systemic absorption and permeation of the BBB and BCSFB 
 
The dietary ingestion of flavonoids results in the exposure of the gastrointestinal system 
to the glycoside conjugate form of the flavonoids, which often possess limited 
absorption into the systemic circulation (Donovan et al., 2006). Within the stomach and 
small-intestine, these glyosidic forms come into contact with lactase phloridzin 
hydrolase (LPH), which results in an aglycone form of the flavonoids which is then 
absorbed by passive diffusion (Day et al., 2000).  When passing through the small-
intestine and liver, the aglycone form of most flavonoids are then exposed to metabolic 
pathways resulting in the final form found in the circulation being the sulfate, 
glucuronide and/or methylated metabolites as a result of the action of sulfotransferases 
(SULT), uridine-5′-diphosphate glucuronosyltransferases (UGTs) and catechol-O-
methyltransferases (COMT) (Donovan et al., 2006). It is therefore unlikely that the 
conjugated form of the flavonoids would naturally be capable of crossing the BCSFB 
or BBB. 
 
The ability of flavonoids to cross both the BBB and BCSFB and reach the brain/CNS 
biophase has been investigated. In cell culture systems the permeability of naringenin 
and hesperetin (30 μM) have been demonstrated in two brain endothelial cell lines 
(mouse b.END5 and rat RBE4) and an in-vitro model of the BBB (ECV304 cells co-
cultured with C6 glioma cells) (Youdim et al., 2003).  Furthermore the aglycone form of 
flavonoids demonstrated a significantly greater penetration across the BBB compared 
to the conjugated form [aglycone: naringenin (Papp=350 nm/s) and hesperetin (Papp = 
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290 nm/s); conjugated (Papp = 113-182 nm/s)] (Youdim et al., 2003).  In an in-situ rat 
brain perfusion model the aglycone form of [3H]-naringenin was detected in most brains 
regions (Youdim et al., 2004). In-vivo studies in rats have demonstrated that 
kaempferol and isorhamnetin were detected in brain tissues (293 ng/g brain) and high 
concentrations of quercetin detected in the hippocampus, stratum and cerebellum, with 
levels exceed 1000 ng/g protein, following the administration of a standard extract of 
Ginkgo biloba (extract EGb761) given to rats at a single dose of 600mg/kg (Rangel-
Ordonez et al., 2010).  Furthermore Peng et al (Peng et al., 1998) demonstrated that 
the aglycone form of naringenin was detected in the cerebral cortex of rats following an 
IV bolus dose. 
 
1.8.4.     Flavonoids as modulators of BCRP efflux function 
 
As a result of their ability to penetrate the BBB and BCSFB, flavonoids have also been 
shown to act directly upon BCRP. Quercetin, genistein and 17-β-estradiol were able to 
prevent the efflux of the BCRP substrate mitoxantrone in MCF-7 cells with limited 
accumulation in BCRP knockdown cells (Zhang and Morris, 2003).  In another study, 
the effects of flavonoids on mitoxantrone accumulation in both MCF-7 MX100 and NCI-
H460 MX20 cells were investigated for apigenin, biochanin A, chrysin, genistein and 
kaempferol and which all demonstrated high BCRP inhibition activity and significantly 
increased mitoxantrone accumulation (Zhang and Morris, 2003). In a robust screening 
study 20 out of 33 flavonoids screened in K562/BCRP possessed BCRP inhibition 
properties, with 3',4',7-trimethoxyflavone showing the strongest inhibition (Katayama et 
al., 2007).  In a recently study a number of grape-fruit juice constituents (bergamottin, 
6′,7′-dihydroxybergamottin (DHB), quercetin, and kaempferol), orange juice 
constituents (tangeretin and nobiletin) and apple juice constituents (hesperetin) greatly 
inhibited BCRP-mediated dasatinib efflux at the concentration of 50 μM (p < 0.001) 
(Fleisher et al., 2015).  In another study, the role of phytochemicals such as quercetin, 
epicatechin, chrysin, genistein, curcumin, resveratrol and flavone on their ability to 
modulate BCRP gene expression was investigated (Ebert et al., 2007).  
 
1.8.5. Flavonoids as modulators of AhR function 
Only a few studies have previously been reported demonstrating the 
agonist/antagonism of AhR regulatory functions by flavonoids (Mukai et al., 2010, 
Ashida et al., 2000, Nishiumi et al., 2007a, Ciolino et al., 1998b) with the ability to 
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modulate AhR function being concentration dependent (Nishiumi et al., 2007a, Ciolino 
et al., 1998b). At concentrations of 10 μM apigenin and kaempferol have been shown 
to suppress the transformation of AhR by hindering the dissociation of HSP90 and and 
hepatitis-B virus X-associated protein 2 (XAP2), which are important complexes formed 
during the functional role of AhR. Apigenin and kaempferol suppress the dissociation 
of these proteins in Hepa-1c1c7  and hence antagonise the function of AhR (Mukai et 
al., 2010).  In HepG2 cells, quercetin (25 μg/mL) and kaempferol (20 μg/mL) 
demonstrated activation of AhR (Li et al., 2009). Resveratrol (0.5-20 μM) has shown to 
inhibit CYP1A1 expression by preventing the binding of AhR to the promoter sequences 
which induces CYP1A1 transcription (Ciolino et al., 1998b).  
 
1.9.  Novel approaches to modulating BCRP function at the CNS barriers 
BCRP expression and function at the BBB and BCSFB has been studied in a number 
of cellular and in-vivo systems, with a large body of research supporting the view that 
BCRP is a vital transporter and gatekeeper directly affecting the pharmacokinetics of 
drug delivery to the CNS. Existing approaches to modulate its activity, to overcome its 
efflux properties and thereby enhancing delivery of therapeutic agents into the CNS 
shows promise in-vitro, but there is paucity in the clinical translation of such inhibitors.  
 
It is also clear that the regulation of BCRP is highly controlled by nuclear hormone 
receptors, and a clear relationship between the expression of BCRP and AhR has 
recently been identified and reported by Tan et al (Tan et al., 2010). In an attempt to 
identify new and novel candidates that can modulate the activity and function of BCRP, 
phytochemicals are of increasing interest due to their relatively large dietary intake and 
apparent lack of associated cytotoxicity. Furthermore, clear evidence is now available 
demonstrating the ability of phytoestrogens such as flavonoids to both directly inhibits 
the function of BCRP and to modulate the activity of AhR.   
 
When considering the fact that many of these flavonoids are capable of crossing the 
BBB (and potential therefor the BCSFB), phytoestrogens/flavonoids are potentially 
viable novel leads for modulating BCRP expression and function at the BBB and 
BCSFB to enhance CNS drug delivery. 
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1.10. Aims and Objectives  
The overall aim of the thesis was examining the approaches that can modulate the 
expression of BCRP at the BBB and BCSFB with the phytochemicals using in-vitro 
porcine and rat cell culture models respectively. Furthermore, the work also investigated 
the AhR mediated transcriptional regulation of BCRP at the BBB and BCSFB. 
To achieve the aims the overall objectives were: 
 To demonstrate the expression of BCRP in PBMEC/C1-2 and Z310 cells 
 Evaluate the cytotoxicity profile of phytochemicals for BBB and BCSFB in-vitro 
cell culture models 
 Investigate the modulation of genomic, protein and transport expression of BCRP 
in the cell culture models 
 Evaluate the modulation of BCRP and AhR following phytochemical exposure 
 Silencing AhR gene to investigate the AhR mediated modulation of BCRP gene 
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    Chapter 2 
 
Assessment of the interactions of 
phytochemicals on BCRP expression 
and function at the porcine blood brain 
barrier 
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2.1.    Introduction 
 
Microvascular brain endothelial cells act as a primary physical and cellular barrier to 
the delivery of drugs and therapeutic agents into the brain and wider CNS. These cells 
are formed into an intricate network of cerebral capillaries and, at a cellular level, are 
held tightly together by tight junctional proteins to form the blood-brain barrier. A range 
of in-vitro models are commonly used to assess the extent to which new therapeutic 
entities are able to permeate the BBB, and a primary goal of many of these models is 
to assess the potential impact of membrane localised drug transporter proteins, such 
as BCRP, on controlling the permeation of drugs across the BBB. Inhibition of BCRP 
at the BBB has been demonstrated to lead to significantly enhanced penetration of 
BCRP substrates into the brain (Shi et al., 2007). However, many known inhibitors of 
BCRP demonstrate neurotoxicity and have shown limited success clinically (Allen et 
al., 2002b). Approaches are therefore required to identify alternative compounds that 
can diminish the function of BCRP at the BBB to enhance CNS drug delivery.   
Natural compound phytochemicals, such as flavonoids, represent a group of natural 
substances found in fruit, vegetables, grains, tea and wine. Furthermore many 
flavonoids have been shown to directly impact upon the function of BCRP at the BBB 
(Zhang et al., 2000) (Hartz et al., 2010) (Zhang and Morris, 2003) and hence have 
gained increasing interest as modulators of BCRP function. 
2.2.    Aims and objectives 
The aim of the chapter is to characterise the expression of BCRP at the BBB and to 
examine approaches that enable modulation of BCRP at the BBB with phytochemical 
(primarily flavonoids) compounds using a porcine brain microvascular endothelial cell 
culture model (PBMEC/C1-2) and primary porcine brain microvascular endothelial cell 
culture model.  
To achieve the aims the overall objectives were: 
 To demonstrate gene and protein expression of BCRP in PBMEC/C1-2 cells  
 To investigate the cytotoxicity of phytochemical modulators towards 
PBMEC/C1-2 cells 
 Evaluate the modulation of genomic and protein expression and transport 
function of BCRP when exposed to phytochemical modulators in PBMEC/C1-2 
cells 
54 
  
 Isolation and growth of primary porcine endothelial cells in specific cell culture 
conditions and determine the expression of BCRP and evaluate the modulation 
of BCRP transport function in PBMEC/C1-2 cells 
 Evaluate the modulation of transport function of BCRP when exposed to 
phytochemical modulators in a primary BBB cell culture model 
 
2.3.    Materials 
 
Hams F12, IMDM and Dulbecco’s modified essential media with glucose (DMEM), new 
born calf serum (NCS), fetal bovine serum (FBS), penicillin/streptomycin and L-
glutamine were obtained from Biosera (Sussex, UK); GenElute Total RNA extraction 
kits were purchased from Sigma (Dorset, UK); Rat tail I collagen solution from First Link 
(Birmingham, UK) and unless otherwise indicated all other chemicals were obtained 
from Sigma (Dorset, UK). My TaqTM One-step RT-PCR kit and Easy Ladder I obtained 
from Bioline (London, UK).  All reverse transcriptase PCR primers were synthesised by 
IDTDna (Leuven, Belgium); Resveratrol and Ko143 from Santa Cruz Biotechnology 
(Texas, USA); Curcumin from Cayman Chemical (Cambridge, UK); Real time PCR 
housekeeping gene primers were obtained from Invitrogen and BCRP primers were 
obtained from PrimerDesign (Sheffield ,UK); total RNA extraction kits were purchased 
from Qiagen (Manchester, UK) and qPCR master-mixes were obtained from 
PrimerDesign (Sheffield ,UK). Optiblot SDS-page gel and western blot reagents 
obtained from Abcam (Cambridge, UK); ABCG2 antibody, beta-actin (C4), broad range 
markers, goat anti-rabbit IgG-FITC and protease inhibitor cocktail were obtained from 
Santa Cruz Biotechnology (Texas, USA). Stock solutions of all test compounds were 
prepared in dimethylsulfoxide (DMSO) and stored at -20°C until use. 
 
A total of 18 phytochemical derived modulators were selected for studies and their 
structures are detailed in Appendix A. 
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2.4.    Methods 
 
2.4.1.  Culture of C6 rat astrocytes 
 
C6 cells were obtained from Cell Line Services (Germany). The cells were 
resuspended in a T25 flask containing C6 media (Hams F12 50%, IMDM 50%, 7.5% 
NCS, 7mM L-glutamine, 5µg/mL transferrin, 0.5U/mL heparin and 100 U/mL penicillin 
G sodium, 100 μg/mL streptomycin sulphate). Cells were grown at 37°C in a humidified 
atmosphere of 5% CO2 for 24 h and media changed after 24 h. Thereafter the cells 
were passaged 3-4 days post seeding (at 70-80% confluency) by washing with pre-
warmed PBS followed by the addition of 1 mL of trypsin-EDTA to the flask. The flask 
was then placed in an incubator for 5 min and cell suspension was resuspended in 5 
mL of growth media. Cell suspensions were then transferred to a 15 mL centrifuge tube 
and centrifuged at 1500 rpm for 5 min and the pellet was resuspended in 2 mL of the 
media and transferred to a T75. The media was aspirated every other day, sterile 
filtered (0.22 µm) and stored at 4°C for further use.  
This media was labelled as astrocyte conditioning media (ACM). 
 
2.4.2.  Culture of PBMEC/C1-2 cells 
 
2.4.2.1. Preparation and coating of an gelatine extracellular matrix 
 
PBMEC/C-12 cells do not demonstrate optimum growth on the plastic surfaces. In 
order to allow growth on cell culture surfaces, an extracellular matrix support was 
required to enhance attachment and proliferation. To support the growth of PBMEC/C1-
2 cells on plasticware, a 2 % w/v gelatine stock solution was prepared in the water by 
the addition of 4 g of gelatine powder to a sterilised bottle containing 200 mL of water. 
The suspension was autoclaved and stored at 4°C for further use.  
 
Each flask was coated with 1:5 dilution of the gelatine stock with cell culture water to 
obtain a final surface coating of 0.4 % w/v gelatine. The flasks were left to dry in a 
laminar airflow hood for 2 h to ensure thorough surface coating, and any excess 
gelatine was aspirated before the flasks were washed with cell culture water. 
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2.4.2.2. PBMEC/C1-2 cell growth on tissue culture surfaces 
 
PBMEC/C1-2 cells were a kind gift from Dr M.Teifel (Institut für Biochemie, Technische 
Hochschule Darmstadt, Germany). Cells were resuspended in a 50:50 mixture of C6 
media and ACM, referred to as PBMEC media, and seeded onto gelatine coated T25 
flasks. PBMEC media was replaced every other day until the cells reached confluency. 
Subsequently, PBMEC media was aspirated and cells were washed twice with the pre-
warmed PBS and incubated with 1 mL of a 0.25 % w/v trypsin-EDTA solution, sufficient 
to cover the entire cell layer. Flask were then incubated at 37°C in a humidified 
atmosphere of 5% CO2 in air with the slight agitation for 5 minutes. Once cells had 
detached, fresh PBMEC media was added to inactivate  trypsin and the cell suspension 
was transferred to a 15 mL centrifuge tube and centrifuged at 1500 rpm for 10 min. The 
supernatant was removed and cell pellet resuspended in 2 mL of PBMEC media and 
reseeded into appropriately coated plasticware for further use. The coating process 
was performed on all surfaces used to grow PBMEC/C1-2 cells including flasks, 6-well 
and 96-well plates. Approximately 3-4 days post seeding, the cell monolayers were 
examined under an inverted DMI400B microscope (Leica microscope systems (UK) 
Ltd, Milton Keynes, UK). 
 
2.4.2.3. Cryopreservation of the cells 
 
Cells were cryopreserved for further use by centrifugation a cell suspension at 1500 
rpm for 10 min to obtain a cell pellet, followed by resuspension of the pellet in 
cryopreservation media (10% DMSO and 90% PBMEC media). A 1 mL volume of the 
cell suspension was aliquoted to the cryovials and stored overnight at -80˚C in cell 
cooling box (Mr. Frosty, Nalgene®, Thermo Fisher Scientific, UK). After 24 h, cryovials 
were transferred to liquid nitrogen for long-term storage.  
 
 
2.4.2.4. Development of a permeable insert based BBB model 
 
To develop an in-vitro BBB model, 12-well permeable inserts (ThinCert® with 0.4µm 
pore size) were used as a support for cell growth, with the addition of a matrix coating 
of 5 µg/cm2 of rat-tail collagen. Inserts were left to dry for 3-4 h in a laminar airflow hood 
before excess collagen was aspirated and inserts washed twice with PBS. Cell 
suspensions were introduced into the apical chamber of coated inserts at a density of 
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1 x105 cells/cm2 with the basolateral chamber receiving PBMEC media only. Cells were 
grown for 3-4 days in PBMEC media supplemented with 1 µg/mL fibronectin to enhance 
attachment. Monolayer formation was monitored by measuring the transendothelial 
electrical resistance (TEER) using a voltohmmeter (EVOM) (World Precision 
Instrument) directly before and after all transport studies. TEER values were calculated 
as follows: 
 
TEER Values (Ω. cm2) = (RCell monolayer − RBlank filter)xA          (1) 
where A = Surface area of the permeable insert (cm2), RCell monolayer = Resistance across 
permeable insert with cell monolayer and RBlank filter = Resistance across permeable 
insert without cells. 
Control measurements were made using filters without cells (blank filter). The cut-off 
TEER values for an acceptable in-vitro model was set at 300 Ω.cm2 (Lauer et al., 2004).   
 
2.4.3. Cytotoxicity of modulators towards PBMEC/C1-2 cells: 
methylthiazolyldiphenyl-tetrazolium bromide assay 
 
Stock solutions of methylthiazolyldiphenyl-tetrazolium bromide (MTT) were prepared in 
DMSO. Sterile dilutions of each modulator across a 7-fold log concentration range of 
0.001 µM- 1000 µM were freshly prepared on the day. Culture media was used as the 
diluent and the final solvent concentrations did not exceed 1 % (v/v). 
 
PBMEC/C1-2 cells were seeded with a density of 15,000 cells per well onto clear flat 
bottom 96-well plates and incubated for 24 h to attach. The media was subsequently 
removed and fresh media containing the test compounds was added and incubated for 
24 h for subsequent experiments. The medium was then removed and cells were 
washed with the pre-warmed PBS and incubated with fresh media for 30 min. MTT 
powder was dissolved in PBS (5 mg/mL) and filtered through a 0.2 μm pore size. 20 
µL of the pre-warmed MTT solution was added to each well. The plates were protected 
from light and incubated at 37°C in a humidified atmosphere of 5% CO2 for 4 h. 
Thereafter the media was removed and 100µL of DMSO added to the each well to 
solubilise the purple formazan crystals. The plates were incubated for a further 10-15 
min at room temperature (RT). The UV-absorbance of the formazan product was 
measured on a multi-plate reader (Bio-Rad laboratories, Hercules, CA) using 570 nm 
as a test wavelength and 600 nm as a reference wavelength.  
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The mean of the blank UV-absorbance was subtracted from the UV-absorbance of 
each controls and samples and percentage viability was calculated. The percentage of 
cellular viability was calculated (Equation 2).  
 
% cell viability =
absorbance of sample
absorbance of control 
∗ 100           (2)   
  
The IC50 was subsequently calculated using a sigmoidal dose response function within 
the Graphpad Prism version 5.0 (GraphPad Software, Inc. USA). 
 
  
2.4.4. Immunostaining detection of BCRP in PBMEC/C1-2 cells 
 
PBMEC/C1-2 cells were grown on coverslips coated with 0.4 % w/v gelatine for 48 
hours. Media was then aspirated and coverslips were washed three times with pre-
warmed PBS. Cells were fixed with methanol at -20°C for 20 min and washed three 
times with pre-warmed PBS before being rehydrated in PBS for 20 min at room 
temperature. Blocking solution (1 % goat serum in PBS) was added to the coverslips 
and incubated for 30 min at room temperature. The coverslips were then incubated 
with primary anti-ABCG2 antibody (Sigma-Aldrich company ltd, Dorset, UK) (1:200) for 
2 h at 37 °C. Subsequently, the coverslips were washed twice with PBS and incubated 
with the secondary antibody fluorescein iso-thiocyanate (FITC)-labelled mouse anti-
rabbit IgG (1:500) in blocking solution, for 45 min at room temperature in the dark. The 
secondary antibody was then aspirated and cells were washed three times with pre-
warmed PBS.  The coverslips were then rinsed with sterile water and mounted onto the 
glass slide with mounting media containing 4',6-diamidino-2-phenylindole (DAPI). The 
staining of cells with anti-ABCG2 was analysed using an upright confocal microscope 
(Leica SP5 TCS II MP) and visualised with a 40x oil immersion objective. All images 
were acquired using an argon laser at 494 nm to visualise FITC and a helium laser to 
visualise DAPI at 461 nm.  
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2.4.5. Measurement of BCRP cellular functional activity in PBMEC/C1-2 cells 
 
2.4.5.1. Determination of PBMEC/C1-2 optimum seeding density and modulator 
incubation time  
To develop a high-throughput in-vitro screening system to detect modulators of BCRP 
the optimum seeding density of PBMEC/C1-2 cells was assessed to enable the 
intracellular detection of the BCRP substrate H33342. Cells were seeded at densities 
of 1000, 20,000, 50,000 and 100,000 cells per well of a 96-well plate and left to adhere 
for 24 h. Wells were subsequently washed twice with pre-warmed PBS at 37 °C. 100 
µL of PBMEC media containing 10 µM Hoechst 33342 was added to each well and 
incubated for 30 min, 60 min and 90 min at 37°C. Cells were washed twice with warm 
PBS and lysed by storing plates at -80°C for 20 minutes before resuspending in pre-
warmed PBS. The fluorescence of H33342 was determined on a fluorescent plate 
reader with an excitation wavelength of 355 nm and emission wavelength of 460 nm. 
 
2.4.5.2. Functional activity of BCRP in PBMEC/C1-2 using a 96-well plate assay 
The functional activity of BCRP in PBMEC/C1-2 cells was assessed using Ko143, a 
known potent inhibitor of BCRP. 20,000 cells per well were seeded into a 96-well plate 
and allowed to attach for 24 h. Thereafter cells were washed with pre-warmed PBS at 
37°C and fresh media added containing 3.9 nM-5 µM Ko143 and left to pre-incubate 
for 1 h. 100 µL of media containing 10 µM of H33342 and 3.9 nM-5 µM Ko143 was then 
added to the appropriate wells and incubated for a further 30 min at 37°C. Wells were 
then washed twice with ice cold PBS and cells lysed by storage of plates at -80°C for 
20 min before being read on a fluorescent plate reader at an excitation wavelength of 
355 nm and emission wavelength of 460 nm. 
2.4.5.3. Assessment of the intracellular accumulation of H33342 in the presence 
of modulators. 
 
Prior to assessment the impact of modulators on intracellular H33342 accumulation, 
the auto-fluorescence of all modulators was determined. Non-toxic concentrations of 
modulators were prepared in cell culture media and 100 µL added to wells of a 96-well 
plate with H33342 (10 µM) acting as a positive control and a fluorescent substrate for 
BCRP and prepared in the cell culture media with 100 µL added to wells of a 96-well 
plate. The fluorescence of flavonoids was measured using a fluorescent plate reader 
60 
  
at an excitation wavelength of 355 nm and emission wavelength of 460nm and 
compared to the fluorescence obtained from H33342.   
 
The potential for modulators to alter the functional activity of BCRP was then assessed 
by measuring changes in the intracellular accumulation of H33342 in the absence and 
presence of modulators. PBMEC/C1-2 cells were seeded onto clear-bottomed 96-well 
plates for 24 h, where optimal seeding densities and incubation times were determined 
from previous experiments (section 2.4.5.1). To assess the potential for direct inhibition 
of BCRP function, cells were washed with pre-warmed PBS at 37 °C and pre-treated 
with 25 µM of modulators (unless or otherwise stated) and incubated at 37 °C for 1 h. 
Cells were also incubated with 1 µM Ko143 for 1 h (used as a positive control 
comparator). Following pre-incubation with modulators, media was removed and cells 
were washed twice with pre-warmed PBS at 37 °C before the addition of 10 µM H33342 
containing 25 µM of modulators (unless otherwise indicated) and incubated for a further 
30 min. Thereafter cells were washed twice with ice cold PBS and lysed at -80°C for 
20 min before being resuspended in 100 µL of water and fluorescence measured with 
dual-scanning microplate spectroflurometer (Spectra Max Gemini XS, molecular 
devices, Sunnyvale, California) at an excitation wavelength of 355 nm and emission 
wavelength of 460 nm. 
To assess the potential for modulation of BCRP protein expression, cells were washed 
with pre-warmed PBS at 37°C cells and incubated with 25 µM of modulators (unless 
otherwise stated) for 24 h in PBMEC media at 37°C. Following pre-incubation with 
modulators, media was removed and cells were incubated fresh PBMEC media 
(without modulators) for 1 hour (wash-out period).  Thereafter the media was removed 
and cells washed twice with pre-warmed PBS at 37°C before the addition of 10 µM 
H33342 for 30 min.  At the end of the incubation period cells were washed twice with 
ice cold PBS and lysed at -80°C for 20 min before being resuspended in 100 µL of 
water and fluorescence measured with dual-scanning microplate spectroflurometer 
(Spectra Max Gemini XS, molecular devices, Sunnyvale, California) at an excitation of 
wavelength of 355 nm  and emission wavelength of  460 nm. 
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2.4.6.  Determination of BCRP gene expression by reverse-transcriptase PCR 
(RT-PCR) in PBMEC/C1-2 cells 
 
2.4.6.1. Extraction of total RNA 
RNA was extracted according to the manufacturer’s instructions (RNeasy® Mini kit, 
Qiagen). In brief, 50,000 cells per well were seeded in a 6-well plate. Cells were washed 
twice with PBS and 350 µL of the RLT buffer was added to each well. 350 µL of the 70 
% ethanol was added and mixed by pipetting up and down. The lysate was transferred 
to the RNeasy mini spin column placed in 2 mL collection tube and centrifuged for 15 
s at 8000 g. The flow through liquid was discarded and 700 µL of the RW1 buffer was 
added to the column and centrifuge for 15 s at 8000 g and flow through liquid was then 
discarded. 500 µL of the RPE buffer was added to the column and spun for a further 2 
min at 8000 g and the flow through liquid was discarded and column was placed into a 
2 mL collection tube. 30-40 µL of RNA free water was added to the column and spun 
for 1 min at 8000 g. The final resultant RNA was collected in the collection tube and 
aliquoted before being stored at -80°C for further use. 
2.4.6.2. One-step reverse-transcriptase PCR 
A one-step PCR reaction was setup using 80 ng of the template RNA, 
spectrophotometrically determined using a NanoDrop 1000 spectrophotometer 
(ThermoScientific, UK). The ratio of UV-absorbance at 260 nm and 280 nm was used 
to determine the purity of the sample. PCR tube reactions were setup as detailed in 
Table 2.1. 
Table 2.1: Preparation of PCR samples 
Reagents     Volume 
My Taq One-Step Mix  25 µL 
Primer Forward   1.5 µL 
Primer Reverse   1.5 µL 
Reverse Transcriptase Enzyme 0.5 µL 
Ribosafe Inhibitor   1 µL 
DEPC Water   15.5 µL 
Template (80 ng)     5 µL 
Total Volume     50 µL 
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Forward and reverse primers (HKG: β-actin; GOI: BCRP) were designed using the 
PrimerQuest tool (http://www.idtdna.com/primerquest/home/index) and custom 
synthesised (IDTDna, Germany) (Table 2.2).  The thermal cycling was conducted using 
a Hybaid OmniGene Thermal Cycler using a three-step protocol (Table 2.3) 
Table 2.2: Primers used for RT-PCR 
Gene Size Forward Primers   Reverse Primers     
β-actin 806 AAGCCAACCGTGAGAAGATG CAACTAACAGTCCGCCTAGAAG 
BCRP 652 TCCGACCACCATGACAAATC GTACACCGAGCTCTTCTTCTTC   
 
Table 2.3: Thermal cycle reactions for PCR 
 
 
 
 
2.4.6.3. Gel electrophoresis 
Confirmation of a successful PCR product was assessed by gel electrophoresis.  A 2 
% w/v agarose gel was prepared in TAE buffer with 5 µL of ethidium bromide to allow 
visualisation under UV light. 6 µL of the PCR-product was mixed with 8 µL loading 
buffer and loaded into wells. Gel electrophoresis was carried out at 50 Volts for 1.5 h 
and visualised under a UV-transilluminator (Geneflash, Syngene Bioimaging, 
Cambridge, UK) with a 1kbp DNA ladder (Easyladder I) used as a marker ladder for 
size analysis. 
 
2.4.7. Determination of BCRP protein expression by SDS-PAGE and Western 
blotting in PBMEC/C1-2 cells 
 
2.4.7.1. Preparation of cell lysate 
PBMEC/C1-2 cells were grown on gelatine coated 6-well plates with a seeding density 
of 50,000 cells per well for 24 h and allowed to attach. Cells were trypsinised and 
centrifuged at 1500 g for 10 min and pellet was dissolved in 40 µL of RIPA buffer 
containing TBS, 1% nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, 0.004% 
    
Cycles   Temperature Time Procedure 
1  45°C  20 min Reverse Transcription 
1  95°C  1 min Polymerase Activation 
40  95°C  10 s Denaturation 
  55°C  10 s Annealing  
  72°C  30 s Extension   
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sodium azide, PMSF, protease inhibitor and sodium orthovanadate (Santa Cruz 
Biotechnology, Canada) and transferred to an ice cold Eppendorf’s tube before being 
sonicated for 10 s and centrifuged at 4°C at 16000 rcf for 30min. The supernatant was 
then aliquoted and frozen at -80°C until further use.  
To assess the impact of modulators on BCRP protein expression, PBMEC/C1-2 cells 
were grown on 6-well plates and incubated with modulators at 25 µM (unless otherwise 
stated) for a further 24 h. The media was aspirated and whole cell lysate was extracted 
as described above.  
2.4.7.2. Determination of protein concentration: bicinchoninic acid assay 
 
Total protein was quantified using a bicinchoninic acid (BCA) assay (Novagen, BCA 
assay protein kit). In brief, the assay is based upon the reduction of Cu2+ to Cu1+ by 
protein in an alkaline solution. Bicinchoninic acid is a chromogenic reagent that 
chelates with the reduced copper, producing a purple reaction complex with strong UV-
absorbance at 562nm. A standard curve with bovine serum albumin (BSA) was 
prepared in RIPA buffer. BCA working stock was prepared by adding 1 mL of BCA 
solution and 20 µL of the 4 % cupric sulphate just before use. 25 µL of the sample or 
BSA standards were added to the clear 96-well plate and 200 µL of BCA working stock 
was added and plate was incubated for 30 min at 37 °C and the UV-absorbance was 
measured using a multi-plate reader at 570 nm as a test wavelength and 600 nm as a 
reference wavelength (Bio-Rad laboratories, Hercules, CA). 
 
2.4.7.3. Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
Optiblot SDS-PAGE precast gels (8%) (Abcam, UK) were used to conduct SDS-PAGE 
electrophoresis. Optiblot SDS reducing running buffer (Abcam, UK) was prepared by 
the addition of 40 mL of Optiblot 20 X run buffer (Abcam, UK) and 760 mL of ultrapure 
water and stored at 4°C for further use. Samples for SDS-PAGE were prepared as 
outlined in Table 2.4. 
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         Table 2.4: Reagents composition for SDS-PAGE 
Reagents       Volume 
Sample    X µL 
Water    13-X µL 
LDS Loading Buffer 4X  5 µL 
DTT Reducer 10X     2 µL 
Total Volume     20 µL 
 
A total reaction volume of 20 µL (containing 50 µg of protein) was used for SDS-PAGE. 
Samples were heated at 37°C for 30 min. The gel cassette was placed in the tank and 
wells were washed twice with ultrapure water. 20 µL of the SDS-PAGE protein sample 
mix was loaded onto the gel in addition to 7 µL of a broad range marker (6-200 kDa). 
Approximately 400 mL of the running buffer was added to the outer chamber and tank 
was assembled. The gel was run at 180 V for at least 30 min or until the blue dye front 
neared the bottom of the cassette.  
2.4.7.4. Electrophoretic transfer and blotting of proteins 
A Bio-Rad mini trans-blot system was used to transfer the proteins from the gel to a 
polyvinylidene fluoride (PVDF) membrane. The blotting buffer was prepared while the 
SDS-PAGE was running, the trans-blot system and sponges were washed with distilled 
water and sponges were soaked in the blot buffer (Optiblot blot buffer supplemented 
with 20% methanol). The PVDF membrane was activated by subsequently transfer into  
methanol for 15 s, 2 min in ultrapure water and finally 5 min in blotting buffer. The gel 
was placed on the PVDF membrane and sandwiched between blotting paper and 
sponge pads. The electrophoresis tank was placed on ice and two ice packs were 
placed in the tank to avoid overheating. Electrophoretic transfer of protein was 
conducted with ice-cold buffer at 50 V for at least 2 h and 30 min. Following transfer 
membrane was washed in ultrapure water for 2 min, deactivated in methanol for 10 s 
and finally exposed to Ponceau stain (0.1 % w/v Ponceau S in 5% v/v acetic acid) for 
1 min to allow visual observation of the protein transfer.  
2.4.7.5. Immunological detection of BCRP 
Protein-transferred membranes were washed with TBST buffer for 30 min and blocked 
with blocking buffer (5 % w/v milk and TBST) for 1 h at room temperature. The 
membrane was then incubated with the polyclonal anti-ABCG2 antibody (Sigma-
Aldrich,UK) (1:4000) in blocking buffer and incubated for 24 h at 4 °C. Thereafter, the 
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membrane was placed onto an orbital shaker for 2 h before the antibody solution was 
removed and membrane washed with TBST for 30 min and blocked with blocking buffer 
for 30 min at room temperature. The membrane was then incubated for 2 h at room 
temperature with goat anti-rabbit IgG-horse radish peroxidise-conjugated (Santa Cruz 
biotechnology, Sc-2004) (1:7500) in blocking buffer.  
2.4.7.6. Chemiluminescent detection of BCRP 
Detection of BCRP was conducted using laboratory prepared enhanced 
chemiluminescent detection solution (Table 2.5), with 3 µL of solution B combined with 
per 1 mL of solution A prior to detection.  
Table 2.5: Chemiluminescent reagents 
 
 
 
 
 
The chemiluminescent solution was poured onto the PVDF membrane and incubated 
on an orbital shaker for 2 min, before the membrane was then placed on a transparent 
plastic film and transferred to a developing cassette. Subsequent steps were performed 
in a dark room. An X-ray film (CL-X Posure™ film, Thermo Scientific, Belgium) was 
placed on top of the membrane and the developing cassette was closed for 1 min. The 
membrane was carefully transferred to a fixer solution (Kodak GBX fixer, Sigma-
Aldrich, UK) for 10-20 s and then placed into the developer solution (Kodak GBX 
developer, Sigma-Aldrich, UK) for 30 s before being thoroughly washed with water and 
dried in the air for 2-4h.  
2.4.7.7. Membrane stripping 
Following BCRP detection, antibody was removed by membrane stripped using a mild 
stripping method adapted from Legocki and Verma (Bendayan et al., 2006) (Table 2.6). 
 
 
 
 
Solution  A Volume Solution B   Volume 
Coumaric acid (90 mM) 110 µL 30 % Hydrogen peroxide 100 µL 
Luminol (250 mM) 250 µL Ultra-pure water  900 µL 
Tris (1 M)   5 mL         
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Table 2.6: Composition of buffer used for stripping 
Reagents     Quantity 
Glycine   15 g  
SDS   1 g  
Tween 20 
Water 
    10 mL 
To 1000 mL   
 
The membrane was washed with TBST and sufficient stripping buffer added to cover 
the membrane, before being gently shaken on an orbital shaker for 10 min. The 
membrane was subsequently washed for 10 min, twice in PBS followed by twice with 
TBST in 2 min intervals before being blocked with TBST and milk for 1 h.  
2.4.7.8. Immunological detection of β-actin 
To reprobe the membrane for the loading control (β-actin) the membrane was 
incubated with blocking buffer, followed by mouse β-actin horseradish peroxidase 
conjugated monoclonal antibody (1:7500) in blocking buffer for 24 h at 4°C. The 
membrane was then washed with TBST for 45 min before β-actin was detected by a 
chemiluminescent detection approach (section 2.4.7.6). 
2.4.8. Modulation of BCRP gene expression by phytochemicals compound in 
PBMEC/C1-2 cells 
 
2.4.8.1. Extraction of RNA 
PBMEC/C1-2 cells were grown on gelatine coated 6-well plates for 24 h and modulators 
demonstrating BCRP protein induction or down-regulation were incubated with cells for 
24 h at, unless otherwise stated, 25 µM.  RNA was extracted as stated in section 
2.4.6.1. 
2.4.8.2. Reverse transcription 
 
A two-step reverse transcription protocol was utilised involving both annealing and 
extension steps. RNA samples were prepared as recommended by the manufacturer 
(Precision Nanoscript RT kit, PrimerDesign, UK). 
 
For the annealing step, the samples were prepared by the addition of 1 µL of gene 
specific RT primers, 600 ng of RNA template and a final volume of 10 µL was achieved 
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by the addition of RNase-free water. Samples were then transferred to a heat block for 
5 min at 65 °C.  For the extension step, the reagent were prepared as described in 
Table 2.7.  
 
     Table 2.7: Preparation of extension reagents 
Reagents       Volume 
Nano Script 10x Buffer  2 µL 
dNTP Mix 10mM   1 µL 
DTT 100mM   2 µL 
RNase-free Water   4 µL 
Nano Script Enzyme   1 µL 
Annealing mix end-product     10µL 
 
10 µL of the extension reagent mix was added to the 10 µL of each pre-heated sample 
and tubes were vortexed. Samples were then incubated at 55 °C for 20 min on a heat 
block before the temperature was raised to 75°C for 15 min. The subsequent cDNA 
was quantified spectrophotometrically and samples were stored at -20°C for future use.  
2.4.8.3. qPCR cycle parameters 
The qPCR reaction mixture was prepared as outlined in Table 2.8. 
Table 2.8: Preparation of qPCR samples 
Reagents       Volume 
10x Master Mix   10 µL 
Primer Forward (6 pmol)  1 µL 
Primer Reverse (6 pmol)  1 µL 
RNase-free Water   3 µL 
Template (25 ng)   5 µL 
Total Volume     20 µL 
 
qPCR primers were custom synthesised as follows: HPRT1 (NCBI Accession: 
NM_001032376.2) forward primer GGTCAAGCAGCATAATCCAAAG, reverse primer 
CAAGGGCATAGCCTACCACAA and a custom synthesised porcine BCRP (NCBI 
Accession: NM_214010) gene primers (PrimerDesign, UK).  qPCR was conducted 
using a Stratagene MX3000p thermal cycler (Agilent technologies, United States) with 
a SYBR-green detection probe and a two-step cycling protocol (Table 2.9). 
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  Table 2.9: qPCR cycles 
Cycles   Step   Time Temperature 
  Enzyme activation 2 min 95°C  
40 Cycles Denaturation 15 s 95°C  
40 Cycles Data Collection 60 s 60°C   
 
2.4.8.4. qPCR quantification method 
Relative quantification determines the mRNA changes in gene of interest (BCRP) 
relative to the levels of a housekeeping gene (HPRT1) RNA. Threshold cycle (Ct) 
values were determined and changes in the expression of target gene normalised with 
HPRT1 calculated for each reaction condition (ddCT method) (Livak and Schmittgen, 
2001) (see equation 3) 
Fold change = 2−∆(∆𝐶𝑡) (3)    
 where ΔCt = CT,BCRP-CT,HPRT1 
The efficiency of all genes were pre-validated for specificity by the manufacturer. 
2.4.9. Assessing the functional activity of BCRP in an in-vitro permeable insert 
BBB monolayer model 
 
2.4.9.1. Pheophorbide A (PhA) calibration curve 
To assess the function of BCRP in-vitro, the specific BCRP fluorescent substrate 
pheophorbide A (PhA) was used. Stock solutions of PhA were prepared in DMSO and 
a standard curve generated over a concentration range of 0.001 µM to 50 µM, prepared 
in serum free PBMEC media.  PhA fluorescence was quantified by transferring 100 µL 
of each standard solution into wells of a black 96-well plate before quantifying on a 
fluorescent plate reader at an excitation wavelength of 395 nm and emission 
wavelength of 670 nm using a dual-scanning microplate spectroflurometer (Spectra 
Max Gemini XS, Molecular Devices, Sunnyvale, California).  
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2.4.9.2. Optimisation of the in-vitro transport media 
 
Permeable PBMEC/C1-2 inserts were prepared according to section 2.4.2.4. TEER 
values were used as a measure of monolayer formation and suitability of transport 
media.  Preliminary experiments were performed to assess the integrity of monolayers 
when incubated with either HBSS supplemented with glucose (10 mM) and HEPES (10 
mM) or PBMEC serum free media (SFM). TEER values were determined after 30 min, 
60 min, 90 min, 120 min, 150 min and 180 min exposure to media. 
 
2.4.9.3. Lucifer yellow permeability assay 
To further assess the formation of a suitable monolayer, Lucifer yellow (LY) was used 
as a passive diffusion marker. Solutions of LY were prepared in SFM and added to the 
apical chamber of the inserts to achieve a final concentration of 100 µM, and LY-free 
SFM added to the basolateral chamber (1.5 mL).  The inserts were then placed on an 
orbital shaker at 100 rpm at 37 °C for 1 h.  Thereafter, a sample of the basolateral 
media was then collected and quantified for LY permeation on a fluorescent plate 
reader at an excitation wavelength of 428 nm and emission wavelength of 536 nm using 
dual-scanning microplate spectroflurometer (Spectra Max Gemini XS, Molecular 
Devices, Sunnyvale, California). The percentage transport of LY across the permeable 
inserts were calculated (Equation 4). 
% Lucifer yellow transported = 100 ∙ (1 −
𝑅𝐹𝑈𝑏𝑎𝑠𝑜𝑙𝑎𝑡𝑒𝑟𝑎𝑙
𝑅𝐹𝑈𝑎𝑝𝑖𝑐𝑎𝑙
)    (4) 
 
where RFUbasolateral is the relative fluorescence units in the sample taken from 
basolateral compartment and RFUapical is the relative fluorescence unit in the sample 
taken from the apical compartment. Inserts were rejected for permeability assays if the 
percentage LY transport was greater than 1 %. 
 
2.4.9.4. Modulation of BCRP transport function 
To assess the potential for phytochemical modulators to modulate the in-vitro 
transporter function of BCRP in the permeable insert BBB model, modulators identified 
as resulting in induction or down-regulation of BCRP protein from western blotting 
studies (section 2.4.7) were selected to then assess their potential to modulate the 
efflux of PhA.  PBMEC/C1-2 seeded permeable inserts were washed with pre-warmed 
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PBS and freshly prepared working stocks of modulators (optimal non-toxic 
concentrations were used and determined from cytotoxicity and western blotting 
studies) and Ko143 in SFM were added to the permeable inserts and incubated for 
either 1 h (Ko143: to pre-load cells with inhibitor) or 24h (modulators: to modulate the 
protein expression of BCRP) at 37°C.  
Cells were subsequently washed with pre-warmed PBS followed by the addition of SFM 
containing Ko143 (1 µM) or modulators and 10 µM PhA into the apical compartment.  
The basolateral compartment received media with modulators only. 50 µL aliquots were 
taken at 0, 30, 60, 90, 120, 150, 180 and 210 min, replaced by fresh SFM, and the 
fluorescence of PhA determined at an excitation wavelength of 395 nm and emission 
wavelength of 670 nm using a dual-scanning microplate spectrofluorometer (Spectra 
Max Gemini XS, molecular devices, Sunnyvale, California). For modulators 
demonstrating induction of BCRP, all compounds were added into the basolateral 
compartment and sampling of the apical compartment was conducted. 
2.4.9.5. Measurement of the apparent membrane permeability coefficient  
The apparent membrane permeability (Papp: x10-6 cm/s) of PhA was calculated 
according to equation 5. 
Papp =  𝑑𝑄 𝑑𝑡⁄ ∙
1
𝐴𝐶0
      (5) 
where dQ/dt is the rate of appearance of PhA on the receiver side (calculated from the 
slope of the cumulative transport graph), C0 is the initial concentration of PhA in the 
donor compartment and A (cm 2) is the surface area of the insert.  
2.4.10. Development of an in-vitro primary porcine brain microvascular 
endothelial cell culture model 
BBB cellular models derived from immortalised cells are widely used to study the 
phenotype and genotype of the BBB.  However, immortalised systems are often fraught 
with loss of key BBB markers, reduced expression of regulators and transporter 
proteins and often demonstrate lower TEER values compared to the microvascularate 
in-vivo.  
Cells isolated directly from freshly obtained brain tissues can be used to develop a 
more representative in-vitro BBB model, and a recently described primary porcine BBB 
model system has been demonstrated to yield a high number of cells from brain 
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hemispheres, retention of BBB phonotypic characteristics, close reflection of human 
and porcine genome, anatomy and disease progression (Krishnamurthy et al., 2004, 
Doyle and Ross, 2003a, Patabendige et al., 2013).  
2.4.10.1. Isolation of the primary porcine brain endothelial cells 
Porcine brain endothelial cells were isolated according to the methods described by 
Patabendige et al (Patabendige et al., 2013). Porcine brains were acquired from a local 
abattoir (Long Compton Abbatoir, Oxford, UK) within 1-hour of sacrifice. The brains 
were transferred to the laboratory in sterile box containing L-15 media supplemented 
with 1 % penicillin/streptomycin on ice. Each brain was separated into respective 
hemispheres and thoroughly washed with ice-cold PBS media supplemented with 1 % 
v/v penicillin/streptomycin. The meninges and blood vessels were removed along with 
the choroid plexus and capillaries located within brain sulci. The hemispheres were 
then placed in a clean beaker containing PBS supplemented with HEPES (10 mM) and 
penicillin/streptomycin sulphate. White matter was then carefully removed and grey 
matter dissected and transferred to a beaker containing MEM supplemented with 
HEPES (10 mM) and 1% v/v penicillin/streptomycin. The grey matter tissue was then 
chopped into small 1 cm3 sections using a sterile scalpel before being transferred into 
a 50 mL syringe and passed into a T75 containing 50 mL of MEM supplemented with 
HEPES (10 mM) and 1 % v/v penicillin /streptomycin.  
15 mL of this brain extract was transferred into a homogeniser (Dounce Homogeniser, 
Jencons, UK) and 25 mL of MEM supplemented with HEPES (10 mM) and 
penicillin/streptomycin sulphate was added to the homogeniser. The brain extract was 
then homogenised gently for 15 strokes with a loose pestle (Type B) followed by 15 
strokes with tight pestle (Type A).  The resulting homogenate was then transferred to 
a sterile T175 and process repeated for the remaining tissue. 
200 mL of homogenate was then filtered through a 150 µm pore nylon mesh and the 
filtrate collected and subsequently filtered again through a 60 µm pore nylon mesh 
(Plastok Associates Ltd, Wirral, UK). The filters were removed and placed into separate 
15 cm Petri dishes containing 80 mL of digest mix (M199 containing collagenase (223 
U/mg), trypsin (211 U/mg), DNase I (2108 U/mg), 10 % v/v FCS and 1 % v/v 
penicillin/streptomycin).  Filters were then incubated at 37°C for 1 h in an orbital shaker 
and labelled as 150 and 60s.  
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There after the filters were thoroughly washed and the digest mix transferred to 50 mL 
centrifuge tubes labelled ‘150s’ and ‘60s’ and centrifuged at 4°C for 5 min at 240 g. The 
pellet was resuspended in 10 mL of MEM supplemented with HEPES (10 mM) and 1% 
v/v penicillin /streptomycin sulphate and centrifuged again at 4 °C for 5 min at 240 g. 
This was repeated 3 times. The final pellets were resuspended in cryopreservation 
media (90 % FBS and 10% DMSO) and cryovials maintained at -80°c for 24 h before 
being transferred to liquid nitrogen (-196°C) for long term storage until use.   
2.4.11.      Characterisation of the in-vitro primary porcine BBB model 
 
2.4.11.1. Morphology of the cells     
T75 cell culture flasks were coated with rat-tail type-1 collagen (300 µg/mL in cell 
culture water) for 2-3 h in a laminar air hood. The collagen was aspirated and flasks 
were washed twice with the pre-warmed HBSS. The larger microvessels (150s) were 
resuspended in 16 mL of basic growth media (DMEM supplemented with 10% v/v FCS, 
1% v/v penicillin/streptomycin, 1% v/v L-glutamine, 125 µg/mL heparin) and 8 mL of 
this cell suspension was transferred into two T75s and cells allowed to attached at 37 
°C in a humidified atmosphere of 5 % CO2 in air for 24 h.  
In order to remove contaminating cells, such as pericytes, 3 µg/mL of puromycin was 
added to the flasks 24 h post seeding, and the media maintained for 3 days of 
exposure.  Thereafter the media was removed and fresh basic growth media (without 
puromycin) was added to the flasks maintained at 37 °C in a humidified atmosphere of 
5 % CO2 in air until confluent. At 70-80 % confluency, the cell culture medium was 
removed and cells were washed with pre-warmed PBS and 2 mL of trypsin-EDTA 
solution was added. The flasks were returned to the incubator at 37°C for 10 min. An 
equal volume of the media was then added and the resulting cell suspension was 
centrifuged at 1500 rpm for 10 min and pellet was resuspended with the basic growth 
media and cells were seeded for subsequent experiments.  
 
2.4.11.2. Assessment of barrier integrity 
To develop the in-vitro BBB model, the smaller microvessel fractions (60s) were 
seeded into permeable inserts (ThinCert™, pore size 1 µm) that had been pre-coated 
with 300 µg/mL collagen for 3-4 h in a laminar air hood. 1 x105 cells/cm2 were seeded 
into the permeable inserts and the inserts maintained in basic growth media and 
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allowed to attach for 24 h. To enhance the formation of the monolayer, the cell culture 
media was switched on day 4 to serum free media supplemented with 250 µM CPT-
cAMP, 17.5 µM RO20-1724 and 500 nM of hydrocortisone (Woodward et al., 2009, 
Ishiwata et al., 2005, Schwerk et al., 2012) and TEER values used to assess the 
development of a tight monolayer with an acceptable cut-off of 400-500 Ω.cm2 in a 6-
well transwell system (Patabendige et al., 2013).  
2.4.11.3. Immunostaining detection of BCRP grown on permeable inserts 
Primary porcine brain endothelial cells (60s) were grown on pre-coated permeable 
inserts for the detection of BCRP as described in section 2.4.2.4. Cell culture media 
was aspirated and inserts washed three times with pre-warmed PBS before being fixed 
with methanol at -20°C for 20 min and thereafter washed three times with pre-warmed 
PBS. Cells were subsequently rehydrated in PBS for 20 min at room temperature 
followed by incubation with blocking solution (1% goat serum in PBS) for 30 min at 
room temperature. The cell monolayers were then incubated with primary anti-ABCG2 
antibody (Sigma-Aldrich, Dorset, UK) (1:200 dilution) for 2 h at 37 °C. Cell monolayers 
were washed twice with PBS and incubated with secondary antibody fluorescein iso-
thiocyanate (FITC)-labelled mouse anti-rabbit IgG (1:500 dilution) prepared in blocking 
solution, for 45 min at room temperature in the dark. Secondary antibody was then 
aspirated and cells were washed three times with pre-warmed PBS. The insert 
membranes were then carefully cut and rinsed with MilliQ water and mounted onto 
glass slides with mounting media containing 4',6-diamidino-2-phenylindole(DAPI). The 
localisation of BCRP was determined using an upright confocal microscope (Leica SP5 
TCS II MP) and visualised with a 40x oil immersion objective. All images were acquired 
using an argon laser at 494 nm to visualise FITC and a helium laser to visualise DAPI 
at 461 nm. 
2.4.11.4. Determination of BCRP protein in primary porcine brain microvascular 
endothelial cells. 
Primary porcine brain endothelial cells (150s) were grown on collagen coated 6-well 
plates for 10 days. Whole cell lysate was extracted as described in section 2.4.7.1. 
Protein was quantified using the BCA assay as described in section 2.4.7.2. SDS-
PAGE was performed by loading 50 µg of protein onto gels as described in section 
2.4.7.3 and proteins immunological detection of BCRP was performed as detailed in 
section 2.4.7.4 and 2.4.7.6. 
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2.4.11.5. Cytotoxicity of modulators towards primary porcine brain 
microvascular endothelial cells: methylthiazolyldiphenyl-tetrazolium 
bromide 
Primary porcine brain microvascular endothelial cells (150s) were seeded with a 
seeding density of 25,000 cells per well onto a clear flat bottom 96-well plates. 8-10 
days post seeding the media was carefully removed and fresh media containing the 
modulator compounds at concentrations optimised from PBMEC/C1-2 studies (MTT 
section 2.4.3, Hoechst 33342 section 2.4.5.3 and WB section 2.4.7) were added and 
incubated for 24 h. The medium was then removed and cells were washed with the 
pre-warmed PBS and incubated with fresh media for 30 min. MTT powder was 
dissolved in PBS (5 mg/mL) and filtered through a 0.2 μm pore. 20 µL of the pre-
warmed MTT solution was added to each well. The plates were protected from light 
and incubated at 37°C in a humidified atmosphere of 5% CO2 for 4 h.  Thereafter the 
media was removed and 100 µL DMSO added to each well of a 96-well plate to 
solubilise the purple formazan crystals. The plates were incubated for a further 10-15 
min at room temperature (RT).The UV-absorbance of the formazan product was 
measured on a multi-plate reader (Bio-Rad laboratories, Hercules, CA) using 570 nm 
as a test wavelength and 600 nm as a reference wavelength. The mean of the blank 
UV-absorbance was subtracted from the UV-absorbance of each control and samples 
and percentage viability (see equation 2). The IC50 was subsequently using a sigmoidal 
dose response function within the Graphpad Prism. 
2.4.12.  Phytochemical modulation of BCRP transport function in a primary 
porcine in-vitro permeable insert BBB model 
 
To assess the ability of modulators to impact upon the efflux function of BCRP, 
modulators were incubated with primary porcine brain microvascular endothelial cells 
grown on permeable inserts as described in section 2.4.11.2. 
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2.4.13.    Statistical analysis 
 
All statistical analyses were performed in Graphpad Prism (La Jolla, California, USA). 
One-way ANOVA and t-tests were carried out to determine the differences between 
the mean values. For all multi-well based assay replicates of at least 6 were used in 
three independent experiments. For western blot and transport studies replicates of at 
least three were used and repeated in three independent experiments. IC50 and EC50 
metrics were calculated using sigmoidal fit functions within Graphpad Prism. A 
significance p-value of < 0.05 (*P≤0.05, **P≤0.01, *** P ≤ 0.001 and **** P ≤ 0.0001) 
was considered as statistically significant.   
76 
  
2.5. Results 
 
2.5.1. PBMEC/C1-2 cell morphology 
 
PBMEC/C1-2 cells were grown on gelatine-coated flasks and visually observed using 
light microscopy. Cells demonstrated typical endothelial cellular morphology with 
elongated to cobblestone shaped cells (Figure 2.1).  
 
 
Figure 2.1: Morphology of PBMEC/C1-2 cells. 
The PBMEC/C1-2 cells were seeded on a gelatine-coated flasks for 3 days at 37°C in a humidified 
atmosphere of 5% CO2 in air. The cells morphology were examined under light microscope at 10x (A) and 
40x (B) lenses. 
 
2.6. Development of a PBMEC/C1-2 in-vitro BBB model 
 
2.6.1. Assessment of monolayer formation and barrier integrity 
 
The formation of a stable monolayer was determined by measuring TEER values for 4 
days post seeding. TEER values significantly increased on day 2 (42 ± 10 Ω.cm2) and 
3 (78 ± 6 Ω.cm2) post-seeding (p ≤ 0.0001) compared to day 1 (22 ± 3 Ω.cm2), before 
declining thereafter (Figure 2.2).  
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Figure 2.2: Measurement of TEER values. 
PBMEC/C1-2 cells were seeded onto collagen coated permeable inserts and grown for 4 days at 37°C in 
a humidified atmosphere of 5% CO2 in air. Serum free media supplemented with 250µM CPT-cAMP, 
17.5µM RO20-1724 and 500nM hydrocortisone was added for 24 h post seeding and TEER values were 
measured. Statistical analysis compares TEER values to day 1. *** P ≤ 0.001 and **** P ≤ 0.0001. 
 
 
2.6.2. Stability of ACM 
ACM was initially frozen once collected but it was discovered that using fresh ACM 
significantly (P ≤ 0.01) increased TEER values on day 2 (45 ± 3 Ω.cm2) and day 3 (78 
± 6 Ω.cm2) when compared with media supplemented with frozen ACM on day 2 (41 ± 
6 Ω.cm2) and day 3 (60 ± 3 Ω.cm2) (Figure 2.3).  
 
Figure 2.3: Stability of ACM  
80,000 cells were seeded onto collagen coated permeable inserts and cells maintained in PBMEC media 
prepared with using either freshly collected or frozen ACM media to assess the impact of ACM stability on 
monolayer formation. The media was changed every day for 4 days and TEER values were measured 
using EVOM Voltmeter. Significant differences between freshly collected ACM and frozen ACM are 
indicated above the appropriate error bars * P ≤ 0.05 and ** P ≤ 0.01. 
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2.7. Cellular toxicity of modulators towards PBMEC/C1-2 cells 
To investigate the cellular toxicity of modulators towards the PBMEC/C1-2 cells, a MTT 
cellular toxicity assay was conducted whereby cells were exposed to a 7-fold log 
concentration range of modulators, 0.001 µM-1000 µM, for 24 h. Modulators 
demonstrated a range of toxicities towards PBMEC/C1-2 cells. The lowest IC50 (1.5 
± 2.7 µM) was observed for α-napthoflavone (Figure 2.4L). Similarly, baiclain 
(Figure 2.4B), 17-β-estradiol (Figure 2.4F), hesperidin (Figure 2.4J) and hesperetin 
(Figure 2.4I) demonstrated low micromolar IC50 values of 27.9 ± 6 µM, 48.9 ± 1.1 
µM, 36.9 ± 1.5 µM and 57.5 ± 3.54 µM respectively. Additionally a number of 
modulators demonstrated minimal toxicities up to 1000 µM and included chrysin 
(Figure 2.4D), fistein (Figure 2.4G) and naringin (Figure 2.4M) 
All other modulators possessed IC50 of > 100 µM (Figure 2.4).  
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Figure 2.4: Cytotoxic assessment of modulators (A-F). 
PBMEC/C1-2 cells were seeded onto gelatine coated 96-well plates at 37°C in a humidified atmosphere 
of 5% CO2 in air for 24 h. Media was aspirated and cells were subsequently incubated with a 7-fold log 
concentration range (0.001 µM-1000 µM) of apigenin (A), baiclain (B), biochanin A (C), chrysin (D), 
curcumin (E) and 17-β-estradiol (F) for 24 h, prior to an MTT assay being performed. Data reported as 
IC50 ± SD. 
                  
80 
  
                 
Figure 2.4: Cytotoxic assessment of modulators (G-L) 
PBMEC/C1-2 cells were seeded onto gelatine coated 96-well plates at 37°C in a humidified atmosphere 
of 5% CO2 in air for 24 h. Media was aspirated and cells were subsequently incubated with a 7-fold log 
concentration range (0.001 µM-1000 µM) of fistein (G), flavone (H), hesperetin (I), hesperidin (J), indole -
3-carbinol (I3C) (K) and α-napthoflavone (L) for 24 h prior to an MTT assay being performed. Data reported 
as IC50 ± SD.  
      
81 
  
              
 
Figure 2.4: Cytotoxic assessment of modulators (M-R) 
PBMEC/C1-2 cells were seeded onto gelatine coated 96-well plates at 37°C in a humidified atmosphere 
of 5% CO2 in air for 24 h. Media was aspirated and cells were subsequently incubated with a 7-fold log 
concentration range (0.001 µM-1000 µM) of naringin (M), quercetin (N), resveratrol (O), rutin (P), silymarin 
(Q) and TMF(R) for 24 h, for 24 h prior to an MTT assay being performed. Data reported as IC50 ± SD. 
 
82 
  
2.8.   Determination of BCRP expression in PBMEC/C1-2 cells 
 
2.8.1. Determination of BCRP genomic and protein expression 
 
PBMEC/C1-2 cells were characterised to determine the protein and genomic 
expression of BCRP. Reverse–transcriptase PCR confirmed the genomic expression 
of BCRP in PBMEC/C1-2 cells with an expected product size of 652 base pairs 
alongside the presence of β- actin (BA) loading control product size of 806 base pairs 
(Figure 2.5A). Western blot analysis further confirmed BCRP protein in PBMEC/C1-2 
cells with an expected product size of 72 kDa (Figure 2.5B). 
 
 
 
Figure 2.5:  Genomic expression of BCRP in PBMEC/C1-2 cells.  
(A) Genomic expression of BCRP. Cells were seeded onto a 6-well plate for 24 h. Total RNA was extracted 
and 400 ng of RNA was loaded reverse transcribed prior to PCR being performed. cDNA was resolved 
using a 2% agarose gel. A 1 kbp DNA ladder was used a size marker. (B) Protein expression of BCRP. 
Cells were seeded onto a 6-well plate for 24 h. Whole cell protein was extracted using RIPA buffer. 
Approximately 50 µg of the protein was loaded to the gel and transferred onto the PVDF membrane. The 
membrane was blocked and incubated with primary ABCG2 antibody for 24 h at 4°C and then incubated 
with goat anti-rabbit IgG-horse radish peroxidise-conjugated (Santa Cruz biotechnology, Sc-2004). 
Chemiluminesence detection was performed with lab made ECL. 
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2.8.2. Immunostaining detection of BCRP  
The localisation of BCRP in PBMEC/C1-2 cells was investigated using immunostaining 
techniques. Following immunostaining of cells grown on cover slips, confocal laser 
microscopy was used to detect the membrane localisation of BCRP in PBMEC/C1-2 
cells (Figure 2.6).  
 
 
Figure 2.6: Localisation of BCRP in PBMEC/C1-2 cells. 
Cells were grown on coverslips for 2-3 days and fixed with 4% paraformaldehyde and stained for BCRP 
using the anti-ABCG2 primary antibody and goat anti-rabbit IgG-FITC secondary antibody (green). Cell 
nuclei were visualised using DAPI (blue). A negative control excludes antibodies. 
 
 
2.9. Measurement of BCRP cellular functional activity in PBMEC/C1-2 cells 
 
2.9.1. Determination of optimum seeding density and incubation time 
To identify an optimal seeding density and incubation time to assess the intracellular 
accumulation of H33342 through fluorescence measurements, H33342 accumulation 
was assessed under three cell densities of 1000, 10,000 and 50,000 cells per well, with 
incubation times of 30, 60 and 90 mins. Significantly higher (p ≤ 0.01) intracellular 
H33342 accumulation was observed with 50,000 cells per well after 30 minutes of 
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incubation when compared with 1000 and 10,000 cells per well and 60 and 90 minutes 
incubation time (Figure 2.7). 
 
 
Figure 2.7: Optimisng the seeding density and incubation time of PBMEC/C1-2 cells to 
assess the intracellular accumulation of H33342 
PBMEC/C1-2 cells were seeded with a seeding density of 1000,  10000 and 50000 cells per well of 96-
well plate for 24 h. After 24 h cells were washed with HBSS and incubated with HBSS for 30 min. The cells 
were washed with warm HBSS prior to the addition of H33342 (10 µM) prepared in HBSS and incubated 
for 30 min, 60 min and 90 min. After each time point, cells were washed with ice cold HBSS twice and 
plates lysed at at -80°C for 2 min before the intracellular accumualtion of H33342 assessed using a 
fluoresecent plate reader with an excitation wavelength of 355 nm and an emission wavelength of 460 nm. 
Significant differences between cell number (1000,10,000 and 50,000) and incubation times (30,60 and 
90 min) with control (1000,10,000 and 50,000 cells but without H33342) are indicated above the 
appropriate error bars (** P ≤ 0.01). 
 
 
2.9.2. Assessment of the intracellular H33342 accumulation in the absence and 
presence of Ko143  
 
The intracellular accumulation of H33342 in the absence and presence of Ko143, a 
known potent inhibitor of BCRP, was assessed to investigate the functional expression 
of BCRP in PBMEC/C1-2 cells. Our results demonstrated that the intracellular 
accumulation of H33342 was significantly increased (p < 0.0001) following a 1 h 
incubation with Ko143 over a wide concentration range of Ko143 (0.0039 µM - 5 µM) 
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leading to an approximately 3.5-fold increase in H33342 accumulation (Figure 2.8) over 
all concentration studied. 
 
 
 
Figure 2.8: Ko143 mediated inhibition of BCRP efflux function in PBMEC/C1-2 
20,000 cells/well were seeded into a clear 96-well plate and left to attach at 37°C and 5% CO2 for 24 h. 
Subsequently cells were washed with PBS to remove media and 200 µL of growth media a range of Ko143 
concentration (0.0039 µM-5 µM) was added and the plate pre-incubated for 1 h before the media was 
removed.  Thereafter the cells were again incubated with media containing Ko143 (0.0039 µM-5 µM) in 
addition to 10 µM H33342 for 30 min before the intracellular accumualtion of H33342 assessed using a 
fluoresecent plate reader with an excitation wavelength of 355 nm and an emission wavelength of 460 nm.  
Significant differences between control and Ko143 concentrations are indicated above the appropriate 
error bars (**** p ≤ 0.0001). 
 
 
2.9.3. Measurement of the auto-fluorescence of phytochemicals 
The inherent fluorescent properties of modulators were important to assess when using 
a fluorescent probe substrate for BCRP in an intracellular accumulation studies. 
Modulators were screening for their fluorescent properties using H33342 as a 
reference.  The majority of modulators demonstrated no fluorescence signals when 
compared to H33342 (data not shown, p < 0.05).  However, fistein, α-napthoflavone 
and baiclain demonstrated no statistically significant differences in fluorescence when 
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compared to H33342, and hence were classified as compounds that possessed auto-
fluorescence which overlaps with H33342 (Figure 2.9).  
 
Figure 2.9: Auto-fluorescence of modulators. 
25µM working stocks of baiclain, fistein and napthoflavone were prepared and transferred to a black 96-
well plate. The autofluorescence of modulators was measured on a fluorescence plate reader at an 
excitation wavelength of 360 nm and emission wavelength of 460 nm. Statistical comparison were made 
between background (HBSS+) and H33342/modulators. **** p ≤ 0.0001. 
 
 
2.9.4. Modulator mediated inhibition of BCRP function in a H33342 intracellular    
accumulation assay 
 
To assess the potential for modulators to directly inhibit BCRP function, the intracellular 
accumulation of H33342 was assessed following the incubation PBMEC/C1-2 cells with 
modulators. Our results demonstrated significant increase of H33342 accumulation (p 
≤ 0.0001) with most of the modulators studied across a concentration range of 1-100 
µM (Figure 2.10). Furthermore the fold change in H33342 was significantly greater than 
that observed for Ko143 for apigenin (1 µM), hesperidin (1 µM), I3C (1-100 µM) and 
2,6,4-trimethoxyflavone (TMF) (1-100 µM) and increasing H33342 accumulation by 2.5 
± 0.2 fold, 2.6 ± 0.5 fold, 3.5 - 4.5 mean fold range and 4.5 - 6.5 mean fold range 
respectively when compared with the known inhibitor of BCRP, Ko143 (represented by 
the grey shaded area in figure 2.10). Interestingly, quercetin, resveratrol and rutin did 
not show any significant accumulation when compared to Ko143.  
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Figure 2.10: Modulation of intracellular accumulation of H33342 following a 1-hour incubation with modulators. 
Cells were grown in a 96 well plate for 48 h and washed with warm HBSS supplemented and incubated for 1 h with media containing 1-100µM of test compound. 
Subsequently cells were incubated with media containing H33342 for 30 min and lysed. The change in H33342 intracellular accumulation in the presence of Ko143 is 
highlighted by the shaded region. Significant differences between Ko143 and modulators are indicated above the appropriate error bars. * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 
0.001 and **** P ≤ 0.0001. The hash symbol (#) indicates modulators excluded due to auto-fluorescence.  
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2.9.5. Modulator mediated changes in BCRP function following 24 hours 
incubation  
Time dependent functional activity of BCRP was also evaluated following incubation 
of H33342 in the presence of modulators for a 24 h period. PBMEC/C1-2 cells were 
exposed to modulators at 1 µM, 10 µM and 100 µM.  Our results demonstrated that 
apigenin (1 µM and 10 µM), chrysin (1-100 µM),17-β-estradiol (1 µM  and 10 µM), I3C 
(10 µM and 100 µM), silymarin (1-100 µM) and (TMF) (1-100µM) has shown significant 
increase in intracellular H33342 accumulation by 1.15-1.25, 1.26-1.35, 1.3, 1.25 -1.26, 
1.25-1.6 and 1.20-1.45 mean fold change when compared to control (Figure 2.11). 
Furthermore, hesperetin (0.7-0.8 mean fold change), naringin (0.3-0.71 mean fold 
change) and quercetin (0.75-1 mean fold change) demonstrated significant 
downregulation of intercellular H33342 accumulation by when compared to control 
across all concentration (1-100 µM) studied. 
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Figure 2.11: Modulation of intracellular accumulation of H33342 following a 24-hour incubation with modulators. 
Cells were grown in a gelatine coated 96 well plate for 24 h and washed with pre- warm HBSS supplemented and incubated for 24h with media containing 1-100µM of 
test compound . After 24 h cells were incubated with media containing H33342 for 30 min and lysed. Significant differences between control and modulators are indicated 
above the appropriate error bars. * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001 and **** P ≤ 0.0001.  The hash symbol (#) indicates modulators excluded due to autofluorescence. 
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2.10. Modulation of BCRP protein expression by phytochemical modulators  
To assess the impact of modulators on the protein expression of BCRP, PBMEC/C1-
2 cells were exposed to modulators for 24 hours and changes in protein expression 
were assessed through western blotting.   A significant induction of BCRP protein was 
observed for biochanin A (2.65 ± 0.12 fold), hespiridin (2.42 ± 0.19 fold), I3C (1.4 ± 
0.09 fold), naringin (2.2 ± 0.17 mean fold change) and quercetin (2.3 ± 0.12 fold). 
Furthermore, a significant (p ≤ 0.01) down-regulation of BCRP was observed with 
curcumin (0.4 ± 0.2 fold) and 17-β-estradiol (0.41 ± 0.1 fold) (Figure 2.12 and 2.13).  
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Figure 2.12: Changes in BCRP protein expression under 24-hours exposure to modulators  
Cells were seeded in a 6-well plate for 24 h to attach and subsequently incubated with 25 µM modulator except for 17-β-estradiol (100nM) for 24 h. Whole cell protein 
was extracted using RIPA buffer and approximately 50 µg of isolated protein was loaded onto a SDS-PAGE gel to separate proteins bands.  The resulting gel was then 
transferred onto a PVDF membrane and incubated with anti-ABCG2 antibody for 24 h at 4°C followed by incubation with goat anti-rabbit IgG-horse radish peroxidise-
conjugated antibody. Chemiluminesence detection was performed with lab made ECL and a representative image is displayed.  Primary PBMEC and PBMEC/C1-2 
bands are non-modulator (control) samples for each cell line. 
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Figure 2.13: Fold change in BCRP protein expression following 24-hours exposure to 
modulators 
Cells were seeded in a 6-well plate for 24 h to attach and subsequently incubated with 25 µM modulator 
except for 17-β-estradiol (100nM) for 24 h. Significant differences in protein expression when compared 
to control are indicated above the appropriate error bars. * p ≤ 0.05, ** p ≤ 0.01 and **** p ≤ 0.0001. 
 
2.11. Quantitative PCR assessment of the changes in BCRP genomic 
following exposure to modulators 
The modulation of BCRP genomic expression was evaluated by qPCR with two up-
regulators (quercetin and naringin) and two down-regulators (curcumin and 17-β-
estradiol) selected from the western blot results. A significant increase (p ≤ 0.0001) 
in the genomic expression of BCRP was observed for quercetin (1.63 ± 0.28 fold) and 
naringin (1.36 ± 0.71 fold), relative to control samples, whereas curcumin and 17-β-
estradiol demonstrated significant down-regulation of 1.78 ± 0.05 fold (p ≤ 0.0001) 
and 1.54 ± 0.05 fold (p ≤ 0.01) respectively (Figure 2.14). 
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Figure 2.14: Modulation of BCRP gene expression after 24 h incubation with modulator 
compounds. 
PBMEC/C1-2 cells were seeded onto a 6-well plate and allowed to attach for 24 h. The media was 
removed and modulators prepared in media were added to the wells and incubated for 24 h. After 24 h 
the media was removed and cells washed with pre-warmed PBS prior to RNA extraction. Total RNA was 
reverse transcribed and gene expression assessed by qPCR using a SYBR green master mix.  Dashed 
line indicated 0.5-fold change.  Significant differences between control and modulators are indicated 
above the appropriate error bars. *** P ≤ 0.001 and **** P ≤ 0.0001. 
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2.12. Modulation of BCRP transport function in an in-vitro permeable insert 
BBB model 
 
2.12.1.   Generation of a PhA standard curve 
A standard curve for the fluorescent detection of PhA was developed over a 
concentration range of 0.01-50 µM. A linear correlation was displayed over this 
concentration range with an r2 =0.9967 (Y=1.5897 x-3.4248) (Figure 2.15). The 
lowest limits of quantification was found to be 0.01 µM.   
 
 
Figure 2.15: PhA standard curve  
Concentrations of PhA (0.1µM-100µM) were prepared in serum free transport media and 100 µL 
transferred into wells of a 96-well for fluorescence measurement.  
 
2.12.2.    Impact of transport media on in-vitro BBB monolayer integrity 
To assess the impact of transport media on the stability of the monolayer formation, 
preliminary transport studies were conducted assessing the impact of HBSS transport 
media (HBSS supplemented 10mM glucose and 10 mM HEPES) and SFM on the 
resistance of the monolayer. It was demonstrated that the TEER of the inserts 
maintained in HBSS media started to significantly decrease (p ≤ 0.05) over the study 
period from 75-80Ω.cm2 at 30 min to 32-35 Ω.cm2 at 150 min (Figure 2.16).  In 
contrast, TEER values of the inserts maintained in SFM were relatively consistent 
over 210 min with no significant decrease in TEER when compared to 30 min. 
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Figure 2.16: TEER values of PBMEC/C1-2 cells maintained in HBSS and SFM, grown on 
permeable inserts. 
Cells were seeded onto collagen coated permeable inserts and allowed to grown for 4 days. The inserts 
were transferred to either HBSS or SFM media and maintained for up to 210 min, with TEER values 
measured during the study period. Significant, differences between HBSS and serum free media are 
indicated above the appropriate error bars * p ≤ 0.05, ** p ≤ 0.01. 
 
2.12.3.   Functional assessment of BCRP in an in-vitro permeable insert BBB  
model  
The function of BCRP in a representative in-vitro BBB model was assessed by 
measuring the transport of PhA in the presence or absence of Ko143, a known BCRP 
inhibitor. Our results demonstrated that 1 h incubation with Ko143 (1 µM) significantly 
increased the apical-to-basolateral (AB) flux of PhA from 90 min onwards during our 
transport studies (p < 0.05) (Figure 2.17) and this was associated with an increase in 
Papp,AB from 27.2 ± 0.23 x10-6 cm/s to 43.23 ± 0.32 x 10-6 cm/s following Ko143 
incubation.  
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Figure 2.17: Cumulative transport of PhA across an in-vitro BBB model. 
Cells were grown on permeable inserts and transport studies were performed on day 4 in the presence 
and absence of Ko143.  Statistically significant differences between control and Ko143 samples at each 
data point are indicated. * P ≤ 0.05. 
 
2.12.4. Modulation of BCRP function in the absence and presence of up-
regulators  
To assess the impact of BCRP protein up-regulators on the functional efflux of PhA, 
quercetin and naringin were incubated with PBMEC/C1-2 cells, grown on permeable 
inserts, for 24 h prior to the initiation of a transport studying with PhA alone. When 
the transport study was initiated with PhA added to the apical compartment and 
sampling from the basolateral compartment, no significant differences in the transport 
kinetics of PhA were observed for quercetin and naringin when compared to control 
(Figure 2.18) 
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Figure 2.18: Transport of PhA across an in-vitro BBB cell culture model following 24 
hour incubation with quercetin or naringin 
Cells were grown on permeable inserts and pre-treated for 24 h with quercetin and naringin.  Thereafter 
the transport of PhA was assessed on day 4 following the addition of PhA to the apical compartment 
and sampling basolaterally.  
 
As an induction-effect was expected, incubation was repeated by the addition of 
compounds into the basolateral compartment with sampling from the apical 
compartments. Our results demonstrated that 24 h incubation of naringin (25 µM) 
significantly increased the basolateral-to-apical (BA) transport of PhA during our 
transport studies (p < 0.01) (Figure 2.19), with a BA permeability (Papp,BA) of PhA of 
74.23 ± 0.29 x10-6 cm/s when compared to the absence of naringin (23.13 ± 0.31 x 
10-6 cm/s). Similarly for quercetin (25 µM), our results demonstrated a significant 
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increase (p ≤ 0.01) in the BA transport of PhA with a BA permeability (Papp,BA) of PhA 
of 63.21 ± 0.54 x10-6 cm/s. 
 
Figure 2.19: Transport of PhA across an in-vitro BBB cell culture model following 24 
hour incubation with quercetin or naringin.  
Cells were grown on permeable inserts and pre-treated for 24 h with quercetin and naringin.  Thereafter 
the transport of PhA was assessed on day 4 following the addition of PhA to the basolateral compartment 
and sampling apically.  Statistically significant differences between control and modulator exposed 
conditions are indicated as * P ≤ 0.05, ** P ≤ 0.01. 
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2.12.5. Functional assessment of BCRP in the presence of BCRP down-
regulating modulators  
 
The functional assessment of BCRP was evaluated in the presence of BCRP down-
regulators namely, curcumin (1 µM) and 17-β-estradiol (100 nM) in an in-vitro BBB 
model by measuring the transport of PhA. Our results demonstrated that 24 h 
incubation of curcumin and 17-β-estradiol significantly increased the apical-to-
basolateral (AB) passive permeability (Papp,AB) of PhA from 27.20 ± 0.23 x10-6 cm/s 
in the absence of modulators to 78.81 ± 0.65 x10-6 cm/s and 48.11 ± 0.34 x10-6 cm/s 
in the presence of curcumin and 17-β-estradiol respectively (Figure 2.20).  
 
Figure 2.20: Transport of PhA across an in-vitro BBB cell culture model following 24 
hour incubation with curcumin or 17-β-estradiol. 
Cells were grown on permeable insert and transport studies were performed on day 4 using 1 µM 
curcumin and 100 nM 17-β-estradiol. Statistically significant differences between control and modulator 
exposed conditions are indicated as * P ≤ 0.05. 
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2.13. Characterisation of an in-vitro primary porcine brain BBB model 
 
2.13.1.  Morphology of porcine brain primary endothelial cells 
Primary porcine brain microvascular endothelial cells were successfully isolated and 
grown on collagen coated T75 flasks. Explants seeded on the coated flasks were 
visually observed under light microscope using 10x and 40x lenses. The isolated 
capillaries explants were observed initially as short fragments. On the day 3, explants 
had fully attached and endothelial cells proliferated from the explants and formed 
island of cells. On day 5, the cell patches began to reveal a uniform packed monolayer 
and reached confluence on day 10 (Figure 2.21). 
                 
Figure 2.21: Growth of primary porcine brain endothelial cells  
Explant cells were seeded on collagen coated flasks for 10 days at 37°C in a humidified atmosphere of 
5% CO2 in air. Cells morphology was examined under light microscope at 10x and 40x lenses. 
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2.13.2.   Treatments to enhance barrier integrity 
 
Monolayer formation and barrier integrity was assessed by measuring TEER values 
24 h post-seeding and for a total of 5 days. TEER values increased significantly on 
day 3 reaching 80-95 Ω.cm2 (p ≤ 0.01) and 120-125 Ω.cm2 on day 4 (p ≤ 0.001) before 
declining thereafter (Figure 2.22).  
 
Cells were treated with cAMP, RO 20-1724 and hydrocortisone for 24 h on day 3 and 
demonstrated TEER values that were significantly increased to 120-125Ω.cm2 on day 
4 (p ≤ 0.01) (Figure 2.22).   
 
 
Figure 2.22: The impact of media additives to enhance monolayer formation. 
Primary porcine brain endothelial cells were seeded onto collagen coated permeable inserts for 4 days 
at 37°C in a humidified atmosphere of 5% CO2 in air. TEER values were measured and treatment with 
cAMP, RO 20-1724 and hydrocortisone initiated on day 3 for 24 h.  Statistically significant differences 
before treatment and after treatment are indicated as ** P ≤ 0.01. 
 
 
 
 
 
 
 
 
 
102 
  
2.13.3.   Immunostaining detection of BCRP in primary porcine brain 
endothelial cells 
The expression of BCRP in porcine primary brain endothelial cells (‘60s’) cultured on 
a permeable insert monolayer was investigated using immunostaining techniques. 
BCRP was found to be localised primarily in the plasma membrane regions. 
Furthermore, the formation of a monolayer structure was apparent by the overlapping 
nature of the brain endothelial cells (Figure 2.23). 
             
Figure 2.23: Localisation of BCRP in primary brain endothelial cells.  
Cells were grown on permeable inserts for 3-4 days and fixed with 4% paraformaldehyde and stained 
for BCRP using the anti-ABCG2 primary antibody and goat anti-rabbit IgG-FITC secondary antibody 
(Green). Cell nuclei were visualised using DAPI (blue). Positive control included staining for anti-ABCG2 
whereas the negative control did not include the primary antibody.  
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2.13.4.   Determination of BCRP protein expression 
The protein expression of BCRP in primary endothelial cells was determined by 
western blot analysis. BCRP was successfully demonstrated to be expressed in 
primary porcine brain cells with an expected size of 72 kDa (Figure 2.24).  
 
Figure 2.24: Protein expression of BCRP in primary porcine brain microvascular 
endothelial cells. 
Cells were seeded onto a 6-well plate for 24 h. Whole cell protein was extracted using RIPA buffer. 
Approximately 50 µg of the protein was loaded to the gel and transferred onto the PVDF membrane. 
The membrane was blocked and incubated with primary ABCG2 antibody for 24 h at 4°C and then 
incubated with goat anti-rabbit IgG-horse radish peroxidise-conjugated. Chemiluminesence detection 
was performed with lab made ECL. 
 
 
 
2.13.5.   Determination of cytotoxicity of modulators in primary cells 
 
The cellular toxicity of modulators towards the primary porcine brain endothelial cells 
was investigated using MTT toxicity assay. Cells were exposed to 25 µM and 100 
µM of modulators for 24 h. The highest cytotoxicity was observed for curcumin 
and α-napthoflavone at 100 µM leading to 80-75% reduction in cell growth (Figure 
2.25). Similarly, apigenin, baiclain, biochanin A (100µM), 17-β-estradiol (100µM), 
flavone (100µM), hesperetin (100µM) and TMF demonstrated 25-50 % reduction 
in cellular viability. Additionally a number of modulators demonstrated minimal 
toxicities up to 100 µM and included biochanin A (10µM), chrysin, fistein, 
hesperidin, naringin, quercetin, resveratrol, rutin and silymarin (Figure 2.25). 
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 Figure 2.25: Cellular toxicity of modulators towards primary porcine brain endothelial cells. 
Cells were seeded onto collagen coated 96-well plates for 10 days. The media was aspirated and cells were incubated for 24 h with 25 µM and 100 µM of modulators. 
Thereafter the media was replaced and 20 µl of MTT solution added to each well and plate was incubated at 37°C for 4h. The media was carefully aspirated and 100µl 
of the DMSO was added to each well and the UV-absorbance was measured at wavelength of 560nm.  
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2.13.6. Modulation of BCRP transport function in a permeable insert based 
in-vitro BBB model 
 
2.13.6.1. Functional assessment of BCRP  
 
BCRP functionality was investigated in a representative in-vitro BBB permeable insert 
model by measuring the transport of PhA in the presence or absence of Ko143, a 
known BCRP inhibitor. Our results demonstrated that a 1 h incubation with Ko143     (1 
µM) significantly increased the apical-to-basolateral (AB) transport of PhA from 30 min 
onwards during our transport studies (p < 0.05) with a Papp,AB of 109.75 ± 1.21 x10-6 
cm/s compared to the absence of Ko143, 60.57 ± 1.32 x10-6 cm/s (Figure 2.26).  
 
 
Figure 2.26: Transport of PhA across an in-vitro primary BBB cell culture model 
following 1-hour incubation Ko143.  
Cells were grown on permeable inserts and transport studies were performed on day 4 in the absence 
and presence of Ko143.Statistically significant differences between control and Ko143 are indicated.* P ≤ 
0.05. 
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2.13.6.2. Modulation of BCRP function in the absence and presence of up-
regulators  
Naringin and quercetin demonstrated up-regulation of BCRP protein expression in 
PBMEC/C1-2 cells and were selected as modulators to assess in the primary cell 
culture model.  Primary cells were seeded onto permeable inserts and incubated with 
quercetin and naringin for 24 h with the addition of PhA and modulators into the 
basolateral chamber and sampling from the apical chamber.  
Our results demonstrated that 24 h incubation of quercetin (25 µM) significantly 
increased the basolateral-to-apical (BA) transport of PhA during our transport studies 
(p< 0.01) (Figure 2.27A), with a BA permeability (Papp,BA) of PhA of 102.93 ± 1.98 x 
10-6 cm/s in the presence of quercetin compared to 38.57 ± 2.15 x10-6 cm/s in the 
absence of quercetin.  Similarly for naringin (25 µM), our results demonstrated a 
significant increase (p ≤ 0.01) in the BA transport of PhA with a BA permeability 
(Papp,BA) of PhA of 98.21 ± 1.23 x10-6 cm/s (Figure 2.27B). 
 
107 
 
 
Figure 2.27: Transport of PhA across an in-vitro primary BBB cell culture model 
following 24 hour incubation with naringin or quercetin. 
Cells were grown on permeable inserts and (A) naringin or (B) quercetin at 25 µM were added on day 3 
followed by the initiation of the transport study 24 h later. Statistically significant differences between 
control and modulator exposed conditions are indicated. ** P ≤ 0.01 and **** P ≤ 0.001. 
 
 
 
108 
 
2.13.6.3. Modulation of BCRP function in the absence and presence of down-
regulators  
Curcumin and 17-β-estradiol demonstrated downregulation of BCRP protein 
expression in PBMEC/C1-2 cells and were selected as modulators to assess in the 
primary cell culture model. Primary cells were seeded onto permeable inserts and 
incubated with curcumin or 17-β-estradiol for 24 h with the addition of PhA and 
modulators into the apical chamber and sampling from the basolateral chamber. 
Our results demonstrated that 24 h incubation of curcumin (1 µM) significantly 
increased the apical-to-basolateral (AB) transport of PhA during our transport studies 
(p< 0.01) (Figure 2.28A), with an AB permeability (Papp,AB) of PhA of 83.23 ± 1.25 x 
10-6 cm/s in the presence of curcumin compared 60.57 ± 1.32 x10-6 cm/s in the 
absence of curcumin. Similarly for 17-β-estradiol (100 nM), our results demonstrated 
a significant increase (p ≤ 0.01) in the AB transport of PhA with a AB permeability 
(Papp,AB) of PhA of 83.87 ± 3.25 x10-6 cm/s (Figure 2.28B). 
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Figure 2.28: Transport of PhA across an in-vitro primary BBB cell culture model 
following 24 hour incubation with curcumin or 17-β-estradiol.  
Cells were grown on permeable inserts and (A) curcumin (1 µM) or (B) 17-β-estradiol (100 nM) were 
added on day 3 followed by the initiation of the transport study 24 h later. Statistically significant 
differences between control and modulator exposed conditions are indicated. *P ≤ 0.05, ** P ≤ 0.01,***P 
≤ 0.001. 
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2.14. Discussion 
 
Drug delivery to the CNS has become a major challenge due to the presence of the 
BBB, which acts as a physical and metabolic barrier for the transport of therapeutic 
agents into the wider CNS. The endothelial cells forming the cerebral capillaries act as 
a physical barrier by limiting the transport of molecules in and out of the brain. 
(Pardridge, 2007, Ulrike Tontsch and Bauer, 1989). Drug metabolising enzymes 
present at the BBB and within the brain mass metabolise drugs and reduce circulating 
concentrations and the expression of a range of drug transporter at the BBB play an 
important role in limiting the penetration of drugs into the brain (Pardridge, 2007).  
Breast cancer resistance protein (BCRP) is a member of ATP-binding cassette family 
of membrane transporters and is known to be expressed at the BBB of humans, cows, 
rats, mice and pigs (Cooray et al., 2002, Warren et al., 2009). Chemotherapeutic 
agents were the first identified substrates for BCRP and it is now known that BCRP 
possess a diverse substrate specificity  (Mao, 2005) (Breedveld et al., 2004). 
The use of inhibitor molecules to modulate the efflux transport function of BCRP is a 
viable approach to enhance CNS delivery of BCRP substrates. Ko143 (Choi et al., 
2012) and fumitremorgin C (FTC) (Allen et al., 2002a) are specific known potent 
inhibitors of BCRP but their clinical translation is limited due to the neurotoxic and 
cytotoxic effects.  In an attempt to identify novel candidates that may modulate BCRP 
expression and function, phytochemicals (primarily flavonoids) show promise. 
Flavonoids are important constituents of diet and are present in fruits, fruit juices, 
vegetables, nuts, potatoes and corn (Spencer, 2008). The daily intake of flavonoids 
through the human diet is approximately 200-1000 mg (Kühnau, 1976). It has also 
been reported that phytochemical also reach the plasma circulation, for example 
hesperetin, naringin and quercetin plasma concentrations have been reported as 325 
nmoL/L, 112.9 nmoL/L and 52 nmoL/L in healthy females on high vegetables diet 
(Erlund et al., 2002). Similarly, another study demonstrated increased plasma 
concentrations of epicatechin to 204.4 nmoL/L in adult human after giving flavonoid-
rich dark chocolate (Engler et al., 2004).  
The interest in phytochemicals and flavonoids has stemmed from their proposed health 
benefits flavonoids includes antioxidant, anti-inflammatory, cell proliferation, 
angiogenesis, estrogen biosynthesis and detoxification of carcinogens (Havsteen, 
2002).  
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The ability of flavonoids and other phytochemical compounds to modulate the 
expression and function of BCRP has been reported previously. The exposure of rat 
brain capillaries to 17-β-estradiol was shown to decrease BCRP function and protein 
expression, by down-regulating BCRP transcription and translation through 
interactions with regulatory mechanism resulting the expression of BCRP  (Hartz et al., 
2010). Genistein and naringenin has also been shown to inhibit BCRP at a 
concentration of 3 µM (Imai et al., 2004).   
The primary aim of the chapter was to characterise a porcine brain microvascular 
endothelial cell culture model (PBMEC/C1-2 cells) and to develop an in-vitro BBB 
model which could be used to investigate the gene and protein modulation of BCRP 
when exposed to a range of modulators compounds. These studies were developed 
to identify suitable modulator compounds, which were then further assessed in a 
primary porcine brain microvascular endothelial cell culture model.  Our rationale for 
this approach was that the primary cell cultures model utilised has been reported to 
better resemble the in-vivo BBB model with higher transporter expression levels and a 
more representative BBB phenotype (as judged by the presence of tight junctions 
proteins and BBB markers) (Patabendige et al., 2013). 
2.14.1.   The use of PBMEC/C1-2 cells to develop an in-vitro BBB model 
PBMEC/C1-2 are immortalised cells and developed from the porcine primary brain 
endothelial cells after transfection with SV 40 large T-antigen by lipofection (Teifel and 
Friedl, 1996). The cells show typical morphology of endothelial cells and presence of 
blood brain barrier markers such as γ-glutamyltranspeptidase (γ-GT), the glucose 
transporter Glut-1, and apolipoprotein A-1(Teifel and Friedl, 1996). 
Our results have shown that when grown on the correct extracellular matrix, gelatine, 
PBMEC/C1-2 cells demonstrated a typical elongated to cobblestone endothelial cell 
morphology (Figure 2.1 A and B). Although the PBMEC/C1-2 cells were immortalised 
to induce the barrier integrity, the cells were recommended to be grown in a 50:50 
mixture of astrocytes conditioning media (ACM) obtained from rat glioma C6 cells. The 
use of C6 astrocyte conditioning media with the addition of cyclic AMP and the type IV 
phosphodiesterase inhibitor (RO20-1724) induced TEER values up to 78 ± 6 Ω.cm2 on 
a 12-well permeable inserts (1.1 cm2). Lauer et al (Lauer et al., 2004) and Novotna et 
al (Novotna et al., 2014) achieved the TEER values of 300 Ω.cm2 on 6-well transwell 
insert (4.4 cm2) after the addition of additives. It was also demonstrated that the use of 
freshly obtained ACM showed better effects on the integrity of the monolayer compared 
to frozen ACM (Figure 2.2).  
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Our studies demonstrated that when PBMEC/C1-2 cells were grown on 12-well 
permeable inserts, we achieved TEER values of 78 ± 6 Ω.cm2 which was in a good 
agreement with the published TEER values of 300 Ω.cm2 that were reported from 6-
well inserts (Lauer et al., 2004). Our results are consistent with the TEER values 
reported as we used 12-well permeable inserts with surface area of 1.12 cm2 where as 
other studies reported have used 6-well inserts with surface area of 4.67cm2.  
Several studies have also shown that astrocyte interactions with endothelial cells help 
to induce the BBB morphology, function and protein expression of junctional proteins 
(Denison et al., 1988, Lee et al., 2015, Revalde et al., 2015a). Soluble factors such as 
transforming growth factor β (TGFβ), interferon and Interleukin present in the ACM are 
known to induce the development of BBB (Katayama et al., 2007). Our results 
demonstrated that the use of fresh ACM has enhanced the TEER values significantly 
(Figure 2.3). Freeze thawing ACM might inactivate or degrade the soluble factors in 
the ACM and reduces the TEER values when compared to fresh ACM. 
2.14.2. Cytotoxicity of modulators towards PBMEC/C1-2 cells 
 
A total of 18 phytochemicals, primarily flavonoids (Appendix A) were selected from 
literature for this project, and which had previously demonstrated significant 
modulation of BCRP expression and function in other non-cerebral cell lines. To our 
knowledge there have been no studies reporting the cytotoxicity of phytochemical 
modulators on PBMEC/C1-2 cells. Our results demonstrated that the majority of 
modulators exhibited IC50 values in excess of 100 µM (Figure 2.4). However a number 
of modulators demonstrated low IC50 values ranging from 1.5 - 63 µM and included 
flavones such as baiclain (Figure 2.4B), α-napthoflavone (Figure 2.4L) and flavonones 
such as hesperidin (Figure 2.4J) and hesperetin (Figure 2.4I) and 17-β-estradiol 
(Figure 2.4F) and curcumin (Figure 2.4E). 
 
Whilst difficult to compare with reported studies, the IC50 values determined for 
modulators were found to be within the same order of magnitude as published reports 
from, often, non-cerebral origin cell lines. For example, the IC50 for apigenin was 
demonstrated to be 673.8 ± 1.6µM in PBMEC/C1-2 cells, however Bai et al (Bai et al., 
2014) used 80-100 µM to induce apoptosis in human breast cancer line (MCF-7). 
Similarly, the IC50 reported for apigenin in lung epithelium cancer (A549) cells was 93.7 
± 3.7 µM (Livak and Schmittgen, 2001).  
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Baiclain demonstrated an IC50 of 4.96 µg/ml (11.12 nM) in enterovirus 71 (Rice-Evans, 
1995), similarly the IC50 for curcumin has been reported in the literature for CCRF-CM 
human T cell leukaemia cells as 8.68 µM (Morris and Zhang, 2006). α-napthoflavone 
(Figure 2.4L) demonstrated a very low IC50 values of 1.5 µM in PBMEC/C1-2 cells, and 
this concerns with other reports of concentrations ranging from 10-1000 nM (Middleton 
Jr, 1998, Narayana et al., 2001).  
 
Bacanli et al (Bacanli et al., 2015) reported the IC50 of naringin as 1976 µM in Chinese 
hamster fibroblast cell line (V79). Our results were consistent with the study showing 
no cytotoxicity caused up to 1000 µM (Figure 2.4M). Zhang et al (Zhang et al., 2005) 
demonstrated limited cytotoxicity with chrysin at 50 µM in MCF-7 MX100 cells. In our 
study chrysin was demonstrated to show no toxicity, even at higher concentration of 
1000 µM (Figure 2.4 D). The IC50 calculated for quercetin in PBMEC/C1-2 cells was 
169 µM (Figure 2.4 N). This was within the range used in -vivo studies in rats, from 1- 
400 µM  (van Zanden et al., 2007). 
 
2.14.3. Assessment of BCRP expression  in PBMEC/C1-2 cells 
 
To date, BCRP expression in PBMEC/C1-2 cells has not been reported previously. 
Our results confirmed the presence of BCRP protein expression in PBMEC/C1-2 cells 
using reverse transcriptase PCR (Figure 2.5A), western blotting (Figure 2.5B), 
immunofluorescence confocal microscopy (Figure 2.6) and qPCR (Figure 2.14).  
 
BCRP expression at the BBB and other cerebral cell lines has previously been 
reported. Eisenblatter et al (Eisenblätter et al., 2003), confirmed the genomic 
expression and localisation of BCRP by northern blot, RT-PCR and immunostaining in 
porcine brain capillary endothelial cells. Genomic expression of BCRP was 
demonstrated by RT-PCR in primary porcine brain endothelial cells (Thomsen et al., 
2015). Furthermore, human brain tissues and cerebro-microvascular endothelial cells 
have shown protein and genomic expression of BCRP (Zhang et al., 2003b). Thomsen 
et al (Thomsen et al., 2015) recently demonstrated the genomic expression of BCRP 
in porcine brain endothelial cells. Furthermore, BCRP has been found to be expressed 
in human, cow rat and mouse BBB (Warren et al., 2009, Cooray et al., 2002, Lee et 
al., 2007, Revalde et al., 2015b). Furthermore, when assessing the expression of 
BCRP in porcine primary brain microvascular endothelial cells, we confirmed the 
presence of BCRP using immunostaining techniques (Figure 2.23) and western 
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blotting (Figure 2.24), giving the expect protein size of 72 kDa and demonstrating 
primarily membrane localisation. 
 
2.14.4. Functional assessment of BCRP in the absence or presence of 
modulators  
 
The functional activity of BCRP has been extensively studied through the use of the 
BCRP fluorescent substrate H33342 (Zhang et al., 2000, Lai et al., 2004, Choi et al., 
2004).  We adapted these studies to initially assess whether we could detect BCRP in 
PBMEC/C1-2 by measuring its intracellular accumulation. This was then followed by 
assessing the impact of modulator incubation in a short-term assay of 1 h to mimic a 
direct inhibition of functional activity study, followed by a 24 h incubation to detect 
potential genomic/proteomic changes in BCRP, which are translated to changes in 
functional activity. 
We were able to successfully demonstrate functional activity through inhibition of 
BCRP efflux activity by using Ko143 (1 µM), which manifested itself in a significant 
increases in intracellular H33342 concentrations (Figure 2.10) of 1.8-2.3 mean fold that 
of H33342 in the absence of Ko143. 
To then screen the modulators for their ability to directly impact upon the functional 
activity of BCRP, we incubated cells with modulators for 1 h and assessed changes in 
intracellular H33342 accumulation. Our results demonstrated highly significant (p ≤ 
0.0001) increases in intracellular H33342 accumulation after 1 h incubation with 
apigenin (2.5 ± 0.2 fold), hesperidin (2.6 ± 0.5 fold), indole-3-carbinol (4.5 ± 0.4 fold), 
and TMF (6.5 ± 0.8 fold) when compared to Ko143 (Figure 2.10).  
 
TMF demonstrated the greatest increases in intracellular H33342 accumulation and 
hence appears to be a potent inhibitor of BCRP efflux activity at the BBB. Katayama 
et al (Katayama et al., 2007) also identified TMF as a potent BCRP inhibition in a 
screening study where 32 flavonoids were screened for their anti-BCRP activity, 20 
demonstrated inhibition of BCRP in BCRP-transduced human leukaemia K562 cells 
(Katayama et al., 2007). Of these, TMF showed the strongest anti-BCRP activity and 
very low levels of P-gp inhibitor activity. Thus, TMF is a highly potent inhibitor of BCRP 
activity at the BBB. Furthermore, other flavonoids have also demonstrated similar 
inhibitor activity of BCRP-mediate mitoxantrone efflux and include apigenin, chrysin, 
hesperetin, naringin and quercetin (Zhang et al., 2004a). In addition, chrysin (50 µM) 
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and benzoflavone (BF) (5 µM) have been reported to also act as potent inhibitors of 
BCRP-mediated mitoxantrone efflux in MCF-7 MX100 cells (Zhang et al., 2005).  
 
These finding indicate that modulators may play a role in directly inhibiting BCRP at 
the BBB. The exact mechanism of BCRP inhibition is not clear. But it has been reported 
that glycosylated flavonoids have anti-BCRP activity due to their water solubility (Imai 
et al., 2004). Modulators lacking significant inhibitory activity may be hindered by their 
low lipophilicity and reduced permeability. This may explains why we observed no 
inhibitory effects for hesperetin, resveratrol and rutin which are glycosides and have 
lower lipophilicity compared with their respective aglycons (Kühnau, 1976).  
Furthermore, the binding of flavonoids to the nucleotide-binding domain of BCRP has 
been identified as being important the inhibition process (Fleisher et al., 2015, 
Katayama et al., 2007), leading to inhibition of the ATPase function and hence halting 
of the conformational changes required to transport substrates across the cell 
membrane. Additionally QSAR analyses have demonstrated a strong structure-
inhibition relationship between BCRP and flavonoids. Flavonoids with a hydroxyl group 
at position 5, double bond between position 2 and 3 and methoxyl moiety at position 3 
or 6 (Pick et al., 2011) show preference for binding to BCRP and inhibiting the 
functional transport. This may explain why the greatest intracellular accumulation of 
H33342 was observed with TMF, as O-methylation at position 2, 4 and 6 increases the 
local hydrophobicity and hence signifies TMF mediated anti-BCRP activity.  
 
We were also interested to identify the effects of flavonoids on BCRP gene or protein 
expression over longer periods of exposure, namely 24 h. Our results demonstrated 
that incubation with the majority of flavonoids studied resulted in limited change in 
H33342 intracellular accumulation. Of those studied, apigenin, chrysin, curcumin, 17-
β-estradiol, I3C, rutin, silymarin and TMF demonstrated at least a 1.25 fold increase 
(relative to control) in H33342 intracellular accumulation at 1-10 µM (Figure 2.11) and 
hence suggesting a ‘down-regulation’ type effect. Also of note, is naringin and 
quercetin, which resulted in a reduction in H33342 intracellular accumulation of < 0.75 
fold of control, suggesting an ‘up- regulation’ effect (Figure 2.11). 
 
Of the published reports available, curcumin has been reported to inhibit BCRP 
function in HEK293 cells without altering protein levels over 72-hours of incubation nor 
inhibiting the ATPase function of the NBD (Wolfman et al., 1994). Furthermore, it has 
recently been recommended that curcumin be used as the ‘best’ in-vivo inhibitor of 
BCRP (Lee et al., 2015).  
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Our results also demonstrated that 17-β-estradiol increased H33342 accumulation to 
1.35 ± 0.2 fold compared to control. 17-β-estradiol is another widely reported inhibitor 
of BCRP function (Hartz et al., 2010, Mahringer and Fricker, 2010). Estrogens are 
known to regulate BCRP in human in-vitro, rat, and mice in-vivo models (Imai et al., 
2005a, Tanaka et al., 2005, Wang et al., 2006, Wang et al., 2008a). An estrogen 
responsive element in the promoter region of ABCG2 (gene-encoding BCRP) was 
identified in human ovarian cancer cells (Ee et al., 2004b) hence suggesting 17-β-
estradiol may play a role in the down-regulation of BCRP transcription/translation via 
regulatory network.   
 
Naringin and quercetin were also highlighted as leading to reduced H33342 
intracellular accumulation, suggesting they possess BCRP down-regulatory 
properties. Of the reported studies available, quercetin has been demonstrated to 
induce BCRP expression by 5.3 fold in Caco-2 cells at concentration of < 25 µM (Ebert 
et al., 2007). Interestingly, naringin at 50 µM, did not show any effect on the 
accumulation of mitoxantrone in BCRP-overexpressing MCF-7 MX100 cells (Zhang et 
al., 2004a), potentially as a result of being a flavonoids glycoside. 
 
 
2.14.5. Modulation BCRP protein expression in PBMEC/C1-2 cells 
In order to further explore the potential modulation of BCRP protein expression in the 
presence of modulators, western blotting analysis was conducted on all modulators at 
identical concentrations studied for the H33342 accumulation assays. Our results 
demonstrated that biochanin A, hesperidin, I3C, naringin and quercetin significantly 
induced BCRP protein expression leading fold change of 1.7 ± 0.1, 1.7 ± 0.3, 1.5 ± 0.1, 
2.2 ± 0.2 and 2.3 ± 0.1 respectively (Figure 2.12 and 2.13). Notably, naringin and 
quercetin demonstrated the greatest fold-change (> 2 fold) in BCRP protein expression 
and concurs with the H33342 accumulation observations. Additionally, in contrast to 
the study, naringin lead to an induction of BCRP protein expression (Zhang et al., 
2004a). It has been reported that exposure of 25 µM of quercetin, chrysin and I3C to 
Caco-2 cells, for 24 h, leads to a BCRP protein induction-effect and concurs with our 
studies demonstrated induction of BCRP expression with I3C and quercetin (Ebert et 
al., 2007). The lack of correlation following exposure to chrysin, flavone and resveratrol 
is uncertain by may be a result of differences in study time-scales (24 h vs. 72 h) or 
differences in the cell lines utilised (endothelial vs. epithelial). 
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Our studies also identified curcumin (0.4 ± 0.2) and 17-β-estradiol (0.4 ± 0.1) as ‘down-
regulators’ of BCRP protein expression (Figure 2.12 and 2.13). It has been recently 
investigated that curcumin and 23 analogous of curcumin are highly potent than 
curcumin in inhibiting BCRP mediated efflux and reversed BCRP mediated drug 
resistance. However, there are no current studies that have investigated changes in 
BCRP protein expression when exposed to curcumin for prolonged time-period 
(Revalde et al., 2015a). On the other hand, a number of studies have demonstrated 
the down-regulation of BCRP protein and genomic expression with 17-β-estradiol and 
includes modulation of BCRP activity in the mice brain capillaries (Hartz et al., 2010). 
Furthermore Mahringer and Fricker (Mahringer and Fricker, 2010) reported the 
reduced functional and protein expression of BCRP following 6 h incubation with 17-β-
estradiol (1-10 nM) in rat brain capillaries.  
 
2.14.6. Functional assessment of BCRP activity in an in-vitro permeable insert 
BBB model 
 
The functionality of BCRP was further demonstrated using the BCRP substrate 
pheobhorbide A (PhA) and assessing its transport across the PBMEC/C1-2 monolayer 
in the absence and presence of Ko143 or modulators. Initial studies demonstrated 
significant increase in PhA transport when exposed to Ko143 after 90 min and lasting 
until the final time point (180 min) (Figure 2.17), demonstrating the presence of 
functional BCRP. Furthermore, the apparent permeability in the apical-to-basolateral 
direction (Papp,AB) significantly increased (p < 0.01) when cells were exposed to Ko143, 
rising from 27.2 ± 0.23 x10-6 cm/s to 43.23 ± 0.32 x10-6 cm/s. 
 
Cells grown on permeable inserts were then exposed to modulators for 24 h followed 
by assessing the transport of PhA. Western blot and qPCR results (Figure 2.13 and 
2.14) confirmed that quercetin and naringin are potential up-regulators of BCRP at the 
BBB, and these were selected for transport studies. The apical-to-basolateral transport 
of PhA with quercetin and naringin was negligible (Figure 2.18). Thereafter the 
modulators were pre-incubated for 24 h in a similar fashion, but PhA was added into 
the basolateral compartment and the flux of PhA from basolateral-to-apical was 
assessed. Under these conditions both naringin and quercetin demonstrated 
significant increases (p ≤ 0.01) in PhA transport from basolateral-to-apical at all time 
points when compared to control (Figure 2.19) leading to increases in Papp,BA to  74.23 
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± 0.29 x10-6 cm/s and 63.21 ± 0.54 x10-6 cm/s respectively when compared to control 
Papp,BA 23.13 ± 0.31 x10-6 cm/s (p ≤ 0.01).   
 
As the modulators were inducing BCRP expression, the addition of PhA in the apical 
compartment would not alter the concentrations of PhA over the time-course of the 
study due to the ‘retention’ of PhA in the donor compartment as a result of BCRP efflux. 
When the donor compartment was switched to the basolateral compartment, 
alterations in BCRP transporter activity resulted in a more apparent change in receiver 
(apical) compartment concentration. 
 
Western blot and qPCR (Figure 2.13 and Figure 2.14) confirmed that curcumin and 
17-β-estradiol are potential down-regulators of BCRP at the BBB, and these were 
selected for transport studies. In our studies curcumin (1 µM) and 17-β-estradiol (100 
nM) significantly increased PhA Papp,AB to 78.81 ± 0.65 x10-6 cm/s and 48.11 ± 0.34 
x10-6 cm/s when compared to control Papp,AB 27.20 ± 0.23 x10-6 cm/s (p ≤ 0.001) 
representing BCRP down-regulation (Figure 2.20). In both cases the increase in Papp,AB 
is indicative of an increase in the apical-to-basolateral flux, and is a result of the 
associated changes in BCRP protein expression potentially reducing the abundance 
of BCRP in the monolayer and hence reducing the overall kinetic flux of PhA molecules 
across the monolayer. Furthermore, the increase apical-to-basolateral PhA flux when 
exposed to 17-β-estradiol concurs with reports highlighting the potent down-regulation 
imparted by 17-β-estradiol on BCRP expression (Mahringer and Fricker, 2010, Hartz 
and Bauer, 2010). 
 
 
2.14.7. Characterisation of a primary porcine brain endothelial cell BBB model 
 
Whilst immortalised cell models are widely used in BBB research, the use of primary 
cell culture models often leads to a more representative and viable model system. 
Primary porcine brain microvascular endothelial cells were successfully isolated in the 
lab from the fresh porcine brain hemispheres. Cells became confluent after 10-12 days 
post seeding and demonstrated typical elongated, spindle shape morphology under 
light microscopy (Figure 2.21). Patabendige et al (Patabendige et al., 2013) recently 
reported the detailed isolation process, morphology and characteristics of primary 
brain endothelial cells. Our results were consistent with Patabendige and other studies 
reported (Imai et al., 2003, Spencer, 2008). The primary porcine brain endothelial cells 
were seeded onto collagen coated permeable inserts and 3 µg/mL was used to kill the 
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contaminating cells and obtain pure monolayers. On a 12-well permeable inserts (1.1 
cm2) the primary endothelial cells showed the TEER values of 150-200 Ω.cm2.  
 
The type of collagen and amount of collagen is very important for growth of primary 
cells. Our results found that primary porcine brain microvascular endothelial cells take 
longer 12-13 days to confluent when compared with other studies (10 days) 
(Patabendige et al., 2013, Spencer, 2008). The discrepancies between the numbers 
of days could be a result of the use of commercial collagen rather than collagen 
extracted from rat tails, as conducted by Patabendige et al (Patabendige et al., 2013). 
Furthermore, the barrier integrity of the in-vitro was enhanced by switching on day 4 to 
serum free media supplemented with 250 µM CPT-cAMP, 17.5 µM RO20-1724 and 
500 nM of hydrocortisone, as reported elsewhere (Woodward et al., 2009, Ishiwata et 
al., 2005, Schwerk et al., 2012).  
 
The cytotoxicity for the primary cells was also investigated. PBMEC/C1-2 cells 
provided a broad understanding of the potential cellular toxicities of modulators and 
this was used as a basis with which to select two concentrations (25 µM and 100 µM) 
(Figure 2.25), for screening against primary porcine brain endothelial cells. Our results 
demonstrated higher cellular viabilities for most modulators at both 25 µM and 100 µM.  
Where cell viability reduced, this was typically in the range of a viability of between 50-
100%. Of note however is the reduction of cellular viability for modulators at 25 µM for 
baiclain (76 ± 11 %) and α-napthoflavone (63 ± 7 %) and at 100 µM for baiclain (62 ± 
12 %), curcumin (29 ± 18 %), 17-β-estradiol (64 ± 4 %), hesperetin (53 ± 0.8 %) and 
α-napthoflavone (25 ± 7 %) (Figure 2.25). 
 
When compared to cytotoxicity with PBMEC/C1-2 cells, baicalin, curcumin, 17-β-
estradiol, flavone, hesperetin, hesperidin, napthoflavone and resveratrol demonstrated 
similar trends of cytotoxicity in both cell lines although the toxicity with primary cells 
was found to be lower than PBMEC/C1-2 cells. Furthermore, chrysin, fistein, naringin 
and silymarin demonstrated no cytotoxicity above 100 µM and similar trends were 
found in primary cells with no toxicity observed under 100 µM. 
 
Structural and functional relationship of flavonoids has suggested that flavones and 
flavonols are more cytotoxic, whereas flavanones are less toxic (Wen et al., 2005) to 
cells. Our results have demonstrated that flavanones such as naringin did not 
demonstrate any cytotoxicity at higher concentrations unlike baiclain, α-napthoflavone, 
curcumin and hesperidin in PBMEC/C1-2 cells. Naringin is identical to apigenin with 
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the exception of the 2,3-double bond on the C-ring (Figure 2.4 M). In our results, we 
have shown that naringin did not cause any cytotoxicity and apigenin has shown IC50 
of 673.8 µM (Figure 2.4 A) in PBMEC/C1-2 cells. The planar nature of the compound 
and presence of B-ring attached at the 2-position of the benzopyran core is required 
to induce cytotoxicity. The planarity of the compound can help them to cross the cell 
membrane and enter the cytoplasm and B-ring is important to bind to protein targets 
(Wen et al., 2005).  
 
The localisation of BCRP protein expression was further confirmed by immunostaining 
(Figure 2.23) and western blot (Figure 2.24), demonstrating both elongated, tightly 
packed endothelial cell morphology when grown on permeable insert, in addition to the 
confirmed of the expected 72 kDa BCRP protein in western blotting studies. To identify 
and confirm functional BCRP in primary porcine brain microvascular endothelial cells, 
a permeable insert model was developed and the transport of PhA across the 
monolayer was assessed in the absence and presence of Ko143. Our results 
demonstrated a significant increase (p ≤ 0.01) in apical-to-basolateral transport of PhA 
at all time points studied in the presence of Ko143 demonstrating the inhibition of 
BCRP (Figure 2.26).  This is highlighted when considering increase in Papp,AB from 
60.57 ± 1.32 x10-6 cm/s in the absence of and 109.75 ± 1.21 x10-6 cm/s in the presence 
of Ko143 (Figure 2.26).  Furthermore, quercetin and naringin were identified as BCRP 
inducers (Figure 2.13) and when studied in the transport model, demonstrated 
significant increases (p ≤ 0.01) in PhA transport from basolateral-to-apical at all time 
points when compared to control (Figure 2.27). This led to an increase in Papp,BA for 
quercetin and naringin to 102.93 ± 1.98 x 10-6 cm/s and 98.21 ± 1.23 x10-6 cm/s 
respectively when compared to the absence of modulators,  38.57 ± 2.15 x10-6 cm/s. 
In a similar fashion the BCRP down-regulators curcumin and 17-β-estradiol 
demonstrated increased apical-to-basolateral transport of PhA and significantly 
increased Papp,AB to a Papp 83.23 ± 1.25 x 10-6 cm/s and 83.87 ± 3.25 x10-6 cm/s 
respectively when compared to PhA alone 60.57 ± 1.32 x10-6 cm/s (Figure 2.28).   
Whilst gene or protein changes in BCRP expression may suggest at a possible change 
in the functional expression of BCRP, without conducting transport studies using a 
BBB monolayer model, the consequences of any gene/protein level changes in BCRP 
cannot be assessed in a functional sense.  Across both PBMEC/C1-2 and primary cell 
culture model we identified similar behaviours of induction or down-regulation of BCRP 
expression and the functional consequences of this was confirmed using the 
permeable insert models. 
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In this chapter, we characterise the PBMEC/C1-2 cells and primary porcine brain 
microvascular endothelial cells for the protein, genomic and functional expression of 
BCRP. Our results confirmed that BCRP is expressed in PBMEC/C1-2 cells and 
primary porcine brain microvascular endothelial cells. Furthermore, the interaction of 
flavonoids with BCRP was investigated in the presence or absence of modulators. Our 
results indicated that modulators interact with BCRP and can modulate BCRP function, 
protein and genomic expression at BBB. 
The findings presented in this chapter suggest that 17-β-estradiol and curcumin are 
viable down-regulators of BCRP expression and efflux function whereas quercetin and 
naringin are viable inducers of BCRP expression and efflux function. This has clear 
implications for modulating the efflux role of BCRP at the BBB towards either clearing 
agents from the brain biophase back into the systemic blood or forcing equilibrium 
towards enhanced brain delivery of therapeutic compounds. 
2.15. Conclusion 
Due to the limited impose by structural barrier (BBB) the drug delivery to the CNS 
remains a challenge. The Porcine brain endothelial microvascular cell culture model 
has been extensively used due to more close resemblance with human model. The 
phytochemicals have shown less or no cytotoxicity in PBMEC/C1-2 cells whereas 
primary cells have shown more cytotoxicity. This chapter demonstrated that the 
quercetin and naringin has shown to up-regulate the BCRP protein, genomic and 
functional expression, whereas curcumin and 17β-estradiol were down-regulators of 
BCRP. This work can be further exploited to investigate the modulation of BCRP in 
disease conditions to enhance the CNS drug delivery.  
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Chapter 3 
 
Assessment of the interactions of 
phytochemicals on BCRP expression 
and function at the rat blood 
cerebrospinal fluid barrier 
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3. Introduction 
 
The choroid plexus (CP) epithelium represents an important site controlling the 
development and maintenance of brain and CNS biophase and presents itself as the 
key barrier between the systemic blood and the CSF, often termed the blood-CSF-
barrier (BCSFB). Despite the importance, the CP only accounts for approximately 0.25 
% of the total brain weight.  However, due to its limited tissue mass, the isolation of 
primary choroid plexus epithelial cells for laboratory studies is labour and time 
consuming.  
 
A well-characterised in-vitro BCSFB cellular model would present itself as a valuable 
tool to understand the important role the BCSFB plays in controlling entry of 
compounds into the CNS. As a result of this, a number of immortalised choroid plexus 
cell culture models have become important tools to study pathological diseases of the 
CP (Nutt et al., 2003, Rennels et al., 1985), drug permeability (Szentistvanyi et al., 
1984), transporter function (Baehr et al., 2006) and modulation of transporters 
expression (Oldendorf, 1967). The rat chorodial epithelial Z310 cell culture model was 
developed by Dr Wei Zheng, (Zheng and Zhao, 2002) and has been widely 
characterised to assess the epithelial cell morphology, tight junctions and functional, 
genomic and protein expression of drug transporters (Zheng and Zhao, 2002, 
Goodman, 1985, Juliane Kläs et al., 2010, Halwachs et al., 2011), and is therefore a 
viable in-vitro model for the study of the function of the BCSFB. 
 
3.1. Aims and objectives 
The aim of the experimental work reported in this chapter was to develop and 
characterise the use of an in-vitro BCSFB cell culture model to investigate the genomic 
and proteomic modulation of the drug transporter BCRP. To accomplish this, a range 
of phytochemical modulators was screened for the ability to modulate the functional, 
genomic and protein expression of BCRP in Z310 cells.  
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To achieve the aims the objectives were:  
 To demonstrate the formation of an in-vitro BCSFB model using Z310 cells  
 To investigate the genomic and protein expression of BCRP in the Z310 cells 
 To investigate the cytotoxicity of phytochemical modulators towards Z310 cells 
 To demonstrate the efflux function of BCRP in Z310 cells 
 To identify phytochemical modulators capable of eliciting genomic/proteomic 
changes in BCRP expression  
 
3.2. Materials  
Dulbecco’s modified essential media with glucose (DMEM), fetal bovine serum (FBS), 
amphotericin B, penicillin/streptomycin and gentamycin were obtained from Biosera 
(Sussex, UK); Resveratrol and Ko143 from Santa Cruz Biotechnology (Texas, USA); 
Curcumin from Cayman Chemical (Cambridge, UK); GenElute Total RNA extraction 
kits were purchased from Sigma (Dorset, UK); Rat-tail I collagen solution from First 
Link (Birmingham, UK) and all other chemicals were sourced from Sigma (Dorset, UK). 
My TaqTM One-step RT-PCR kit and Easy Ladder I obtained from Bioline (London, UK). 
All reverse transcriptase PCR primers were synthesised by IDT Dna (Leuven, 
Belgium); Real time PCR housekeeping primers were obtained from Invitrogen, AhR 
and BCRP were custom designed by Primer Design (Sheffield, UK), Total RNA 
extraction kits were purchased from Qiagen (Manchester, UK) and SYBR-green 
master mix were obtained from Primer Design (Sheffield, UK), Optiblot SDS-page gel 
and western blot reagents obtained from Abcam (Cambridge, UK); ABCG2 (M-70), 
beta-actin (C4), broad range markers, goat anti-rabbit IgG-FITC and protease inhibitor 
cocktail were obtained from Santa Cruz Biotechnology (Texas, USA). Stock solutions 
of all test compounds were prepared in dimethylsulfoxide (DMSO) and stored at -20°C 
until use. 
 
A total of 18 phytochemical derived modulators were selected for studies and their 
structures are detailed in Appendix A. 
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3.3. Methods 
 
3.3.1. Culture of Z310 cells 
Z310 cells were grown in T25 flasks containing Z310 media:  DMEM, 10 % v/v FBS, 
1% v/v amphotericin B, 1 % v/v penicillin/streptomycin and gentamycin (20 mg in 500 
mL of media) and epidermal growth factor (EGF) at the final concentration of 10 ng/mL. 
Cells were allowed to attach at 37°C for 24 h. Thereafter the media was changed cells 
grown until 70-80 % confluent before 1 mL of trypsin-EDTA was added to the flask. 
The flask was placed maintained for 5 min at 37°C and the cell suspension was 
resuspended in a 5 mL of media. This cell suspension was transferred to a 15 mL 
centrifuge tube and centrifuged at 1500 rpm for 5 min. The pellet was resuspended in 
2 mL of media and transferred into T75s for subsequent experiments.  
 
3.3.2. Cryopreservation of cells 
After harvesting cells, the pellet was resuspended in cryopreservation media (10% 
DMSO and 90% FBS). 1 mL aliquots of the cell suspension was aliquoted into cryovials 
and stored overnight at -80˚C in a controlled freezing environment (Mr. Frosty, 
Nalgene®, Thermo Fisher Scientific, UK) before being transferred to the liquid nitrogen 
for long term storage. 
 
3.3.3. Development of an in-vitro permeable insert based model of the BCSFB 
 
3.3.3.1. Extracellular matrix coating with collagen  
 
12-well permeable inserts (Greiner ThinCert®) were coated with 200 µL of 0.01% rat 
tail collagen type 1 solution in sterile water, and incubated for 3-4 h in a laminar air flow 
hood. Excess collagen solution was then aspirated and inserts washed with pre-
warmed PBS. The permeable inserts were then immediately used for seeding of cells. 
1 mL of a cell suspension containing 2 x105 cells were seeded onto the permeable 
inserts and cells were grown in the Z310 medium supplemented with 1 µM 
dexamethasone (Shi and Zheng, 2005). 
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3.3.3.2. Visualisation of cell monolayers under light microscopy 
 
Approximately 2-3 days after seeding, cell monolayers were examined using a 
DMI400B microscope (Leica microscope systems (UK) Ltd, Milton Keynes, UK) with a 
10x and 40x objective lenses.  
 
3.3.3.3. Measurement of transcellular electrical resistance 
 
The media was changed every other day and the trans-cellular electrical resistance 
(TEER) values were measured every day up to 8 days post seeding. Monolayer 
formation was monitored by measuring the TEER using a voltohmmeter (EVOM) 
(World Precision Instrument) directly before and after all transport studies.  
 
TEER values were calculated as follows: 
 
TEER Values (Ω. cm2) = (RCell monolayer − RBlank Filter)xA                (1) 
where A = surface area of the permeable insert (cm2), RCell monolayer = resistance across 
permeable insert with cell monolayer and RBlank filter = resistance across permeable 
insert without cells.  Control measurements were made using filters without cells (blank 
filter). A cut-off TEER range of 95 ± 8 Ω.cm2 (Zheng and Zhao, 2002, Juliane Kläs et 
al., 2010) was used a measure of a suitable BCSFB model. 
 
3.3.4. Cellular toxicity of modulators towards Z310 cells: 
methylthiazolyldiphenyl-tetrazolium bromide assay 
 
Stock solutions of all modulators were prepared in DMSO. Sterile working stocks of 
each compound were freshly prepared on the day. Culture medium was used as the 
diluent and the final solvent concentrations in all test drug concentrations did not 
exceed 1 % (v/v).  Cells were seeded with an optimum density of 10,000 cells per well 
onto clear flat bottom 96-well plates and at 60-70 % confluency the media was carefully 
removed and fresh media containing phytochemical modulators over a 7-fold log 
concentration range (0.001 µM-1000 µM) was added and incubated for 24 h. The 
media was then removed and cells were carefully washed with the pre-warmed PBS 
to 37°C and incubated with fresh media for 30 min for the cells to equilibrate. MTT 
powder was dissolved in PBS (5 mg/mL) and filtered through a 0.2 μm pore size filter 
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to sterilise the solution and remove any insoluble residues. 20 µL of the pre- warmed 
MTT solution was added to each well. The plates were protected from light and 
incubated at 37 °C in a humidified atmosphere of 5 % CO2 in air for 4 h. After 4 h 
medium was removed and 100 µL of DMSO was added to the each well of the 96-well 
plate to stop the reaction and solubilise the purple formazan crystals. The plates were 
incubated for 10-15 min at room temperature under dark conditions.  
The UV-absorbance of the samples was measured on a multi-plate reader (Bio-Rad 
laboratories, Hercules, CA) using 570 nm as a test wavelength and 600 nm as a 
reference wavelength. The mean of the blank UV-absorbance was subtracted from the 
UV-absorbance of each controls and samples and percentage viability was calculated. 
The percentage of cellular viability was calculated using the equation below:  
% cell viability =
absorbance of sample
absorbance of control 
∗ 100           (2)   
  
The IC50 was subsequently using a sigmoidal dose response function within the 
Graphpad Prism version 5.0 (GraphPad Software, Inc. USA). 
 
      
3.3.5. Immunostaining detection of breast cancer resistance protein in Z310 
cells 
 
A 2 mL cell suspension containing 30,000 cells were seeded onto uncoated coverslips 
for 24 h in an air humidified atmosphere of 5% CO2. Subsequently cell culture media 
was aspirated and coverslips were washed three times with pre-warmed PBS. Cells 
were then fixed with methanol at -20°C for 20 min and washed three times with pre-
warmed PBS. Coverslips were then exposed to blocking solution (1 % BSA in PBS) 
incubated for 30 min at room temperature before being incubated with primary ABCG2 
antibody M-70 (1:200) for 2 h at 37°C. Coverslips were washed twice with PBS and 
incubated with secondary antibody fluorescein iso-thiocyanate (FITC) -labelled mouse 
anti-rabbit IgG (1:500) in blocking solution, for 45 min at room temperature in the dark. 
The secondary antibody was aspirated and cells were washed three times with pre-
warmed PBS.  
 
The coverslips were then carefully removed from the 12-well plate, rinsed with MilliQ 
water and mounted onto glass slides with mounting media containing 4',6-diamidino-
2-phenylindole (DAPI). The coverslips were analysed using an upright confocal 
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microscope (Leica SP5 TCS II MP) and visualised with an oil immersion objective. All 
images were acquired using an argon laser to visualise FITC localisation and a helium 
laser to visualise DAPI localisation at 494 nm and 461 nm respectively.  
 
3.3.6. Measurement of BCRP functional activity in Z310 cells 
 
3.3.6.1. Functional activity of BCRP in Z310 cells using a 96-well plate assay  
The functional activity of BCRP in Z310 cells was assessed using the BCRP inhibitor 
Ko143.  20,000 cells per well were seeded into a 96-well plate and allowed to attach 
for 24 h. Thereafter the cells were washed with pre-warmed HBSS at 37°C and fresh 
media added containing 3.9 nm - 5 µM Ko143 and left to pre-incubate for 1 h. 100 µL 
of media containing 10 µM of H33342 and 3.9 nm - 5 µM Ko143 were added to the 
appropriate wells and incubated for a further 30 min at 37°C. Wells were then washed 
twice with ice cold HBSS and cells lysed by storage of plates at -80°C for 20 minutes 
before being read on a fluorescent plate reader at an excitation wavelength of 355 nm 
and emission wavelength of 460 nm. 
 
3.3.6.2. Assessment of the intracellular accumulation of H33342 in the presence 
of modulators in Z310 cells.  
 
The potential of modulators to alter the functional activity of BCRP in Z310 cells was 
assessed by measuring changes in the intracellular accumulation of H33342 in the 
absence and presence of modulators. Z310 cells were seeded onto clear-bottomed 
96-well plates for 24 h. The experimental assessment for modulators to directly inhibit 
BCRP function or modulate BCRP protein expression was conducted as described in 
section 2.4.5.3 and 2.4.7. 
 
 
3.3.7. Determination of BCRP gene expression by reverse-transcriptase PCR in 
Z310 cells  
 
3.3.7.1. Extraction of total RNA 
 
Isolation of total RNA from Z310 cells was obtained as described in section 2.4.6.1. 
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3.3.7.2. One-step reverse-transcriptase PCR 
 
A one-step RT-PCR assay was developed as described in section 2.4.6.2 using 100 
ng of template (Table 3.1). 
 
       Table 3.1: Preparation of PCR samples 
Reagents     Volume 
My Taq One-Step Mix  25 µL 
Primer Forward   1.5 µL 
Primer Reverse   1.5 µL 
Reverse Transcriptase Enzyme 0.5 µL 
Ribosafe Inhibitor   1 µL 
DEPC Water   15.5 µL 
Template(100ng)      5 µL 
Total Volume     50 µL 
 
Forward and reverse primers (HKG: β-actin and TTR; GOI: BCRP) were designed 
using the PrimerQuest tool (http://www.idtdna.com/primerquest/home/index) and 
custom synthesised (IDTDna, Germany) (Table 3.2).  The thermal cycling was 
conducted using a Hybaid OmniGene Thermal Cycler using a three-step protocol 
(Table 3.3). 
Table 3.2: Primers used for RT-PCR 
Gene Gene Accession Forward Primers   Reverse Primers   
TTR NM_022712 CCACAAGCCAAACAATATCCG  CCAAATGCTCAACGACCACA 
BCRP NM_181381 CTTCTCCATTCACCAGCCTC  TGTAGGGCTCACAGTGGTAA 
β-actin NM_031144 CATGAAGATCCTGACCGAGC  CAGCTCAGTAACAGTCCGC 
 
Table 3.3: Thermal cycle reactions for PCR 
 
 
 
 
    
Cycles   Temperature Time Procedure 
1  45°C  20 min Reverse Transcription 
1  95°C  1 min Polymerase Activation 
40  95°C  10 s Denaturation 
  55°C  10 s Annealing  
  72°C   30 s Extension   
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3.3.7.3. Gel electrophoresis 
Visual confirmation of successful PCR product was conducted by agarose gel 
electrophoresis as described in section 2.4.6.3. 
 
3.3.8. Determination of BCRP protein expression in Z310 cells 
 
3.3.8.1. Preparation of cell lysate 
Z310 cells were grown on 6-well plates for 48 h and whole cell obtained as described 
in section 2.4.7.1. To assess the impact of modulators on BCRP protein expression, 
Z310 cells were also incubated with modulators at 25 µM (unless otherwise stated) for 
a further 24 h post-seeding and the whole cell lysate subsequently extracted.  
 
3.3.8.2. Determination of protein concentration: bicinchoninic acid assay 
 
Protein concentration was quantified by a bicinchoninic acid (BCA) assay (Novagen, 
BCA assay protein kit) as described in section 2.4.7.2. 
 
3.3.8.3. Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was 
conducted using 8% SDS precast gels (Abcam, Cambridge, UK) as described in 
section 2.4.7.3. 
 
3.3.8.4. Electrophoretic transfer and blotting of proteins 
 
Electrophoretic transfer and blotting of proteins was conducted as described in section 
2.4.7.4. 
 
3.3.8.5. Immunological detection of BCRP 
The electrophoretic transferred protein membrane was washed with TBST buffer for 
30 min and then blocked with the blocking buffer (5% milk and TBST) for 1 h at room 
temperature. The membrane was subsequently incubated with polyclonal ABCG2 
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antibody (M-70) in blocking buffer (1:500) and incubated overnight at 4 °C. Thereafter 
the membrane was placed on an orbital shaker for 2 h and washed with TBST for 30 
min before being blocked with blocking buffer for 30 min at room temperature. The 
membrane was then incubated for 2 h at room temperature with goat anti-rabbit IgG-
horse radish peroxidise-conjugated (1:5000) in blocking buffer. 
 
3.3.8.6. Chemiluminescent detection of BCRP 
 
Laboratory prepared enhanced chemiluminescent solution was freshly prepared to 
detect BCRP, as described in section 2.4.7.6.  
 
3.3.8.7. Membrane stripping  
 
To allow reprobing of the membrane, a mild stripping agents was used to remove 
attached antibodies (Bendayan et al., 2006) and is described in section 2.4.7.7. 
 
3.3.8.8. Immunological detection of  β-actin 
To reprobe the membrane for the loading control (β-actin) the membrane was 
incubated with blocking buffer, followed by mouse β-actin horseradish peroxidase 
conjugated monoclonal antibody (1:7500) in blocking buffer for 24 h at 4°C. The 
membrane was then washed with TBST for 2 h. Chemiluminescent detection was 
performed as described in section 2.4.7.6. 
 
3.3.9. Determination of modulation of BCRP gene expression by 
phytochemical compounds using quantitative PCR in Z310 cells 
  
3.3.9.1. Isolation of RNA 
Z310 cells were grown on 6-well plates for 24 h followed by the addition of modulators 
at 25 µM (unless otherwise stated) before being incubated for a further 24 h. RNA was 
extracted as detailed in section 2.4.6.1. 
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3.3.9.2. Reverse transcription 
 
A two-step reverse transcription protocol was utilised involving both annealing and 
extension steps and is detailed in section 2.4.8.2. 
 
3.3.9.3. qPCR cycle parameters 
 
The qPCR reaction mixture was prepared as outlined in Table 3.4. 
 
Table 3.4: Preparation of PCR samples 
Reagents       Volume 
10x Master Mix   10 µL 
Primer Forward (6 pmol)  1 µL 
Primer Reverse (6 pmol)  1 µL 
RNase-free Water   3 µL 
Template (25 ng)   5 µL 
Total Volume     20 µL 
 
qPCR primers were custom synthesised as follows: GADPH (NCBI Accession: 
NM_017008) forward primer GGTCAAGCAGCATAATCCAAAG, reverse primer 
CAAGGGCATAGCCTACCACAA and a custom synthesised porcine BCRP (NCBI 
Accession: NM_181381) gene primers (PrimerDesign, UK).  Samples were loaded 
onto a Stratagene MX3000p thermal cycler (Agilent technologies, United States) using 
a SYBR-green detection probe and a two-step cycling protocol (Table 3.5). 
 
  Table 3.5: qPCR thermal cycles 
Cycles   Step   Time Temperature 
  Enzyme activation 2 min 95°C  
40 Cycles Denaturation 15 s 95°C  
40 Cycles Data Collection 60 s 60°C   
  
 
3.3.9.4. qPCR quantification method 
Relative quantification determines the mRNA changes in gene of interest (BCRP) 
relative to the levels of a housekeeping gene (GADPH) RNA. Threshold cycle (Ct) 
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values were determined and changes in the expression of target gene normalised with 
GADPH calculated for each reaction condition (ddCT method) (Livak and Schmittgen, 
2001) (Equation 3) 
Fold change = 2−∆(∆𝐶𝑡) (3)    
 where ΔCt = CT,BCRP-CT,GADPH 
The efficiency of all genes were pre-validated for specificity by the manufacturer. 
 
3.3.10.  Assessing the functional activity of BCRP in an in-vitro BCSFB 
monolayer model  
 
3.3.10.1. HPLC detection of sulfasalazine 
 
To assess the function of BCRP in-vitro, the BCRP substrate sulfasalazine was used. 
A isocratic HPLC method was utilised for the HPLC-UV detection of sulfasalazine, 
(Gurvitch and Metzler, 2009). HPLC analysis (Shimadzu, LC- 2010A HT) of 
sulfasalazine was performed using a reversed-phase C18 column (Phenomenex Luna 
5-µm) with a mobile phase consisting of 70:29:1 methanol:millQ water:acetic acid and 
flow rate of 1 mL/min. The method was validated by evaluating the parameters such 
as linearity, limit of quantification (LOQ) and limit of detection (LOD). The linearity was 
determined by analysing the sulfasalazine standards (0.01-50 µM). The standards 
were prepared in triplicates and a calibration curve was generated to determine the 
coefficient (r2). The LOD is the lowest amount of a substance that can be detected and 
LOQ is the concentration at which the quantitative results can be reported. The LOD 
and LOQ was determined by as follows:  
 
LOD =  3.3(σ S)⁄   (4) 
LOQ = 10(σ S)⁄   (5) 
 
where σ is the standard deviation of the response; S is slope of the calibration curve. 
Regression analysis was performed with the standards to calculate the standard 
deviation and slope of the calibration curve. 
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3.3.10.2. Optimisation of in-vitro transport media 
 
Permeable Z310 inserts were prepared according to section 3.4.3. TEER values were 
used a measure of monolayer formation and suitability of transport media.  Preliminary 
experiments were performed to assess integrity of monolayers when incubated with 
either HBSS supplemented with glucose (10 mM) and HEPES (10 mM) or Z310 serum 
free media. TEER values were determined after 30 min, 60 min, 90 min, 120 min, 150 
min and 180 min exposure to media. 
 
3.3.10.3. Lucifer yellow permeability assay 
 
To assess the formation of a suitable monolayer, lucifer yellow was used as a 
permeation marker, as described in section 2.4.9.3. Inserts were rejected for 
permeability assays if the percentage LY transported was greater than 1 %. 
 
3.3.10.4. Modulation of BCRP transport function  
To assess the potential for phytochemical modulators to modulate the in-vitro 
transporter function of BCRP in the permeable insert BCSFB model, modulators 
identified as resulting in induction or down-regulation of BCRP protein from western 
blotting studies (section 3.4.8) were selected to assess their potential to modulate the 
efflux of the BCRP substrate sulfasalazine.  Cells were seeded onto collagen-coated 
permeable inserts (see section 3.4.3) and TEER values used to assess the formation 
of a monolayer.   
Z310 seeded permeable inserts were washed with pre-warmed PBS and freshly 
prepared working stocks of modulators (optimal non-toxic concentrations were used 
and determined from cytotoxicity and western blotting studies) and Ko143 in serum 
free media were added to the permeable inserts and incubated for either 1 h (Ko143: 
to pre-load cells with inhibitor) or 24h (modulators: to modulate the protein expression 
of BCRP) at 37°C.  
Cells were subsequently washed with pre-warmed PBS followed by the addition of 
serum free media (SFM) containing Ko143 (1 µM) or modulators and 10 µM 
sulfasalazine into the apical compartment.  The basolateral compartment received 
media with modulators only. 50 µL aliquots were taken at 0, 30, 60, 90, 120, 150, 180 
and 210 min and the transport of sulfasalazine determined by HPLC-UV methods.  For 
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modulators demonstrating induction of BCRP, all compounds were added into the 
basolateral compartment and sampling of the apical compartment was conducted. 
3.3.10.5. Calculation of permeability coefficients 
The apparent membrane permeability (Papp: x10-6 cm/s) of sulfasalazine was 
calculated according to equation 6. 
Papp =  𝑑𝑄 𝑑𝑡⁄ ∙
1
𝐴𝐶0
      (6) 
where dQ/dt is the rate of appearance of sulfasalazine on the receiver side (calculated 
from the slope of the cumulative transport graph), C0 is the initial concentration of 
sulfasalazine in the donor compartment and A (cm2) is the surface area of the insert. 
3.3.11. Statistical analysis 
 
All statistical analyses were performed in Graph pad Prism (La Jolla, California, USA). 
One-way ANOVA and t-tests were carried out to determine the differences between 
the mean values. For all multi-well based assay replicates of at least 6 were used in 
three independent experiments. For western blot and transport studies replicates of at 
least three were used and repeated in three independent experiments.  IC50 and EC50 
metrics were calculated using sigmoidal fit functions within Graph pad Prism. A 
significance p-value of < 0.05 was considered as statistically significant.  
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3.4. Results 
 
3.4.1. Z310 cell morphology 
Z310 cells were grown on uncoated plastic surfaces and typically became confluent in 
2-3 days.  Cells show formation of closely packed islands under light microscopy with 
typical polygonal epithelial morphology at 10X and 40X (Figure 3.1).  
             
             Figure 3.1: Morphology of Z310 cells grown on tissue culture surfaces.  
Z310 cells were seeded at a density of 4x104 cells/cm2 and incubated at 37˚C with 5% CO2 in a humidified 
atmosphere for two days. The cells were examined under 10x (A) and 40x (B) objective lens.  
 
 
 
3.4.2. Development of a Z310 in-vitro BCSFB model 
 
3.4.2.1. Assessment of monolayer formation and barrier integrity 
 
The formation of a monolayer was determined by assessing the TEER values for 12 
days post seeding in order to identify the optimal growth time on inserts. TEER values 
demonstrated a steady increase as the monolayer started to form and reached 92 ± 5 
Ω.cm2 on day 8 before starting to decline thereafter (Figure 3.2).  
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Figure 3.2:  Monolayer resistance of Z310 grown on permeable inserts. 
Z310 cells were seeded at a density of 2.0 x105 cells/cm2 onto collagen coated inserts at 37˚C with 5% 
CO2 in a humidified atmosphere. The media was replaced every other day and TEER values were 
measured with EVOM voltammeter up to 12 days. Statistical analysis compares TEER at day 2 to all other 
data points. *** P ≤ 0.001 and ****P≤0.001. 
 
 
3.4.2.2. Measurement of CSF formation 
A key function of the choroid plexus epithelial cells is the production of cerebrospinal 
fluid (CSF). Z310 cells grown on permeable inserts demonstrated the production of 
fluid in the inner chamber and an increase in the volume height, which was maintained 
at > 2 mm for 48 h (Figure 3.3).  
 
 
Figure 3.3: Measurement of fluid formation in permeable inserts 
Z310 cells were seeded at a density of 2.0 x105 cells/cm2 onto the collagen coated inserts for 7 days at 
37˚C with 5% CO2 in a humidified atmosphere. The media was replaced every other day. After 3-4 days 
when the monolayer was formed the volume of inner chamber was increased and remained consistent 
for at least 48 h. 
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3.4.3. Cellular toxicity of modulators towards Z310 cells 
To investigate the cellular toxicity of modulators towards the Z310 cells, a MTT cellular 
toxicity assay was conducted whereby cells were exposed to a 7-fold log 
concentration range of modulators, 0.001 µM-1000 µM, for 24 h. 
The majority of modulators demonstrated IC50 values above 140 ± 1.5 µM.  The lowest 
IC50 values (1.4 ± 0.8 µM) was identified for α-napthoflavone (Figure 3.4L) followed by 
quercetin (107 ± 2.3 µM) (Figure 3.4N).  Additionally a number of modulators 
demonstrated minimal toxicities up to 1000 µM and included chrysin (Figure 3.4D), 
17-β-estradiol (Figure 3.4F), hesperidin (Figure 3.4J), naringin (Figure 3.4M), silymarin 
(Figure 3.4Q) and TMF (Figure 3.4R). 
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Figure 3.4: Phytochemical cytotoxicity towards Z310 cells  (A-F) 
The Z310 cells were seeded on to the  96-well plates at 37°C in a humidified atmosphere of 5% CO2 in 
air for 24h. The media was aspirated and cells were incubated with 7-fold log concentration range (0.001 
µM-1000 µM) of apigenin (A), baiclain (B), biochanin A (C), chrysin (D), curcumin (E) and 17-β-estradiol 
(F) for 24 h, prior to the assessment of cytotoxicity. 
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Figure 3.4: Phytochemical cytotoxicity towards Z310 cells (G-L) 
The Z310 cells were seeded on to the gelatine coated 96-well plates at 37°C in a humidified atmosphere 
of 5% CO2 in air for 24h. The media was aspirated and cells were incubated with a 7-fold log concentration 
range (0.001 µM-1000 µM) of fistein (G), flavone (H), hesperetin (I), hesperidin (J), indole 3 carbinol (K) 
and α-napthoflavone (L) for 24h prior to the assessment of cytotoxicity.  
141 
 
 
Figure 3.4: Phytochemical cytotoxicity towards Z310 cells (M-R) 
The Z310 cells were seeded on to the  96-well plates at 37°C in a humidified atmosphere of 5% CO2 in 
air for 24h. The media was aspirated and cells were incubated with a 7-fold log concentration range (0.001 
µM-1000 µM) of naringin (M), quercetin (N), resveratrol (O), rutin (P), silymarin (Q) and TMF (R) for 24h 
prior to the assessment of cytotoxicity.  
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3.5. Determination of BCRP expression in Z310 cells 
 
3.5.1. Determination of BCRP genomic and protein expression  
 
Z310 cells were characterised to determine the expression of BCRP along with the 
choroid plexus marker transthyretin (TTR). Reverse–transcriptase PCR confirmed the 
genomic expression of BCRP in Z310 cells with an expected product size of 146 base 
pairs alongside the presence of choroid plexus phenotypic markers transthyretin (TTR) 
and β-actin (BA) loading control (Figure 3.5A). Western blot analysis confirmed the 
BCRP protein expression in Z310 cells with an expected size of 72 kDa (Figure 3.5B). 
 
 
   
       
Figure 3.5: Genomic expression of BCRP in Z310 cells. 
(A) Cells were seeded to a 6-well plate for 48h. Total RNA was extracted and 500ng of the RNA was 
loaded to the reverse transcriptase prior to PCR. Gel electrophoresis was performed with the PCR 
product. The amplicon products for transthyretin (TTR), loading control β-actin and BCRP were detected 
(B) Protein expression of BCRP in Z310 cells. Cells were seeded into a 6-well plate for 48 h. Whole cell 
protein was extracted using RIPA buffer. Approximately 80 µg of the protein was loaded to the gel and 
transferred onto the PVDF membrane. The membrane was blocked and incubated with ABCG2 M-70 
antibody for 24h at 4°C and then incubated with goat anti-rabbit IgG-horse radish peroxidise-conjugated 
(Santa Cruz biotechnology, Sc-2004).  
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3.5.2. Immunostaining detection of BCRP in Z310 cells 
The expression of BCRP in Z310 cells was investigated using immunostaining 
techniques. Confocal laser microscopy was able to demonstrate BCRP localisation in 
Z310 cells with staining against BCRP throughout the cells and greater localisation in 
the cell membrane (Figure 3.6).  
 
             
Figure 3.6:  Localisation of BCRP in Z310 cells.  
Cells were grown on coverslips for 2-3 days and fixed with 4% paraformaldehyde and stained for BCRP 
using the ABCG2-M70 primary antibody and goat anti-rabbit IgG-FITC secondary antibody (green). Cell 
nuclei were visualised using DAPI (blue). The positive control includes ABCG2-M70 and FITC secondary 
whereas a negative control excludes the primary antibody. 
 
 
3.6. Measurement of BCRP cellular functional activity in Z310 cells  
 
3.6.1. Assessment of intracellular H33342 accumulation in the absence and 
presence of Ko143  
To assess the functional activity of BCRP in Z310 cells a 96-well plate assay was 
utilised to measure the intracellular accumulation of H33342, a substrate of BCRP in 
the absence and presence of Ko143, a known potent inhibitor of BCRP. When exposed 
to Ko143 over a concentration range of 0.039 nM-5 µM, the intracellular accumulation 
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was significantly increased by approximately 3-fold (p ≤ 0.0001), regardless of the 
Ko143 concentration used (Figure 3.7).  
      
 
Figure 3.7:  Functionality of BCRP in Z310 cells.  
15,000 cells/well were seeded into wells of a clear 96-well plate at 37°C and 5% CO2 for 24 h. 
Subsequently cells were washed with PBS to remove media and 200 µL of growth media a range of Ko143 
concentration (0.0039 µM-5 µM) was added and the plate pre-incubated for 1 h before the media was 
removed.  Thereafter the cells were again incubated with media containing Ko143 (0.0039 µM-5 µM) in 
addition to 10 µM H33342 for 30 min before the intracellular accumualtion of H33342 assessed using a 
fluoresecent plate reader with an excitation wavelength of 355 nm and an emission wavelength of 460 
nm.  Significant differences between control and Ko143 concentrations are indicated above the 
appropriate error bars (**** p ≤ 0.0001). 
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3.6.2. Modulator inhibition of BCRP function in an H33342 intracellualr 
accumulation assay 
To assess the potential of modulators to directly inhibit BCRP, BCRP functional activity 
was assessed by measuring the accumulation of H33342 in the presence of 
modulators and Ko143 for 1 h. Our results demonstrated significant increase of 
intracellular H33342 accumulation for apigenin, chrysin (100 µM), curcumin (1µM), 17-
β-estradiol (1 µM), hesperetin (10 and 100 µM) (P≤0.01), naringin and TMF (100µM) 
(p ≤ 0.001) by a fold change of 1.05-1.35 (mean fold change), 1.35 ± 0.5, 1.37 ± 0.2, 
1.40 ± 0.70, 1.35-1.42 (mean fold change), 1.6 ± 0.1 and 1.6 ± 0.2 respectively when 
compared to control (Figure 3.8).  
Similarly, flavone (100 µM), indole 3 carbinol (1 and 100 µM), rutin (100µM), silymarin 
(100µM) and TMF (10 µM) also shown significant increases (P≤0.05) of intracellular 
H33342 accumulation by 1.15 ± 0.4, 1.28-1.32 (mean fold change), 1.29 ± 0.5, 1.32 ± 
0.1 and 1.33 ± 0.3 respectively when compared to control.  
Furthermore, 17-β-estradiol (100 µM), flavone (1 µM), quercetin (100 µM) 
demonstrated significant reduction in H33342 intracellular accumulation leading to a 
fold change of 0.25 ± 0.1, 0.26 ± 0.2, 0.45 ± 0.05.  Whereas, biochanin A, hesperidin 
and resveratrol did not demonstrate any change in intracellular H33342 accumulation.   
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Figure 3.8: Modulation of intracellular accumulation of H33342 following a 1-hour incubation with modulators. 
Cells were grown in a 96 well plate for 48 h and washed with warm HBSS supplemented and incubated for 1 h with media containing 25 µM of test compound, except  
α-napthoflavone (1µM) and 17-β-estradiol (100nM).  Subsequently cells were incubated with media containing H33342 for 30 min and lysed. The change in H33342 
intracellular accumulation in the presence of Ko143 is highlighted by the shaded regions (2-fold change). Significant differences between Ko143 and modulators are 
indicated above the appropriate error bars. * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001 and **** P ≤ 0.0001. The hash symbol (#) indicates modulators excluded due to auto 
fluorescence.
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3.6.3. Modulator mediated changes in BCRP function following 24 hours 
incubation  
The time dependent functional activity of BCRP was also evaluated following 
incubation of H33342 in the presence of modulators for a 24 h period. Z310 cells were 
exposed to modulators at 1 µM, 10 µM and 100 µM. 
 Our results demonstrated that I3C (1 µM) and naringin (1 µM) significantly increased 
(p ≤ 0.001) the intracellular H33342 accumulation by 1.65 ± 0.1 and 1.75 ± 0.2 fold 
respectively, when compared to Ko143 a known potent inhibitor of BCRP. Similarly, 
apigenin (1-100 µM), biochanin A (10 and 100 µM), chrysin (1-100 µM), curcumin (1 
µM), 17-β-estradiol (1 and 10 µM), hesperetin (1 µM), resveratrol (100µM), rutin 
(100µM), silymarin (1-100 µM) and TMF (1 µM) also increased the H33342 
accumulation leading to a fold change of 1.15 -1.35 (mean fold change), 1.20-1.22 
(mean fold change), 1.25-1.27 (mean fold change),  1.25 ± 0.2, 1.25-1.30 (mean fold 
change), 1.45 ± 0.5, 1.35 ± 0.3, 1.35 ± 0.1, 1.25-1.27 (mean fold change) and 1.35 ± 
0.1 respectively when compared to control. Interestingly, 17-β-estradiol (100 µM), 
quercetin, resveratrol and rutin (1 µM) significantly reduced (p ≤ 0.01) intracellular 
H33342 accumulation (Figure 3.9). 
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Figure 3.9: Modulation of intracellular accumulation of H33342 following a 24-hour incubation with modulators  
Cells were grown in a 96 well plate for 24 h and washed with pre- warm HBSS supplemented and incubated for 24h with media containing 1-100 µM of test compound, 
except  α-napthoflavone (1 µM) and 17-β-estradiol (100 nM). After 24h cells were incubated with media containing H33342 for 30 min and lysed. H33342 fold change 
in the control is represented by shade. Significant differences between control and modulators are indicated above the appropriate error bars. * P ≤ 0.05, ** P ≤ 0.01, 
*** P ≤ 0.001 and **** P ≤ 0.0001. The hash symbol (#) indicates modulators excluded due to auto fluorescence. 
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3.7. Modulation of BCRP protein expression by phytochemical modulators 
 To assess the effect of modulators on BCRP protein expression, Z310 cells were 
incubated with modulators for 24 h and western blot analysis was performed. Our 
results demonstrated a significant increase (p ≤ 0.0001) in BCRP protein for flavone 
(2.65 ± 0.12 fold), baicalin (2.42 ± 0.19 fold) and hesperidin (2.43 ± 0.09 fold) (Figure 
3.10 and 3.11). Furthermore, a significant down-regulation in BCRP was observed for 
naringin (p ≤ 0.001) (0.16 ± 0.07 fold) and silymarin (p ≤ 0.001) (0.22 ± 0.09 fold), 
quercetin (p ≤ 0.01) (0.29 ± 0.08 fold) and 17-β estradiol (p ≤ 0.05) (0.49 ± 0.11 fold).   
α-napthoflavone was excluded from the study due to its cytotoxicity. 
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              Figure 3.10: Changes in BCRP Protein expression under 24-hours exposure to modulators  
Cells were seeded in a 6-well plate for 24 h to attach and subsequently incubated with 25µM modulators except 17-β-estradiol (100 nM) for 24 h. Whole cell protein 
was extracted using RIPA buffer. Approximately 100 µg of the protein was loaded onto a SDS-PAGE gel to separate proteins bands.  The resulting gel was then 
transferred onto a PVDF membrane and incubated with ABCG2 M-70 antibody for 24 h at 4°C and then incubated with goat anti-rabbit IgG-horse radish peroxidise-
conjugated (Santa Cruz biotechnology, Sc-2004). Chemiluminescence detection was performed with lab made ECL and a representative image is displayed. Z310 
represent  BCRP expression in the absence of modulators. 
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.   
 
 
Figure 3.11: Fold change in BCRP protein expression.  
The cells were seeded to a 6-well plate for 24h. The cells were incubated with 25µM modulators except 17-β-estradiol (100 nM) for 24h. Whole cell protein was 
extracted using RIPA buffer. 100 µg of the protein was loaded to the gel and transferred onto the PVDF membrane. The membrane was blocked and incubated 
with ABCG2 M-70 antibody for 24h at 4°C and then incubated with goat anti-rabbit IgG-horse radish peroxidise-conjugated (Santa Cruz biotechnology, Sc-2004). 
Chemiluminescence detection was performed with lab made ECL. Significant differences in protein expression are indicated above the appropriate error bars. * P 
≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001 and **** P ≤ 0.0001. 
152 
 
3.8. Quantitative PCR assessment of the changes in BCRP genomic expression 
following exposure to modulators 
 The modulation of BCRP genomic expression was evaluated by qPCR using 4 
identified modulators of BCRP protein expression, namely baiclain, flavone as up-
regulators and naringin and quercetin as down-regulators. A significant increase (p ≤ 
0.0001) in genomic expression of BCRP for baiclain (1.48 ± 0.23 fold) and flavone 
(1.22 ± 0.25 fold), whereas naringin was slightly downregulated but this was not 
significant.  On the other hand quercetin was significantly (p ≤ 0.01) down regulated by 
0.75 ± 0.11 fold of control (Figure 3.12).  
 
Figure 3.12: Modulation of BCRP gene expression after 24 h incubation with modulator 
compounds. 
Z310 cells were seeded onto a 6-well plate in the growth medium and incubated at 37°C and 5% CO2 for 
24h. The media was removed and modulators prepared in media were added to the wells and incubated 
for 24h. After 24 h the media was removed cells were washed with the pre-warmed PBS and RNA was 
extracted according to manufacture s instructions. Total RNA was reverse transcribed and gene 
expression assessed by qPCR using a SYBR green master mix.  Dashed line indicated 0.5-fold change.  
Significant differences between control and modulators are indicated above the appropriate error bars *** 
P ≤ 0.001 and **** P ≤ 0.0001. 
.
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3.9. Modulation of BCRP transport function using an in -vitro BCSFB model 
 
3.9.1.  HPLC-UV Detection of sulfasalazine  
 A HPLC method for the detection of sulfasalazine successfully detected sulfasalazine 
with a consistent retention time of 3.36 min (Figure 3.13) with a second smaller solvent 
front peak at 1.81 min. The serum free media was used as a solvent in the transport 
study and the solvent front is more likely glucose as for the Z310 cells DMEM high 
glucose was used as stated in methods.  
              
Figure 3.13: Chromatogram of sulfasalazine.  
Sulfasalazine was detected with a rentetion time of 3.36 min using a reversed-phase C18 column 
(Phenomenex Luna 5-µm) with a mobile phase consisting of 70:29:1 methanol:millQ water:acetic acid 
and flow rate of 1 mL/min.   
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3.9.2. Linearity  
 
The linearity of the HPLC method determined by constructing a calibration curve with 
over a concentration range of 0.1 µM-50 µM.  The area under the curve was linearly 
regressed under the concentration range used and the coefficient of correlation (r2) 
was 0.9998. The slope and intercept were 31872.15 ± 3181 and 4991.831 ± 586 
respectively. The LOD and LOQ were found to be 0.081 ± 0.004 and 0.089 ± 0.006 
µM respectively. 
 
           
Figure 3.14: Linearity of sulfasalazine.  
Concentrations of sulfasalazine (0.1 µM-100 µM) were prepared in serum free transport media and 20 µL 
of the each concentration was injected to the HPLC machine and area under curve was obtained. 
Calibration curve was constructed by plotting average peak area against concertation. LOD and LOQ was 
calculated by using regression analysis.   
 
3.9.3. The impact of transport media on in-vitro BCSFB monolayer integrity 
 
To assess the impact of transport media on the stability of the monolayer formation, 
preliminary transport studies were conducted assessing the impact of HBSS transport 
media (HBSS supplemented with 10 mM glucose and HEPES (10 mM) and serum free 
media (SFM) on the TEER of the monolayer. 
It was demonstrated that SFM provided a more stable media for the preservation of 
TEER values over the duration of the incubation study with no significant difference in 
TEER values when compared to the start of the study (Figure 3.15).  Furthermore, the 
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use of HBSS resulted in a significant (p ≤ 0.001) decline in TEER values 92 ± 5 Ω.cm2  
to 25 ± 8 Ω.cm2  after 180 min (Figure 3.15).    
 
 
Figure 3.15: TEER values of Z310 cells maintained in HBSS and SFM, grown in permeable 
inserts 
Cells were seeded onto the collagen coated permeable inserts for 8 days, TEER values were measured 
on the day before, and after running the assay for 210 min. Significant, differences between HBSS and 
serum free media are indicated above the appropriate error bars * P ≤ 0.05, ** P ≤ 0.01. 
3.9.4. Functional assessment of BCRP in an in-vitro permeable insert BCSFB 
model  
 
The in-vitro BCSFB model was developed by growing Z310 cells on permeable inserts 
for 8-10 days. The functionality of BCRP was assessed by measuring the transport of 
sulfasalazine, a substrate of BCRP, in the presence or absence of Ko143, a known 
BCRP inhibitor. Our results demonstrated a significant increase in sulfasalazine 
transport from apical-to-basolateral from all time points when compared with control, 
signifying the functional presence of BCRP with a 10% increase in sulfasalazine 
transport in the presence of Ko143 (Figure 3.16) and causing an apical-to-basolateral 
apparent permeability (Papp,AB) increase from 1.32 ± 0.12 x10-6 cm/s to 2.11 ± 0.09 x10-
6 cm/s when exposed to Ko143. 
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Figure 3.16:  Assessment of BCRP functionality in an in-vitro BCSFB model.  
Cells were grown on permeable insert and transport studies were performed on day 8 (TEER ≥ 60 Ω.cm2) 
following 1 h incubation with Ko143. Results are reported as the fraction of sulfasalazine transporter 
(receiver concentration/ donor concentration). Statistically significant differences between control and 
Ko143 conditions are indicated. * P ≤ 0.05 and ** P ≤ 0.01.   
 
 
 
3.9.5. Functional assessment of BCRP in the presence of BCRP up-regulating 
modulators 
Modulators identified as demonstrating significant up-regulation of BCRP at in Z310 
cells, namely baiclain and flavone were assessed for their ability to modulate BCRP 
function in an in-vitro transport model. Baicalin (Figure 3.17A) demonstrated a 
significant decrease (p ≤ 0.05) the transport of sulfasalazine across the insert by 
approximately 10 % (CR/CD) for portions of the assay and this was coupled with a 
significant (p < 0.05) decrease in Papp,AB from 1.32 ± 0.12  x10-6 cm/s to 1.10 ± 0.08 
x10-6 (Figure 3.17A). However exposure to flavone did not result in any significant 
change in the transport of sulfasalazine across the in-vitro BCSFB barrier model 
(Figure 3.17B). 
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Figure 3.17: Transport of sulfasalazine across an in vitro BCSFB model following 24 
hour incubation with baicalin or flavone.  
Cells were grown on permeable insert and transport studies were performed on day 8 (TEER ≥ 60 
Ω.cm2) following 24 h incubation with modulators, baicalin (A) or flavone (B).  Results are reported 
as the fraction of sulfasazine transporter (receiver concentration/ donor concentration). Statistically 
significant differences between control and modulator are indicated. * P ≤ 0.05 and ** P ≤ 0.01.   
 
 
 
 
3.9.6. Functional assessment of BCRP in the presence of BCRP down-
regulating modulators 
 The functional assessment of BCRP was evaluated in the presence of BCRP down-
regulators namely, naringin, silymarin and 17-β-estradiol in the in-vitro BCSFB model 
by measuring the transport of sulfasalazine. Naringin, silymarin and 17-β-estradiol 
resulted in significant increases in sulfasalazine Papp,AB to 3.83 ± 0.34 x10-6 cm/s, 3.33 
± 0.61 x10-6 cm/s and 2.01 ± 0.23 x10-6 cm/s respectively, when compared to the 
absence of modulators 1.32 ± 0.12 x10-6 cm/s (Figure 3.18). This translated into an 
increase of 43% in sulfasalazine transport for naringin and 36% increase for silymarin 
with a smaller 11% increase for 17-β-estradiol.  
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Figure 3.18:  Transport of sulfasalazine across an in vitro BCSFB model following 24 
hour incubation with 17-β-estradiol, naringin or silymarin. 
Cells were grown on permeable insert and transport studies were performed on day 8 (TEER ≥ 60 
Ω.cm2) following 24 h incubation with modulators, namely 17-β-estradiol (A), naringin (B) 
or silymarin (C). Results are reported as the fraction of sulfasalazine transporter (receiver 
concentration/ donor concentration). Statistically significant differences between control 
and modulator are indicated. * P ≤ 0.05 and ** P ≤ 0.01.   
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3.10. Discussion 
 
The BBB and the BCSFB regulate the influx and efflux of endogenous substrates and 
drugs into the brain. Drug transporters at the BBB limit the ability of drugs to permeate 
into the brain biophase but not in the CSF (Abbott and Romero, 1996), similarly, the 
transporters at the BCSFB affects the transport of drugs into the CSF not into the brain 
parenchymal tissues.  
 ABC transporters are key membrane localised proteins, which often serve a xenobiotic 
protective mechanism for the CNS but are often the primary cause of poor therapeutic 
distribution into the CNS. BCRP is an ABC efflux transporter that has been shown to 
confer resistance to large number of therapeutic agents such as mitoxantrone, 
methotrexate, topotecan, SN38, doxorubicin and flavopiridol (Doyle and Ross, 2003b, 
Maliepaard et al., 2001). Although the body of work assessing the important role the 
BBB plays in governing CNS drug distribution is significant, very little has been 
reported on the functional role of BCRP at the BCSFB and the role it plays in controlling 
drug transport across the BCSFB.  Knock-out animals data have demonstrated that 
cells at the BCSFB differ from the BBB in the distribution of ABC transporters and, 
therefore, the effects of changes in transporter expression on drug distribution. For 
example, topotecan distribution into the brain was reported to be increased but its 
penetration into the ventricular CSF was reduced with Bcrp KO mice (Shen et al., 2009) 
as a result of the asymmetrical expression of the transporter at the BBB and BCSFB 
(Urquhart and Kim, 2009, Rao et al., 1999). However results can be contrasting 
depending on the site/location of CSF sampling (i.e. ventricular CSFs vs bulk CSF 
sampling from the cisterna magna) (Doran et al., 2005, Shen et al., 2009). 
Furthermore, the complexities in site-specific knock-down of Bcrp (in the CP alone, the 
CP+BBB or the CP +parenchymal cells) would further compound the interpretation of 
the changes in gross drug transport. 
Several strategies have been considered to enhance drug accumulation into the CNS, 
the most common of which is to directly inhibit BCRP using chemical modulators such 
GF120918 (elacridar) or Ko143 (Breedveld et al., 2006, Pick et al., 2008). 
Unfortunately these inhibitors cause severe neurotoxicity which limits their clinical 
applications (Thomas and Coley, 2003, Varma et al., 2003).  
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In an attempt to identify novel candidates that may modulate BCRP expression and 
function, phytochemicals (primarily flavonoids) show promise as potential BCRP 
expression and transport function modulators (see section 2.14.5 and 2.14.6). 
 
The key focus of this chapter was to characterise the Z310 rodent choroid plexus 
epithelial cell line to assess whether BCRP is expressed and to subsequently examine 
the role phytochemical modulators may play in the cytotoxicity towards Z310 cells but 
also their ability to modulate BCRP expression and transport functions.  
 
3.10.1.  The use of Z310 cells to develop an in-vitro BCSFB model  
 
 Z310 were first established by Zheng and Zhao (Zheng and Zhao, 2002) by 
transfection with a viral plasmid (pSV3neo). The cells show typical epithelial cell 
morphology and presence of BCSFB markers such as transthyretin (TTR), a thyroxine 
transport protein (Zheng and Zhao, 2002).  Z310 cells were selected for their high 
reported TEER values (130-200 Ω.cm2) and expression of important transporter 
proteins such as P-gp, Mrp1, Mrp4 and BCRP (Juliane Kläs et al., 2010) and presence 
of the key choroid plexus marker (TTR) (Zheng and Zhao, 2002, Juliane Kläs et al., 
2010, Szmydynger-Chodobska et al., 2007, Shi et al., 2008b). In contrast other CP cell 
lines, such as TR-CSFB, demonstrate low TEER value (30-35 Ω.cm2) and require 
growth at reduced lower temperatures (Juliane Kläs et al., 2010) (Kitazawa et al., 
2001). 
 
 Our results demonstrated that Z310 cells, when grown on uncoated tissue culture 
surfaces, demonstrate typical uniform polygonal epithelial cell morphology, with 
tendency to form closely packed islands (Figure 3.1 A and B). The formation of a cell 
monolayer was assessed by measuring the height of the media in the inner chamber 
when compared to permeable inserts without cells. The height of the medium was 
about 2 mm higher for up to 24 h representing the formation of CSF (Shi et al., 2008a) 
(Figure 3.2) and achieved TEER values of 92 ± 5 Ω.cm2 at day 8 post seeding (Figure 
3.3), which would place it within the range of reported TEER values when accounting 
the growth surface area (1.12 cm2 versus 4.4. cm2). 
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3.10.2. Cytotoxicity assessment of modulators 
 
To date no studies have been reported to our knowledge, assessing the interaction of 
phytochemical modulators with Z310 cells. As a result, a clear indication of the 
cytotoxicity for each modulator needed to be identified for subsequent experiments.  
Our results reported that most modulators demonstrated IC50 values of > 100 µM 
(Figure 3.4), with the exception of α-napthoflavone (1.4 ± 0.8 µM) (Figure 3.4 L). 
Furthermore, a number of flavonoids demonstrated no appreciable toxicity at 1000 µM 
and included chrysin, 17-β-estradiol, hesperidin, naringin, silymarin and TMF (Figure 
3.4 D, F, J, M, Q and R, respectively). To date, there is a lack of published cytotoxicity 
data reported for phytochemical modulators against Z310 cells.  However, with some 
level of caution, comparisons can be made with other cell lines. α-napthoflavone is a 
synthetic flavonoid and known as a strong inhibitor of CYP1B1 (Vincent et al., 1998). 
The IC50 calculated to inhibit CYP1B1 in MCF-7 cells was 0.2 nM (Zeichner, 2010), 
which is significantly below our reported values but highlight the potentially cytotoxic 
nature of this modulator. Zhang, et al (Zhang et al., 2005) demonstrated limited 
cytotoxicity with chrysin at 50 µM in MCF-7 MX100 cells. Furthermore in another study 
HepG2 were incubated with 5 µM chyrin to assess changes in the expression of 
UGT1A1 (Sugatani et al., 2004). In Caco-2 cells 150 µM biochanin A was reported to 
show no significant decrease in cellular viability, which compares with our calculated 
IC50 216 ± 1.36 µM (Figure 3.4C).  
In another study (Dornan et al., 2007) it was reported the lack of cytotoxicity of apigenin 
up to 250 µM in rat hepatoma H4IIE cells and C6 glioma cells. Similarly, our results 
report an IC50 of apigenin of 355 ± 8.1µM in Z310 cells (Figure 3.4A). Furthermore, 120 
µM fistein reduced the viability of human colonic cancer (COLO205) cells by 27.6% 
(Wu et al., 2013). Our results demonstrated a 50% reduction in Z310 cell viability by 
fistein at 154 ± 1.78 µM (Figure 3.4H).   
Quercetin has been used in-vivo studies in rats, from 1- 400 µM  (van Zanden et al., 
2007) with no resultant toxicity and concurns with our calculated IC50 of 107 ± 2.3 µM 
(Figure 3.4N). In contrast, naringin was found to use to inhibit BCRP at 3 µM 
concentration in K562 cells (Imai et al., 2004), however our results demonstrated that 
narignin was not toxic to Z310 cells up to 1000 µM (Figure 3.4 M).  Interestingly, the 
IC50` for for α-napthoflavone was similar to that reported at the BBB (section 2.7and 
Figure 2.4 L), however limited correlation was observed with other modulators such as 
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17-β- estradiol, chrysin and naringin, which demonstrated reduced or no toxicity in 
Z310 and PBMEC/C1-2 cells.  
In contrast to their widely cited beneficial effects, flavonoids also have been found to 
be pro-oxidant or mutagenic and to produce toxicity (Sahu and Gray, 1997, Galati et 
al., 2002). The beneficial effects of flavonoids (outside of interacting with BCRP) is 
often perceived to be because of their antioxidant properties (Kris-Etherton and Keen, 
2002, Kelly, 1998, Bonnefoy et al., 2002). In a study comparing 20 flavonoids for their 
sensitivities towards L-02 and HepG2 cells, it was noted that L-02 cells were more 
sensitive towards the flavonoids studied.  It was proposed that this was related to the 
fact that L-02 cells possessed a greater level of intracellular antioxidant enzymes and 
GSH, which are essential and beneficial to help maintain the redox balance in cells 
due to the fact that the cytotoxic effects of flavonoids are associated with their pro-
oxidant activity (Rietjens et al., 2002, Dickancaite et al., 1998, Galati et al., 2002).  
Furthermore, flavonoid cytotoxicity may have also occurred through apoptosis-
inducing properties in cells by interactions with protein kinase, lipid kinase, or other 
apoptosis related signalling pathways (Kampa et al., 2007, Hadi et al., 2000, 
Cunningham et al., 1992), which may produce different extents of toxicity in different 
cell lines, particularly where the expression/abundance of signalling pathway elements 
are diminished/different. 
 
It is also possible that flavonoids produce both an effect on BCRP whilst at the same 
time being highly cytotoxic and act in this manner as conventional hydrogen donators, 
particularly for flavonoids with multihydroxyls, which may form phenoxyl radicals to 
induce cytotoxicity (Galati et al., 2001, Galati et al., 2002).  Furthermore flavonoids 
may result in cytotoxicity by destroying the intracellular antioxidant systems or 
negatively impacting on antioxidant-sensitive signalling pathways (Son et al., 2004, 
Ramos, 2007, Haddad, 2004). Finally, other reports have also suggested the disruption 
of the mitochondrial respiratory chain or depletion of GSH by forming GSSG or GSH 
conjugates (Sabzevari et al., 2004). 
 
 GST is the most abundant phase-II enzyme in the brain and hence may predispose 
the BBB to greater levels of sensitives towards phytochemicals compared to the CP. 
However, given the complex nature of the proposed mechanism of cytotoxicity, the 
difference in cell origin species (porcine versus rats) the potential for inter-species 
variability of the abundance of signally pathway elements or metabolism enzymes may 
confound the mechanism understanding the nature of this toxicity. 
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3.10.3. Assessment of BCRP expression in Z310 cells  
Our results have confirmed the expression of BCRP in Z310 cells using reverse-
transcriptase polymerase chain reaction (Figure 3.5A), western blot analysis (Figure 
3.5B) and immunosfluoresecene confocal microscopy (Figure 3.6).  Our results were 
consistent with previous study reported the portein expression of BCRP in Z310 cells 
(Halwachs et al., 2011). Reichel et al (Reichel et al., 2011) reported BCRP genomic 
and protein expression in rat choroid plexus. Furthermore, BCRP protein expression 
was demonstrated in rat choroid plexus TR-CSFB cell lines (Hosoya et al., 2004).  
 
3.10.4. Functional assessment of BCRP in the absence and presence of 
modulators  
BCRP functional activity was assessed using a H33342 accumulation assay in the 
presence of BCRP inhibitor Ko143 (1 µM), and our results demonstrated a significant 
1.8 ± 0.2 fold increase in intracellular H33342 accamulation (Figure 3.8), signifing the 
presence of functional BCRP in Z310 cells.  This was then followed by assessing the 
impact of modulator incubation in a short-term assay of 1 h to mimic a direct inhibition 
of functional activity study and a 24 h incubation to detect potential genomic/proteomic 
changes in BCRP, which are translated to changes in functional activity. Our results 
demonstrated highly significant (p ≤ 0.001) increases of 1.35 ± 0.5 to 1.6 ± 0.2 fold in 
intracellular H33342 accumulation for a number of modulators following a 1 h 
incubation, however none were able to elicit a similar fold-change as observed with 
Ko143 expect for hesperetin (100 µM), naringin (100 µM) and TMF (100 µM) (Figure 
3.8). This indicated that these modulators may act as competitive inhibitors of BCRP, 
given the short incubation time. In contrast flavone (1 µM), quercetin (100 µM) and 
rutin (1 µM) demonstrated reduced H33342 accumulation (< 0.5 fold) suggesting an 
induced/increased efflux effect has occurred (Figure 3.8). Of the published studies 
available, TMF, apigenin, chrysin, hesperetin, naringin and quercetin have previously 
demonstrated an ability to inhibit BCRP functional efflux of substrates (see section 
2.14.4 for further discussion of these modulators).  The role of glycosylation status, 
resultant hydrophobicity and potential targeting of the ATPase site within the NBD of 
BCRP may also be an important factor governing the eventual effect observed over 
short incubation periods (see section 2.14.4 for further discussion of these 
modulators). 
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We were also interested to identify the effects of flavonoids on BCRP gene or protein 
expression over longer periods of exposure, namely 24 h. Our results demonstrated 
that incubation with the majority of modulators studied resulted significant changes to 
H33342 intracellular accumulation.  The majority of modulators studied resulted in an 
increase in H33342 accumulation by > 25 % (1.25 fold of greater) with naringin         (1 
µM), IC3 (1 µM) and silymarin (100 µM) eliciting a > 1.5 fold increase in H33342 
accumulation, and hence demonstrating potential down-regulation of BCRP to 
enhance H33342 intracellular accumulation.  In contrast curcumin (10 µM), flavone (1 
µM), quercetin (1 µM) and resveratrol (1 µM) significantly reduced intracellular H33342 
accumulation by to 0.5 fold or lower, suggesting at a possible induction of BCRP to 
reduce H33342 intracellular accumulation (Figure 3.9).  
 
Of the published reports available, curcumin, 17-β-estradiol, naringin and quercetin 
have demonstrated the ability to modulate BCRP expression over similar concentration 
ranges studied (see section 2.9.5. for further discussion of these modulators). 
 
When comparing modulators eliciting inhibitor effects between PBMEC/C1-2 and Z310 
cells, there is some clear discord between the extents of inhibition. For example in 
PBMEC/C1-2 apigenin and hesperidin elicits a strong inhibition at 1 µM but these 
effects are absent in Z310.  Furthermore in Z310 concentration dependant effects on 
BCRP modulation are more apparent and which are absent from PBMEC/C1-2 studies 
and examples include chrysin, flavone, naringin, rutin, silymarin and TMF.   The 
rationale for this is relatively unclear.  However a primary cause may be the differences 
in the species that each cell line is derived from. A BLAST 
(www.blast.ncbi.nlm.nih.gov) comparison of both porcine and rat BCRP nucleotide 
sequeces highlights a sequence identity of 80 %, with the key mutation causing non-
functioning BCRP at position 482 missing.  This difference in sequence identity may 
alter the three-dimensinoal structrure of the protein and hence potentially alter the 
extent of modulator-BCRP interactions. Similar mismatches between in-vitro and in-
vivo inhibition across species have been observed (Zhang et al., 2005), however this 
requires further investigation in each cell line to identify the primary cause of this 
mismatch. 
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3.10.5. Modulating BCRP protein expression in Z310 cells 
In order to further explore the potential modulation of BCRP protein expression in the 
presence of modulators, western blotting analysis was conducted on all modulators at 
identical concentrations studied for the H33342 accumulation assays. 
Our results demonstrated that out of the 18 modulators studied, only 8 showed a 
statistically significant change in BCRP expression with baiclain, hesperidin and 
flavone demonstrating a BCRP up-regulation effect (2.5 fold or more) and 17-β-
estradiol, naringin, quercetin and sliymarin demonstrating a down-regulation effect 
(0.16-4.9 fold) (Figure 3.11). Of the non-phytoestrogenic compounds 17-β-estradiol 
demonstrated the expected trend of downregulation of BCRP. This down regulation 
could be the result of interference with 17-β-estradiol signalling pathways by ERα and 
ERβ.  
Despite the fact that H33342 accumulation assay demonstrated a significant increase 
in intracellular accumulation under prolonged exposure (24 h), it is apparent that this 
effect is only tangible in influencing the expression of BCRP in the highlighted 
modulators. It has been reported that H33342 may also be substrate for P-gp, and 
hence the discord between the increased intracellular accumulation of H33342 for all 
modulators and selective changes in BCRP protein expression observed may be 
indicative of a potential change in P-gp expression (Werner  and Schneider 1974).  
Imai et al (Imai et al., 2005a) demonstrated that 17-β-estradiol significantly reduced 
the expression of BCRP in MCF-7 cells at low nanomolar concentrations (3 nmol/L) for 
1,2 and 4 days (2-,5- and 10-fold down regulation respectively). Furthermore, Hartz et 
al (Hartz et al., 2010) found that the protein expression of BCRP was down regulated 
in the presence of 17-β-estradiol in rat brain capillaries. It has been (Ebert et al., 2007) 
reported that 25 µM and 50 µM quercetin increased BCRP protein expression in Caco-
2 by 2.6 and 5.3 fold after 72h incubation. Furthermore at the genomic level a 19-37 
fold increase in BCRP mRNA was reported when exposed to 50µM of chrysin, 
quercetin, resveratrol and flavone.  
When comparing the modulation of BCRP protein expression in PBMEC/C1-2 and 
Z310, the lack of similarity in the modulation of protein expression is evident. For 
example quercetin and naringin are clear up-regulators of BCRP gene and protein 
expression in PBMEC/C1-2 cells (Figure 2.13 and 2.14) whereas in Z310 the opposing 
trend is evident with quercetin being a down-regulator in gene (Figure 3.12) and protein 
expression (Figure 3.11) but naringin shows no significant down-regulation of BCRP 
gene expression (Figure 3.12) but a highly significant decrease in BCRP protein 
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(Figure 3.11). This would suggest that naringin does not interfere with a transcriptional 
element of BCRP but rather is capable of initiate a translational change in BCRP 
expression. The discord between PBMEC/C1-2 and Z310 changes in BCRP protein 
expression may be indicative of differences in cellular mechanisms such as differences 
in the abundance of transcriptional/translational signalling pathways.  Some species 
differences have been identified with AhR, for example differences in the regulation of 
AhR has been reported between humans and rodents (Flaveny et al., 2010), and the 
AhR-mediated BCRP regulator pathway was not able to be demonstrated in mouse 
cell lines but were evident in human intestinal cells (Tan et al., 2010). 
 
3.10.6. Functional assessment of BCRP activity in an in-vitro permeable insert 
BCSFB model 
The functionality of BCRP was further demonstrated using the BCRP substrate 
sulfasalazine and assessing its transport across the Z310 monolayer in the absence 
and presence of Ko143 or modulators, using the SFM as the optimal transport study 
media (Figure 3.15). In the in-vitro construct developed, the apical chamber represents 
the CSF and the basolateral the blood, hence the direction of efflux for BCRP is 
towards the CSF. Initial studies demonstrated that Ko143 significantly increased the 
apical-to-basolateral sulfasalazine flux at all time points leading to an increase in Papp,AB 
from 1.32 ± 0.12 x10-6 cm/s to 2.11 ± 0.17 x10-6 cm/s, and hence demonstrating 
functional activity of BCRP (Figure 3.16) and it’s inhibition leading to enhanced 
penetration across the in-vitro BCSFB and delivery into the basolaterial (blood) 
compartment. 
Cells grown on permeable inserts were further exposed to modulators for 24 h followed 
by assessing the transport of sulfasalazine across the in-vitro BCSFB. Western blot 
and qPCR result (Figure 3.11 and 3.12) confirmed that baiclain and flavone are up-
regulators of BCRP protein at the BCSFB and these were selected to study further to 
assess the functional consequences of this up-regulation. Baiclain demonstrated a 
significant decrease (p ≤ 0.05) in the transport of sulfasalazine across the insert by 
approximately 10 % (CR/CD) for portions of the assay and this was coupled with a 
decrease in Papp,AB from 1.32 ± 0.12  x 10-6 cm/s to 1.10 ± 0.08 x 10-6  and hence 
diminishing of the overall apical-to-basolateral flux (Figure 3.17A). However, when 
examining the impact of flavone on BCRP, no significant differences were observed in 
apical-to-basolateral flux for the duration of the study (Figure 3.17B). This was 
surprising as flavone demonstrated the greatest up-regulation of BCRP protein in 
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western blots (Figure 3.11) and may indicate time-dependant protein decay following 
the up-regulation phenomena.  
When investigating the impact of the down-regulators 17-β-estradiol, naringin and 
silymarin, we observed statistically significant differences across all time-points with 11 
%, 43% and 36% increase in sulfasalazine transport, for 17-β- estradiol, naringin  and 
silymarin leading to an increase in Papp,AB from 1.32 ± 0.12  x10-6 cm/s to 2.01 ± 0.23 
x10-6 cm/s, 3.83 ± 0.34 x10-6 cm/s and 3.33 ± 0.61 x10-6 cm/s respectively (Figure 
3.18). Of interest is the translational effect of downregulation in BCRP protein when 
exposed to naringin and silymarin (0.16 ± 0.07 fold and 0.22 ± 0.09 fold change in 
protein expression, respectively, Figure 3.11) and the resultant effect on ‘CSF-to-blood’ 
sulfasalazine transport where Papp,AB for naringin and silymarin was increased by 2.9- 
and 2.5-fold, respectively. This effect clearly highlights the potential impact of 
prolonged exposure of flavonoids to BCRP may have on substrate transport and how 
this may influence the disposition of transporter substrate at the BCSFB and wider 
CNS.   
It is important to note that the design of the transport study, namely pre-incubation with 
modulators for 24 h followed by a short washout-period and subsequent initiation of a 
transport study in the presence of the substrate along, would negate the impact of 
modulators themselves inhibiting the transporters directly. It is more likely that this 
approach would lead to a change in BCRP protein as evident from western blotting 
studies and the transport studies have therefore demonstrated that the down-
regulators are able to significantly alter the equilibrium of sulfasalazine across the 
BCSFB leading to an increase in flux towards the blood.  As the formation of CSF is, 
in part, related to the draining of ISF from the brain, the bulk flow from ISF-to-CSF 
would drive the equilibrium within the cranium towards the CSF and this would then be 
followed by CSF draining, driving largely by gravity back into the systemic blood via 
dural venous sinuses drainage (Pollay, 2010, Johanson et al., 2008b, Wraith and 
Nicholson, 2012). Hence, both naringin and silymarin and phytochemical modulators 
along with 17-β-estradiol, are potential viable candidates, which may limit the entry of 
systemically administered BCRP substrates into the CSF or enhance the removal of 
compounds from the CSF. This may be an important application in age-associated 
diseases states such as Alzheimer’s disease where the amyloid beta plaques 
circulating the CSF and originating from the brain are drained into the systemic 
circulation through CSF drainage and passage across the BCSFB (Pascale et al., 
2011) . As amyloid-beta peptides (Aβ) has previously been reported to be a substrate 
of BCRP (Xiong et al., 2009, Candela et al., 2010, Carrano et al., 2014). it is possible 
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that down-regulation of BCRP at the BCSFB may enhance the opportunities for 
clearance of Aβ out of the CNS through the traditional sinuses drainage routes and 
enhance flux across the BCSFB, as a result of diminished BCRP protein.   
 
3.11. Conclusion 
In this chapter, the modulation of BCRP by phytochemicals at the BCSFB was 
investigated. Our results confirmed the presence of genomic, protein and functional  
expression of BCRP in choroid plexus Z310 cells. Baiclain and flavone has shown to 
be the up-regulators of BCRP protein, genomic and functional expression whereas, 
17β-estradiol, quercetin and naringin were the down-regulators. From this study, it is 
concluded that phytochemicals can modulate the expression of BCRP at the BCSFB 
model, which can help to enhance the drugs to the CSF or remove neurotoxins from 
the CSF.  
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 Chapter 4 
 
Transcriptional regulation of BCRP by 
the aryl hydrocarbon receptor at the 
BBB and BCSFB 
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4.1. Introduction 
 
The aryl hydrocarbon receptor (AhR) is involved in a wide range of cellular processes 
such as cell proliferation, xenobiotic metabolism and the development of the immune 
system (Lindsey and Papoutsakis, 2012, Ma and Whitlock, 1996, Boitano et al., 2010, 
Mulero-Navarro et al., 2006). AhR is a member of the basic helix-loop-helix (bHLH) 
PER-AhR nuclear translocator (ARNT)-SIM superfamily of transcription factors. AhR 
is localised in the form of a complex with two molecules of heat shock protein 90 
(hsp90) and Ah receptor-interacting protein (AIP) in the cytoplasm. Upon ligand 
binding the AhR with its associated heat shock proteins, forms a dimer complex and is 
translocated to the nucleus where it binds with ARNT and transcribes the required 
target genes (Nebert et al., 2004).  
 
The activity of AhR has been shown to be modulated by several compounds including 
phytochemicals (Ashida et al., 2000, Ciolino et al., 1998a, Nishiumi et al., 2007b).  
Furthermore, AhR has previously been shown to play a role in the induction of BCRP 
through interactions with a range of compounds, including phytochemicals (Ebert et 
al., 2007, Tan et al., 2010). Examples include quercetin, chrysin, flavone and indole-
3-carbinol which have all shown to significantly induce BCRP genomic and proteomic 
levels following exposure concentration of 25µM and 50µM concentration (Ebert et al., 
2007).  
 
The direct inhibition of BCRP, through the use of existing inhibitors has not yielded 
fruition of viable clinical inhibitors as a result of their severe neurotoxicity (Nutton, 1973, 
Allen et al., 2002a) (Allen et al., 2002b).The modulation of regulatory pathways is a 
new promising approach to target BCRP to enhance delivery to BCRP substrates into 
the brain. The expression of drug transporters and drug metabolising enzymes at the 
BBB is thought to be regulated by a network of regulatory pathways including the 
pregnane-X-receptor (PXR), the peroxisome proliferator-activated receptor α 
(PPARα), the constitutive androstane receptor (CAR), and the aryl hydrocarbon 
receptor (AhR) (Jacob et al., 2011, Xu et al., 2005, Dauchy et al., 2008a, Granberg et 
al., 2003, Hoque et al., 2012).  
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Whilst most studies have focussed on the role of AhR in regulating the expression of 
xenobiotic metabolism pathways (e.g. CYP isozymes), a few studies have 
demonstrated the role AhR plays in regulating BCRP expression. A known AhR 
agonists, 3-methylcholanthrene (3MC), has been demonstrated to cause an AhR 
mediated 80-fold induction of BCRP in LS174T cells when exposed to 3MC, with 
reversal of this induction (by 65 %) when AhR was knock-down (Tompkins et al., 2010).  
Wang et al (Wang et al., 2011) also demonstrated that the well-known AhR agonist, 
TCDD, up-regulated the expression and transporter activity of BCRP in rat brain 
capillaries. In a further study (Campos et al., 2012), exposure of the AhR agonist TCDD 
to rat spinal cord capillaries increased BCRP protein expression. 
 
Although BCRP is known to play an important role in governing the entry of a range of 
therapeutic compounds into the brain, approaches to target its transcriptional 
regulation have been poorly studied. This chapter will explore the role AhR plays in 
regulating the expression of BCRP and will attempt to identity suitable candidate 
compounds, which modulate the genomic regulation of BCRP by AhR at the BBB and 
BCSFB. 
 
4.2. Aims and objectives 
The aim of the work reported in this chapter was to investigate whether modulators 
identified from earlier studies with their interactions at the BBB and BCSFB, regulated 
the expression of BCRP by AhR pathways. The objectives were:  
 To demonstrate activation of AhR by a chemically-activated luciferase assay 
system (H1L6.1c2 cells) 
 To assess modulation of BCRP and AhR following modulator exposure in 
PBMEC/C1-2 and Z310 cells 
 To silence the AhR gene by dicer substrate siRNA approaches and assess 
subsequent changes in BCRP expression in PBMEC/C1-2 and Z310 cells. 
 
4.3. Materials 
Alpha-MEM (Corning, USA); fetal bovine serum (FBS) (Biosera, UK); Opti-MEM® (Life 
Technologies, USA); Transfection reagents and fluorescent control plasmid (TYE-563)  
(Mirus, USA); Curcumin (Cayman Chemical, UK); all other chemicals were sourced 
from Sigma (Dorset, UK). 
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Stock solutions of all test compounds were prepared in dimethylsulfoxide (DMSO) and 
stored at -20°C until use.  
The materials used to grow PBMEC/C1-2 cells and Z310 were detailed in chapter 2 
(section 2.3) and chapter 3 (section 3.3). 
 
4.4. Culture of H1L6.1c2 cells 
H1L6.1c2 cells are mouse hepatoma cell lines, which were a kind gift from Dr.Michael 
Denison and was stably transfected with a luciferase firefly plasmid (Garrison et al., 
1996, Nagy et al., 2002). Cells were seeded into a T25 flask containing alpha-MEM 
supplemented with 10% FBS at 37°C and allowed to attach for 24 h before the media 
was changed.  At 70-80% confluency, cells were washed with warm PBS and 1 mL of 
trypsin-EDTA was added to the flask. The flask was placed in the incubator for 5 min 
and cell suspension was resuspened in a 5 mL of media before the being transferred 
to a 15 mL centrifuge tube and centrifuged at 1000 rpm for 5 min. The pellet was 
resuspened in 2 mL of the media and transferred to a T75 for subsequent experiments.  
 
4.4.1. Cryopreservation of the cells 
After harvesting cells as described in section 4.4, the pellet was resuspended in 
freezing media (10% DMSO and 90% FBS). A 1 mL volume of the cell suspension was 
aliquot to the cryovials and stored overnight at -80˚C in cell cooling box (Mr. Frosty, 
Nalgene®, Thermo Fisher Scientific, UK). After 24 h, vials were transferred to the liquid 
nitrogen for long-term storage. 
 
4.4.2. Activation of AhR by omeprazole in H1L6.1c2 cells 
 
Omeprazole is a known non-toxic AhR antagonist. To assess the functional activity of 
AhR in H1L6.1c2 cells, the activation of AhR was assessed across a concentration 
range of omeprazole, to identify an EC50.  Sterile working stocks of omeprazole were 
freshly prepared on the day. Culture medium was used as the diluent and the final 
solvent concentrations in all test drug concentrations did not exceed 1 % (v/v). 
Cells were seeded with a density of 75,000 cells per well onto a clear flat bottom 96-
well plates and grown to 60-70% confluence. Media was then carefully removed and 
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fresh media containing 0.5 µM -100 µM omeprazole or lacking omeprazole (control) 
incubated for 24 h. 
 
To assess the activation of AhR, a commercial luciferase-based luminescence assay 
(Promega, USA) was utilised. Cells were washed with pre-warmed PBS followed by 
the addition of 20 µL of Lysis Buffer (Promega, USA) to each well.  The plates were 
transferred to an orbital plate shaker and shaken at 1000 rpm for 20 minutes. 20 µL of 
the cell lysate was then transferred into opaque 96-well plate and 100 µL of Luciferase 
Reagent was added to each well. The luminescence was measured immediately and 
at 10 seconds intervals for duration of 60 seconds using a Spectra Max MX5 plate 
reader (Molecular Devices LLC, Sunnyvale, CA). The peak average time-resolved 
stable luminescence signal was calculated as a measure of luminosity. 
 
4.4.3. Activation of AhR by modulators in H1L6.1c2 cells 
To assess the potential activation of AhR by phytochemical modulators, a luciferase-
based assay was developed as described in section 4.4.2. All modulators were 
prepared at 25 µM concentration (unless otherwise indicated) and 100 µL added to the 
appropriate wells. The plates were incubated at 37°C for 24 h prior to the luciferase 
assay. 
4.5. Silencing AhR gene expression  
 
4.5.1. Preparation of siRNA reaction 
 
A commercial transfection kit, TransIT-TKO (Mirus Bio, USA), was used for 
transfection studies.  100 µL of Opti-MEM® was added into a sterile tube, followed by 
3 µL of the TransIT-TKO and 1.4 µL of the siRNA (final concentration 25 nM) and 
mixed gently by pipetting up and down. The tube was incubated for 30 min at room 
temperature. Dicer substrate siRNA duplexes were custom synthesised by IDTDna 
against porcine AhR (Table 4.1) and rodent AhR (Table 4.2) and obtained in a 
commercial gene transfection kit, TriFECTa® (IDTDna, Belgium). 
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Table 4. 1: Porcine AhR siRNA duplexes  
Duplex Size Sense         Anti-sense     
1 16566 GAACAUUAUCACUUCCCAUUGGUGCAA CTUGUAAUAGUGAAGGGUAACCACG 
2 16520 UUUCUGACACAGUUGUUGCUGCUGCUC AAAGACUGUGUCAACAACGACGACG 
3 16490 ACACAUUGAAAUAGGUGCCUUAUUCUU TGUGUAACUUUAUCCACGGAAUAAG 
    
 
 Table 4.2: Rodent AhR siRNA duplexes  
Duplex Size Sense       Anti-sense       
1 16506 ACCAAAGACACGGGAUAAACUCACA UUUGGUUUCUGUGCCCUAUUUGAGUGU 
2 16544 CGACAUAACAGACGAAAUCCUGACG UAGCUGUAUUGUCUGCUUUAGGACUGC 
3 16544 AGCAUCAUGAGAAACCUAGGGAUCG UAUCGUAGUACUCUUUGGAUCCCUAGC 
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4.5.2. Culture of PBMEC/C1-2 and Z310 cells 
PBMEC/C1-2 and Z310 cells were grown in 12-well plates for studies as described in 
chapter 2 (section 2.4.2) and chapter 3 (section 3.4.1). Media was aspirated and cells 
were washed with the pre-warmed Opti-MEM®. The three sets of dicer substrate siRNA 
were added to the individual wells to identify the most efficient silencing ‘set’, and 
incubated at 37°C for 6 h. Thereafter the media was removed and replaced with the 
pre-warmed Opti-MEM and incubated for a further 18 h. 
 
4.5.3. Measurement of transfection efficiency using a fluorescent plasmid 
To assess transfection efficiency, PBMEC/C1-2 and Z310 cells were seeded at a 
density of 25,000 and 15,000 into wells of a 6-well plate and allowed to attach for 24 
h. Thereafter, cells were incubated with a fluorescent transfection control duplex  (TYE-
563®) (IDTDna, Belgium) at 5, 10 and 25 nM for 24 h and visually inspected every 6 
hours to assess transfection efficiency. Cells were observed under inverted DMI400B 
microscope (Leica microscope systems (UK) Ltd, Milton Keynes, UK). 
 
4.5.4. Chemically mediated antagonism of AhR 
In addition to gene silencing through siRNA, the AhR antagonist CH223191 (Choi et 
al., 2012) was assessed for its ability to silence AhR. 1 µM and 10 µM CH223191 
solutions were prepared in cell culture media and incubated with cells seeded in 24-
well plates (as described in section 4.4).  RNA was subsequently extracted and AhR 
expression was quantified. 
 
4.5.5. Quantification of AhR and BCRP gene expression  
 
4.5.5.1. Extraction of RNA  
RNA was extracted in triplicate from wells for each set of siRNA or CH223191 as 
described in Chapter 2 section 2.4.8.1. 
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4.5.5.2. Reverse transcription and qPCR analysis of AhR and BCRP gene 
expression 
To confirm the presence of BCRP and AhR genes in cells, reverse transcription and 
qPCR was conducted as described in chapter 2 4.8.2 and for AhR and for BCRP in 
the absence of siRNA.  Furthermore to identify AhR mediated regulation of BCRP, 
knockdown of AhR by siRNA was then used to both confirm successful AhR 
knockdown and also assess any associated changes in BCRP. 
Gene expression levels was measured using a relative quantification method as 
discussed in Chapter 2 (Section 2.4.8.4 and equation 3) and Chapter 3 (Section 
3.4.9.4).  
 
4.5.6. Phytoestrogen mediated modulation of AhR gene expression  
 
To assess whether phytoestrogen identified as modulators of BCRP protein and 
functional expression: 
(i) Could directly alter AhR expression  
(ii) Could directly alter BCRP expression 
(iii) Will show diminished effects on BCRP when silencing AhR (i.e. modulator 
mediated effects on BCRP and directly related to AhR) 
phystoestrogenic modulators were prepared in an incubation mixture combined with 
either siRNA (25 nM) or CH223191 (1 µM or 10 µM) and incubated with cells for 24 h 
(see section 4.4.2). In PBMEC/C1-2 cells, modulators which induced BCRP protein 
included quercetin (25 µM) and naringin (25 µM), with curcumin (1 µM) and estradiol 
(100 nM) selected as down-regulators of BCRP. In Z310 cells, modulators studied 
which induced BCRP protein included baiclain (25 µM) and flavone (25 µM), with 
quercetin (25 µM) and naringin (25 µM) selected as down-regulators of BCRP.      RNA 
was extracted and qPCR was performed as described in section 4.5.5.  
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4.6. Statistical Analysis 
 
All statistical analyses were performed in Graph pad Prism (La Jolla, California, USA). 
One-way ANOVA and t-tests were carried out to determine the differences between 
the mean values. For all multi-well based assay replicates of at least 3 were used in 
three independent experiments. EC50 metrics were calculated using sigmoidal fit 
functions within Graph pad Prism. 
 
A significance p-value of < 0.05 was considered as statistically significant.  
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4.7.   Results 
 
4.7.1.  Activation of AhR by omeprazole in H1L6.1c2 cells 
 
The concentration dependent activation of AhR in H1L6.1c2 cells by the AhR activator 
omeprazole was assessed by measuring the luminescence produced from transfected 
firefly luciferase gene. The concentration dependent activation of AhR was confirmed 
over the concentration range, with a sigmoidal response curve (Figure 4.1) with a 
calculated EC50 of 9.73 ± 0.05 µM. 
 
 
Figure 4.1: Concentration dependent activation of AHR activity.  
The luciferase firefly stably transfected mouse hepatoma cell line, H1L6.1c2, was seeded to a 
96-well plate and incubated for 24 h with omeprazole (0.5 µM-100 µM). A luciferase assay was 
subsequently performed and luminescence was measured and reported as the fold change 
compared to non-activated control. 
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4.7.2. Activation of AhR by modulators in H1L6.1c2 cells  
To assess the activation of AhR by modulators, a chemically-activated luciferase 
(CALUX) assay was employed to screen modulators at optimal concentration of 
25 µM known to modulate BCRP protein expression in both Z310 and 
PBMEC/C1-2 cells Chapter 2 (section  2.10) and Chapter 3 (section 3.8). Using 
the luminescence quantified from the maximum activation of AhR by omeprazole, 
the activation of AhR by modulators was reported as percentage maximum 
omeprazlole induction, with values greater than 1 % indicating induction, 50 % 
reflecting the 50 % of the maximum induction and 100% reflecting identical 
induction as achieved with omeprazole. To simplify the analysis, a cut off which 
equated to 50 % maximum induction was used as a metric for identified 
modulators, with values of greater than 75 % being classified as ‘potent’ 
activators of AhR. 
 Modulators identified as ‘potent’ included biochanin a (73.9 %  4.8 %), chrysin 
(80.6   %  2.7 %), curcumin (81.21 %  3.8 %), hesperidin (88.16 %  9.3 %) 
and rutin (81.17 %  6.3 %). All other flavonoids demonstrated > 50 % maximum 
induction (when considering the SD) (Figure 4.2). 
  
180 
 
 
 
       
 
  Figure 4.2:  The activation of AhR by phytochemical modulators. 
H1L6.1c2 cells were seeded to a 96-well plate and incubated with modulators for 24 h 
and CALUX assay was performed. Shaded areas reflect modulators activation of AhR by 
up to 50% and greater than 75%.       
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4.7.3. Assessing transfection efficiency using a fluorescent plasmid 
Transfection efficacy was assessed using a concentration range of 5, 10 and 25 
nM for 24 h and visually inspected every 6 h to assess transfection efficiency. 
Optimal transfection efficiency was demonstrated at 24 h post-seeding for 25 nM 
concentrations of plasmid which demonstrated successful transfection of the 
TYE™-563 labelled plasmid in PBMEC/C1-2 (Figure 4.3) and Z310 cells (Figure 
4.4).  
 
 Figure 4.3: Assessment of fluorescence efficiency in PBMEC/C1-2 cells.  
 PBMEC1-2 cells were seeded onto a 6-well plate and incubated with fluorescently-
labelled transfection control duplex (TYE 563™) for 24 h and 25 nM. Cells were visualised 
24 h post-transfection under fluorescent microscope (excitation 556 nm, emission max 
570 nm).  
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  Figure 4.4:  Assessment of fluorescence efficiency in Z310 cells.  
Z310 cells were seeded onto a 6-well plate and incubated with fluorescently-labelled 
transfection control duplex (TYE 563™) for 24 h and 25 nM. Cells were visualised 24 h 
post-transfection under fluorescent microscope (excitation 556 nm, emission max 570 
nm).  
 
4.7.4. Modulation of BCRP and AhR gene expression in PBMEC/C1-2 cells 
 
4.7.4.1. Assessment of AhR down-regulation by siRNA and CH223191 
To identify whether AhR and BCRP were present in PBMEC/C1-2 cells, qPCR 
was conducted using porcine specific AhR primers.  The primers were designed 
and pre-validated by PrimerDesign (Sheffield, UK). qPCR was successfully 
performed with single-peak dissociation-curves for both AhR (Figure 4.5A) and 
BCRP (Figure 4.5B).   
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 Figure 4.5: qPCR dissociation curves for AHR and BCRP in PBMEC/C1-2. 
(A) Representative dissociation curves showing the primer specificity for AhR gene and (B) Representative dissociation curves showing primer specificity for the           
BCRP gene in PBMEC/C1-2 cells.  
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AhR knockdown in PBMEC/C1-2 cells was performed using siRNA and 
CH223191. AhR gene expression was successfully detected in PBMEC/C1-2 
cells using qPCR approaches (Figure 4.6). Following incubation with the AhR 
antagonist CH223191, a significant down-regulation of AhR was observed at 1 
µM (p ≤ 0.001) and 10 µM (p ≤ 0.05) resulting in down-regulation of AhR by 1.71 
± 0.12 and 1.17 ± 0.16 fold change in AhR gene levels (Figure 4.6). Furthermore, 
dicer siRNA set 2 demonstrated successful down-regulation of AhR (P ≤ 0.01) 
leading to a 2.31 ± 0.08 fold change in gene expression. 
BCRP gene expression was also quantified in the same samples that were 
treated with CH223191 and demonstrated down-regulation when exposed to 1 
µM (P ≤ 0.001) and 10 µM (P ≤ 0.05) leading to a 1.12 ± 0.09 and 0.79 ± 0.12 
fold change respectively. In samples exposed to dicer AhR siRNA set 2, BCRP 
gene expression was also significantly down-regulated (P < 0.01) leading to a 
1.75 ± 0.08 fold change (Figure 4.6) 
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 Figure 4.6: Modulation of AhR and BCRP gene expression in the presence of siRNA 
or CH223191 in PBMEC/C1-2 cells.  
PBMEC/C1-2 cells were seeded onto a 24-well plate and incubated with siRNA or CH223191 (1 
and 10 µM), followed by RNA isolation and qPCR quantification of AhR and BCRP gene 
expression.  Change in gene expression was calculated relative to normalised control samples 
(absence of siRNA or CH223191). Significant differences between control and siRNA or CH223191 
exposed samples are indicated above the appropriate error bars (*P ≤ 0.05; **P ≤ 0.01; ***P ≤ 
0.001). 
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4.7.4.2. Phytochemical mediated modulation of AhR gene expression  
Modulation of AhR and BCRP gene expression mediated by phytochemicals was 
investigated in PBMEC/C1-2 cells. siRNA transfected cells were incubated with 
modulators which instigated an induction of BCRP protein, quercetin (25 µM) and 
naringin (25 µM) and those causing a down-regulation of BCRP protein, curcumin 
(1 µM) and 17-β-estradiol (100 nM). 
 
In the absence of siRNA, AhR gene expression was significantly increased (p ≤ 
0.0001) when exposed to BCRP protein inducers, namely quercetin (0.62 ± 0.31 
fold) and naringin (0.84 ± 0.08 fold), relative to control samples (Figure 4.7). 
However for BCRP protein down-regulates namely curcumin and 17-β-estradiol, 
no significant differences in AhR gene expression was detected (Figure 4.7). 
 
When AhR was silenced using siRNA, AhR gene expression was significantly 
reduced (when compared to control samples), when exposed to BCRP protein 
inducers, namely quercetin (1.26 ± 0.06 fold) (p ≤ 0.0001) and naringin (0.64 ± 
0.08 fold) (p ≤ 0.05). Additionally, significant differences existed when compared 
the absence and presence of siRNA (p < 0.0001). Furthermore AhR gene 
expression was significantly reduced when exposed to BCRP protein down-
regulators, namely curcumin (1.06 ± 0.09 fold) (p ≤ 0.01) and 17-β-estradiol (0.97 
± 0.09 fold) (p ≤ 0.01 (Figure 4.7).  However, no significant difference was 
detected when comparing samples in the absence or presence of siRNA (Figure 
4.7). 
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Figure 4.7:  Phytoestrogen modulation of AhR gene expression in the absence and 
presence of AhR specific siRNA in PBMEC/C1-2 cells.  
 
PBMEC/C1-2 cells were seeded onto 24-well plates and incubated with quercetin, naringin, 
curcumin and 17-β-estradiol for 24 h along with siRNA targeted to AhR. RNA was extracted and 
qPCR analysis conducted. Significant differences between groups are indicated above the 
appropriate error bars (*P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001 and **** P ≤ 0.0001). 
 
 
4.7.4.3. Phytoestrogen mediated modulation of BCRP gene expression in 
PBMEC/C1-2 cells  
In the absence of siRNA, BCRP gene expression was significantly increased (P 
≤ 0.0001) for BCRP protein inducers, namely quercetin (1.63 ± 0.28 fold) and 
naringin (1.36 ± 0.71 fold), relative to control samples (Figure 4.8). Similarly 
BCRP protein down-regulators demonstrated significant decrease in BCRP gene 
expression, curcumin (1.78 ± 0.05 fold) (P ≤ 0.0001) and 17-β-estradiol (1.54 ± 
0.05 fold) (P ≤ 0.01) (Figure 4.8).   
 
When AhR gene expression was silenced using siRNA, BCRP gene expression 
was reduced compared to control samples for BCRP protein inducers, quercetin 
(0.18 ± 0.12 fold) and naringin (0.41 ± 0.09 fold) and were not significantly 
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different from control (absence of modulators) (Figure 4.8)  but were significantly 
different from results obtained for BCRP expression in the absence of siRNA. For 
BCRP protein down-regulators, BCRP gene expression increased when 
compared to samples in the absence of siRNA for curcumin (0.62 ± 0.10 fold) 
and 17-β-estradiol (0.22 ± 0.21 fold) but were not significantly different from 
control (absence of modulators) (Figure 4.8).  Furthermore, when compared to 
samples in the absence of siRNA significant differences between –siRNA and 
+siRNA samples existed for curcumin (P ≤ 0.01) and naringin (P ≤ 0.05) (Figure 
4.8).      
 
 
Figure 4.8: Phytoestrogen modulation of BCRP gene expression in the absence 
and presence of AhR specific siRNA in PBMEC/C1-2 cells. 
PBMEC/C1-2 cells were seeded onto 24-well plates and incubated with quercetin, naringin, 
curcumin and 17-β-estradiol for 24 h along with siRNA for AhR. RNA was extracted and qPCR 
analysis conducted. Significant differences between groups are indicated above the appropriate 
error bars (*P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001). 
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4.7.5. Modulation of BCRP and AhR gene expression in Z310 cells 
 
4.7.5.1. Assessment of AHR downregulation with siRNA and CH223191  
 
To identify whether AhR and BCRP were present in Z310, qPCR was conducted 
using rodent specific AhR primers.  The primers were designed and pre-validated 
by PrimerDesign (Sheffield, UK). qPCR was successfully performed with single-
peak dissociation-curves for both AhR (Figure 4.9A) and BCRP (Figure 4.9B). 
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   Figure 4.9: qPCR dissociation curves for AHR and BCRP in Z310 cells. 
A) Representative dissociation curves showing the primer specificity for AhR gene and (B) Representative dissociation curves showing primer specificity for  
the BCRP gene in PBMEC/C1-2 cells.  
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AhR knockdown in Z310 cells was performed using siRNA and CH223191.  AhR 
gene expression was successfully detected in Z310 cells using qPCR 
approaches (Figure 4.10). Following incubation with the AhR antagonist 
CH223191, a significant down-regulation of AhR was observed at 1 µM (p ≤ 
0.001) and 10 µM (p ≤ 0.05) resulting in down-regulation of AhR by 1.81 ± 0.05 
and 1.09 ± 0.07 fold change in AhR gene levels (Figure 4.10). Furthermore, dicer 
siRNA set 3 demonstrated successful down-regulation of AhR (P ≤ 0.01) leading 
to a 1.01 ± 0.04 fold change in gene expression. 
BCRP gene expression was also quantified in the same samples that were 
treated with CH223191 and demonstrated down-regulation when exposed to 1 
µM (P ≤ 0.001) and 10 µM (P ≤ 0.001) leading to a 1.86 ± 0.10 and 1.47 ± 0.09 
fold change respectively. In samples exposed to dicer AhR siRNA set 3, BCRP 
gene expression was also significantly down-regulated (P < 0.01) leading to a 
0.75 ± 0.08 fold change (Figure 4.10).  
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Figure 4.10: Modulation of AhR and BCRP gene expression in the presence of  
siRNA or CH223191 in Z310 cells.  
Z310 cells were seeded onto a 24-well plate and incubated with siRNA or CH223191 (1 and 10 
µM), followed by RNA isolation and qPCR quantification of AhR and BCRP gene expression.  
Change in gene expression was calculated relative to normalised control samples (absence of 
siRNA or CH223191). Significant differences between control and siRNA or CH223191 exposed 
samples are indicated above the appropriate error bars (*P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001). 
 
 
4.7.5.2. Phytoestrogen mediated modulation of AhR gene expression  
Modulation of AhR and BCRP gene expression mediated by phytochemicals was 
investigated in Z310 cells. siRNA transfected cells were incubated with 
modulators which instigated an induction of BCRP protein, baiclain (25 µM) and 
flavone (25 µM) and those causing a down-regulation of BCRP protein, narinign 
(25 µM) and quercetin  (25 µM). 
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In the absence of siRNA, AhR gene expression was significantly increased (p ≤ 
0.0001) when exposed to BCRP protein inducers, namely baiclain (1.23 ± 0.31 
fold) and flavone (1.28 ± 0.35 fold), relative to control samples (Figure 4.11). 
However, for BCRP protein down-regulators, namely naringin and quercetin, a 
decrease in AhR gene levels were detected but this was not significant when 
compared to control (absence of modulators), < 0.4 fold (Figure 4.11). 
 
When AhR was silenced using siRNA, AhR gene expression was significantly 
reduced (when compared to the samples in the absence of siRNA) when 
exposed to BCRP protein inducers, namely baiclain (0.25 ± 0.06 fold) (p ≤ 
0.0001) and flavone (0.09 ± 0.16 fold) (p ≤ 0.0001). Additionally, when compared 
to control (absence of modulators), no significant differences were observed. 
However for BCRP protein down-regulators namely naringin and quercetin, 
decrease in AhR gene levels were detected but this was not significant when 
compared to control (absence of modulators), < 0.4 fold (Figure 4.11). 
 
Furthermore, when compared to 1 µM CH223191, AhR gene expression was 
significantly reduced compared to the samples in the absence of siRNA for BCRP 
inducers, namely baiclain (0.41 ± 0.09 fold) (P ≤ 0.0001) and flavone (0.68 ± 0.09 
fold) (P ≤ 0.0001).  When compared to samples in the absence of siRNA 
significant differences between –siRNA and +siRNA or CH223191 existed for 
baiclain (P ≤ 0.0001) and quercetin (P ≤ 0.0001) (Figure 4.11). 
 
However BCRP protein down-regulators (naringin and quercetin) demonstrated 
a non-significant decrease in AhR gene levels, when compared to control 
(absence of modulators), < 0.4 fold (Figure 4.11). 
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Figure 4.11: Phytoestrogen modulation of AhR gene expression in the absence 
and presence of AhR specific siRNA or CH223191 in Z310 cells.  
Z310 cells were seeded onto 24-well plates and incubated with baiclain, flavone, naringin and 
quercetin for 24 h along with siRNA for AhR. RNA was extracted and qPCR analysis conducted. 
Significant differences between groups are indicated above the appropriate error bars (*P ≤ 0.05; 
**P ≤ 0.01; ***P ≤ 0.001). 
 
 
4.7.5.3. Phytoestrogen mediated modulation of BCRP gene expression in 
Z310 cells  
Modulation of BCRP gene expression mediated by phytochemicals was 
investigated in Z310 cells.  In the absence of siRNA, BCRP gene expression was 
significantly increased (p ≤ 0.0001) when exposed to BCRP protein inducers, 
namely baiclain (1.28 ± 0.31 fold) and flavone (1.21 ± 0.35 fold), relative to control 
samples (Figure 4.12). However for BCRP protein down-regulators namely 
naringin and quercetin, a decrease in BCRP gene levels were detected but this 
was not significant for naringin when compared to control (absence of 
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modulators), < 0.4 fold but was significant for quercetin (0.74 ± 0.13 fold)  (p ≤ 
0.05) (Figure 4.12). 
 
When AhR was silenced using siRNA, BCRP gene expression was significantly 
reduced (when compared to the samples in the absence of siRNA) when 
exposed to BCRP protein inducers, namely baiclain (0.15 ± 0.12 fold) (p ≤ 0.001) 
and flavone (0.02 ± 0.16 fold) (p ≤ 0.01). Additionally, when compared to control 
(absence of modulators), no significant differences were observed.  
 
However for the BCRP protein down-regulator naringin, a significant 
downregulation of BCRP was observed (1.78 ± 0.12 fold) (p ≤ 0.0001) when 
compared to control and this was also significantly difference when compared to 
the absence of siRNA (p ≤ 0.01).  For quercetin, a non-significant change in 
BCRP was observed when compared to control (absence of modulators) but this 
was highly significant when compared to modulators in the absence of siRNA 
(Figure 4.12). 
 
Furthermore, when compared to 1 µM CH223191, BCRP gene expression was 
significantly reduced compared to the samples in the absence of siRNA for the 
BCRP inducers baiclain (0.51 ± 0.09 fold) (P ≤ 0.001) but was not significantly 
different for flavone, which has recovered to control levels.  When compared to 
samples in the absence of siRNA significant differences between –siRNA and 
+siRNA for CH223191 existed for baiclain (P ≤ 0.0001) and quercetin (P ≤ 
0.0001) (Figure 4.12). However BCRP protein down-regulators (naringin and 
quercetin) demonstrated a non-significant decrease in AhR gene levels, when 
compared to control (absence of modulators), < 0.4 fold (Figure 4.11). 
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Figure 4.12: Phytoestrogen modulation of BCRP gene expression in the absence 
and presence of AhR specific siRNA or CH223191 in Z310 cells.  
Z310 cells were seeded onto 24-well plates and incubated with baiclain, flavone, naringin and 
quercetin for 24 h along with siRNA for AhR. RNA was extracted and qPCR analysis conducted. 
Significant differences between groups are indicated above the appropriate error bars (*P ≤ 0.05; 
**P ≤ 0.01; ***P ≤ 0.001). 
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4.8. Discussion 
 
AhR plays a vital role in controlling and mediating transcription signals from 
environment toxins such as polycyclic aromatic hydrocarbons (PAHs) (Denison 
and Nagy, 2003), with the classical common environmental pollutants such as 2, 
3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD) and benzo[a]pyrene (BaP) known to 
induce or activate the activity of AhR.  
 
AhR, to date, has primarily been studied for the role it plays in xenobiotic 
signalling. In its non-active state, it can be found in the cytoplasm of cells in an 
intricate protein complex. Activation of AhR leads to nuclear transformation 
(Perdew, 1988) and binding to promoter regions of target genes that contains an 
AhR binding consensus (5’-T/GNGCGTGA/CG/CA-3’) (Denison et al., 1988). 
The role of AhR at the BBB is not well understood. However it has been reported 
that the  higher expression of AhR at the human BBB compared to other 
regulatory genes such CAR and PXR, potentially highlights the important role 
AhR may play in transcriptional regulation of xenobiotic clearance mechanisms 
such as BCRP (Dauchy et al., 2008b). At the BBB, AhR regulates the expression 
of drug metabolising enzymes such as CYP1A1 and CYP1B1 and ABC 
transporters (Granberg et al., 2003, Dauchy et al., 2008a). Furthermore, 
activation or modulation of AhR has previously been shown to alter the 
expression of BCRP. For example 3-methylcholanthrene (3MC) is a known AhR 
agonists and has been demonstrated to lead to an AhR mediated, 80-fold 
induction of BCRP in LS174T cells, which was reduced by 65% in AhR  
knockdown cells (Tompkins et al., 2010). Furthermore TCDD has been 
demonstrated to up-regulated BCRP expression and in rat brain capillaries 
(Wang et al., 2011) and rat spinal cord capillaries (Campos et al., 2012). 
In light of the current clinical failures in specific BCRP inhibitor molecules (Nutton, 
1973, Allen et al., 2002a) (Allen et al., 2002b), the identification of new candidates 
that show limited cellular toxicity and an ability to mediate alterations in BCRP 
expression (transcriptional and translational) is of interest.  In this respect, 
phytochemicals such as flavonoids are promising leads. 
Phytochemicals (primarily flavonoids) are natural compounds found in the foods 
consumed as part of the human diet, with an estimated intake of 1g/per day 
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(Formica and Regelson, 1995). Several studies have demonstrated that 
flavonoids act as agonists and antagonist of AhR in a concentration dependant 
manner (Ashida et al., 2000) (Ciolino et al., 1998a, Zhang et al., 2003a). The 
exact mechanism of action is unclear, but is thought to supress the nuclear 
translocation of AhR (Mukai et al., 2010) with flavonoids such as quercetin, 
flavone, apigenin, kaempferol and galangin (Ebert et al., 2007) (Mukai et al., 
2010) (Tan et al., 2010). 
 
The primary focus of this chapter was to evaluate whether flavonoids were 
capable of modulating AhR, and to further assess the impact of any potential 
modulation of BCRP expression at the BBB and BCSFB. AhR activation by all 
modulators was evaluated using a chemically activated luciferase assay 
(CALUX). Thereafter the regulatory control of BCRP by AhR was demonstrated 
by AhR silencing (dicer substrate siRNA) in both PBMEC/C1-2 and Z310 cells. 
Finally, the impact of up- and down-regulators of BCRP at the BBB and BCSFB 
on BCRP and AhR were identified in +AhR and –AhR cells. 
 
  We selected the stably transfected H1L6.1c2 cell lines along with an associated  
luciferase assay based on the CALUX assay developed by He et al (He et al., 
2004).  We confirmed the functional activity of the luciferase plasmid within the 
cells with a non-toxic agonist of AhR, omeprazole, which has previously been 
used as an AhR activator for the CALUX assay (Zhao et al., 2013). 
 
Our results have shown that omeprazole demonstrated AhR activation in a 
concentration dependent manner by forming typical sigmoidal curve (Figure 4.1). 
The EC50 for omeprazole induction of AHR gene was estimated to be 9.73 ± 0.05 
µM in H1L6.1c2 cells. AhR is known to induce the expression of CYP1A1 and 
omeprazole induction of CYP1A1 in human cancer cells and primary human 
hepatocytes was determined over a concentration range of 10-100 µM (Novotna 
et al., 2014). Furthermore, the EC50 for omeprazole induction of the human 
CYP1A1 gene was found to be 100 µM (Quattrochi and Tukey, 1993). Our 
calculated EC50 is within the same order of magnitude to other reports and 
highlights the functionally active luciferase firefly response.  
It should be noted that the most appropriate agonist to use would have been 
TCDD (He et al., 2004). However TCDD is considered a highly carcinogenic 
compound, even at very low concentrations (Kociba and Schwetz, 1982), and 
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was deemed unsafe for use in this project. However, the similarity of EC50 
calculations for omeprazole, coupled with the concentration dependent sigmoidal 
profile justifies its use.  
 
We next assessed whether modulators were capable of modulating AhR by 
activating a luciferase response following a period of 24 h incubation in H1L6.1c2 
cells. Modulators were assessed for the ability to activate a maximum luminesce 
response based on the maximum fold-change to control obtained with 
omeprazole (Figure 4.1).  To aid in categorising the response, a marker of 50% 
maximum induction and 75% maximum induction of luciferase activity (relative 
to omeprazole maximum induction) was chosen as a moderate and good 
respectively. Chrysin, curcumin, hesperidin and rutin resulted in luciferase 
activity of 75% or above (‘good’) and hence can be classified as potentially potent 
AhR activators, whereas BaP, biochanin A, 17-β-estradiol, flavone, hesperetin, 
I3C, napthoflavone, naringin, quercetin, resveratrol, silymarin and TBHQ 
demonstrated 50% or above (‘moderate’) AhR activation (Figure 4.2).  
It has been reported that quercetin significantly increased AhR activity by 
inducing CYP1A1 in human hepatoma HepG2 cells, whereas rutin a glycoside of 
quercetin failed to induce AHR and activation of CYP1A1 (Vrba et al., 2012).  Our 
results demonstrated that both quercetin and rutin elicited a luciferase response, 
although the response from rutin (84 ± 1.8 %) was greater than that elicited by 
quercetin (70 ± 2.3 %).  However, the concentration used by Vrba et al was 
similar to those used in this study (10-50 µM) (Vrba et al., 2012). Additionally, 
other studies have also confirmed AhR activation by similar modulators identified 
in our studies.  For example quercetin has been shown to activate AhR mediated 
CYP1A1 mRNA expression in Caco-2 cells (Pohl et al., 2006, Niestroy et al., 
2011) and MCF-7 cells (Ciolino et al., 1999) at concentrations of 0.5-10 µM. 
Another study also reported that chrysin, baiclain, galangin and genistein induced 
the luciferase activity in stably transfected Hepa-1 cells whereas quercetin, 
emodin and apigenin demonstrated inhibitory effect on AHR induction relative to 
TCDD and act in a concentration dependant manner(Amakura et al., 2008). 
Having identified the modulation of AhR activity by modulators studied, the 
relationship between BCRP expression and AhR regulation was important to 
elucidate. To this end we first assessed each cell line (PBMEC/C1-2 and Z310) 
for the ability to be transfected using a TYE™-563 fluorescently labelled plasmid 
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with a view to subsequently silencing AhR using dicer substrate siRNA.  Both 
cells lines were amenable to transfection and demonstrate successful 
transfection at 24 hours with an optimal plasmid concentration of 25 nM 
(PBMEC/C1-2: Figure 4.3; Z310: Figure 4.4). 
Thereafter, gene silencing of AhR was conducted using siRNA specific to AhR 
and changes in both AhR and BCRP expression was assessed using qPCR 
approaches. Furthermore, we utilised the selective antagonist of AhR, 
CH223191 (Zhao et al., 2010), as a positive control to compare against siRNA-
based AhR silencing. Using both a chemical antagonist of AhR and siRNA, we 
were demonstrated successful down-regulation of AhR in both PBMEC/C1-2 and 
Z310 cells. In PBMEC/C1-2 cells, CH223191 at 1 µM and 10 µM resulted in a 
1.71 ± 0.12 and 1.17 ± 0.16 fold down-regulation of AhR expression, with 2.31 ± 
0.08 fold down-regulation with siRNA (Figure 4.6). In Z310 cells CH223191 at 1 
µM and 10 µM successfully down-regulated AhR expression by 1.81 ± 0.05 and 
1.09 ± 0.07 fold respectively with siRNA knockdown resulting in 1.01 ± 0.04 fold 
down-regulation (Figure 4.10). 
Of interest however, is the associated downregulation of BCRP under all 
treatment conditions in both cells lines (PBMEC/C1-2- CH223191 1 µM: 1.12 ± 
0.09, 10 µM: 0.79 ± 0.12; siRNA: 1.75 ± 0.08 (Figure 4.6); Z310- CH223191 1 
µM: 1.86 ± 0.10, 10 µM: 1.47 ± 0.09; siRNA: 0.75 ± 0.08) (Figure 4.10).  This 
associated down-regulation of BCRP confirms the role that AhR regulates BCRP 
at transcriptional level, which is clearly evident when considering the statistical 
analysis of results, which show statistically significant differences in AhR and 
BCRP expression under both CH223191 and siRNA treatment when compared 
to control (untreated: fold-change = 0). 
Previously, only one study has reported the modulation of BCRP through AhR 
dependent manner in Caco-2 cells (Tan et al., 2010).  It is demonstrated that a 
1.5-2.0 fold induction in BCRP expression when cells were treated with AhR 
agonist TCDD, and after knockdown of AhR, gene expression of BCRP was 
significantly reduced (Tan et al., 2010). The relationship between AhR and its 
transcriptional regulation of BCRP was also identified by Tompkins et al 
(Tompkins et al., 2010), who reported that activation of BCRP expression in 
human colon adenocarcinoma-derived LS174T cells is regulated by AhR.  Taken 
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together, our results suggest that AhR plays a significant role in the 
transcriptional regulation of BCRP. 
Having identified this relationship, we then wished to assess the potential impact 
of modulators on both AhR and BCRP expression. From the H33342 
accumulation assays, western blots and transport assays we were able to identify 
modulations possessed BCRP induction or down-regulation properties. In 
PBMEC/C1-2 cells, two up-regulators of BCRP protein (quercetin and naringin) 
and two down-regulators (curcumin and 17-β-estradiol) were selected based on 
the western blot (Figure 2.13) and qPCR (Figure 2.14) results in PBMEC/C1-2 
cells. Similarly, for Z310 cells two up-regulators (baiclain and flavone) and two 
down-regulators (quercetin and naringin) were selected (Figure 3.11 and 3.12). 
In PBMEC/C1-2 cells, in the absence of siRNA treatment, quercetin and naringin 
significantly (p < 0.0001) up-regulated AhR expression by 0.62 ± 0.31 and 0.84 
± 0.08 fold (Figure 4.7) which was abolished when treated with siRNA (1.26 ± 
0.06 and 0.64 ± 0.08 fold down-regulated, respectively). Similarly, BCRP 
expression was also up-regulated in the absence of AhR siRNA by 1.63 ± 0.28 
and 1.36 ± 0.71 fold which was abolished when treated with siRNA (0.18 ± 0.12 
and 0.41 ± 0.09 fold down-regulated, respectively).  In both cases highly 
statistically significant differences (p < 0.0001) are evident when comparing – 
with + siRNA, highlighting the important role AhR plays as one potential target 
site for quercetin and naringin interactions.  Interestingly the lack of statistically 
significant differences between control and + siRNA for changes in BCRP 
expression highlight a ‘normalisation’ of BCRP gene expression as it returns to 
baseline and hence no significant difference in gene expression compared to 
control. 
 
Curcumin and 17-β-estradiol were identified as down-regulators of BCRP.  When 
assessing their impact on AhR, no significant differences were observed between 
modulator treated and control in the absence of siRNA, suggesting that curcumin 
and 17-β-estradiol do not alter AhR gene expression (Figure 4.7 and 4.8).  
However when considering their effects on BCRP, curcumin down-regulates 
BCRP to 1.78 ± 0.05 of control and 17-β-estradiol to 1.54 ± 0.05 of control (Figure 
4.8).  Furthermore, in the presence of siRNA, AhR is confirmed as being down 
regulated for both modulators and BCRP expression recovers to 0.51 ± 0.09 and 
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0.29 ± 0.19 of control and is not significantly different from control, again 
suggesting a return to baseline expression for BCRP. 
At the BBB (using PBMEC/C1-2 cells), this confirms that AhR has a significant 
role to play in the regulation of BCRP. Furthermore, the modulators identified as 
up- or down-regulators of BCRP expression may, in part, act to impact directly 
upon the activity of AhR, such as nuclear translocation (Mukai et al., 2010) (Li et 
al., 2009), as a possible mechanism which can alter the gene expression of 
BCRP. 
In Z310 cells, in the absence of siRNA treatment, baiclain and flavone 
significantly (p < 0.0001) up-regulated AhR expression by 1.23 ± 0.31 and 1.28 
± 0.35 fold (Figure 4.11) which was down-regulated when treated with siRNA (< 
0.5 fold and not significantly different from control).  Similarly, BCRP expression 
was also up-regulated in the absence of AhR siRNA by 1.28 ± 0.31 and 1.21 ± 
0.35 fold (Figure 4.12) which was also down-regulated when treated with siRNA 
(< 0.5 fold). In both cases statistically significant differences are evident when 
comparing – with + siRNA, highlighting the important role AhR plays in causing 
the up-regulating phenomena with baiclain and flavone. A similar ‘normalisation’ 
of BCRP gene expression effect was also observed between control and + siRNA 
as it returns to baseline. 
Naringin and quercetin were identified as down-regulators of BCRP in Z310 cells. 
When assessing their impact on AhR, no significant differences were observed 
between modulator treated and control in the absence or presence of siRNA, 
suggesting that naringin and quercetin do not alter AhR gene expression. We 
also confirmed no significant difference in AhR expression when using the 
chemical antagonist CH223191. However when considering their effects on 
BCRP, naringin does not significantly down-regulate BCRP whereas quercetin 
significantly (p < 0.05) down-regulates BCRP 0.86 ± 0.09 of control.  
Furthermore, in the presence of siRNA, BCRP expression is further down-
regulated to 1.78 ± 0.12 for naringin but recovers to 0.22 ± 0.21 for quercetin and 
is not significantly different from control, suggesting a return to baseline 
expression for BCRP.  
  
At the BCSFB (using Z310 cells), this again confirms that AhR has a significant 
role to play in the regulation of BCRP. Interestingly, the trends in modulation of 
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BCRP and AhR were different for Z310 cells compared to PBMEC/C1-2, 
particularly for the down-regulators, where both naringin and quercetin seemed 
to have no significant direct effect on AhR levels. Furthermore, naringin 
demonstrated no significant effects on BCRP expression in the absence of siRNA 
whereas quercetin significantly downregulated BCRP expression. The 
differences observed between the up-/down-regulators of BCRP, with 
PBMEC/C1-2 and Z310 cells, may be a result of the inherently lower expression 
of AhR in Z310 cells compared to PBMEC/C1-2 cells. Indeed, studies have 
reported a similar phenomenon in rodent primary choroid plexus cells and TR-
CSFB cell lines (Halwachs et al., 2011, Reichel et al., 2011). 
 
4.9. Conclusion 
This chapter has highlighted the transcriptional regulation of BCRP by AhR in 
both PBMEC/C1-2 and Z310 cells. We further investigated the up-regulators and 
down-regulators of BCRP in both cell culture models. All phytochemicals were 
shown to the AhR activators when compared to omeprazole. Furthermore, we 
have identified that up-regulators and down-regulators studied are able to directly 
alter BCRP gene expression, which is mediated by AhR.  
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5.1. Conclusion 
 
The overall aim of this work was to investigate whether phytochemical 
modulators were capable of modulating the expression and efflux function of 
BCRP at both the BBB and BCSFB, with a secondary aim of assessing whether 
BCRP transcriptional regulation is mediated by AhR, and whether 
phytochemicals act upon this regulatory pathway. 
In the first part of the work in this thesis, in-vitro models of the BBB and BCSFB 
were used to assess the cytotoxicity of selected modulators. We determined that, 
in general, most modulators demonstrated relatively little toxicity below 100 µM, 
but that species differences between the in-vitro model cell systems resulted in 
distinct differences in the level of toxicity mediated by some modulators. 
In order to screen modulators for the ability to impact upon BCRP, a high-
throughput 96-well plate assay was developed to assess the intracellular 
accumulation of a fluorescent BCRP substrate. In this model system, we 
demonstrated that many phytochemicals are capable of eliciting inhibition of 
BCRP efflux function in both cell lines during a 1 h pre-incubation. Furthermore, 
during a longer incubation time-period (24 h) we also demonstrated that 
modulators mediated potential up-regulation or down-regulation of BCRP 
functional activity resulting in alterations of H33342 intracellular accumulation. To 
confirm that these alterations were at the level of the proteome, western blotting 
identified a number of modulators in both cell lines which significantly altered 
protein expression by induction (2-3 fold) or down-regulation (0.2-0.4 fold). 
Next, we identified phytochemical modulators from both up- and down-regulation 
categories and assessed their ability to mediate functional changes in BCRP 
substrate transport in an in-vitro BBB or BCSFB permeable insert cell culture 
model.  We identified significant changes in BCRP substrate transport under both 
groups at the BBB and BCSFB, however when assessing the transcriptional 
changes using qPCR the down-regulators of protein expression did not seen to 
initiate similar changes in BCRP genome.   
The final part of this work focussed on examining the role AhR plays in regulating 
BCRP expression in knock-down studies employing dicer substrate siRNA 
directed towards AhR.  We demonstrated that with knockdown of AhR came a 
significant decrease in BCRP gene expression that was also confirmed when 
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using the AhR antagonist CH223191.  This demonstrated that BCRP 
transcription is indeed regulated by the AhR.  We then demonstrated that the 
phytochemical modulators were also capable of acting directly upon AhR, 
resulting in changes in AhR gene expression but also initiating subsequent 
alteration of BCRP gene expression, the effects of which were diminished when 
silencing AhR. 
In summary we have demonstrated that phytochemicals demonstrate little 
cytotoxicity in-vitro at both the BBB and the BCSFB and are indeed capable of 
modulating BCRP expression and functional transport of BCRP substrates. 
However further work is required to assess the importance of the translation of 
this work to humans as distinct differences in the impact of phytochemicals on 
BCRP expression and function were also observed between each cell system.  
A potential cause of this could be the differences in species from which the cell 
systems were developed (BBB: porcine and BCSFB: rat), but also differences in 
regulatory networks and other cascade systems are required to be characterised 
in order to make better comparisons between results obtained from each cell 
system/barrier site.  Furthermore, the permeation of flavonoids into the CNS and 
their distribution around the CNS would allow an understanding of the temporal 
changes in phytochemical concentrations within the CNS and therefore whether 
the exposure concentrations are significant enough to translate our in-vitro 
observations into an in-vivo effect, and the role of pharmacokinetic modelling may 
aid in this translation. 
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